Hier finden Sie Studien, die in QualiPRO eingegeben wurden, um die Teilnahme von Prüfärzten und Prüfzentren an diesen Studien zu erleichtern und zu dokumentieren. Die Studien werden nach Indikation und Kurztitel aufgelistet. Um in der Browserdarstellung zu suchen, drücken Sie "Strg.+f" um Suchkriterien in eine Suchmaske einzugeben. Es ist geplant, über einen Filter laufende und abgeschlossene Studien anzeigen zu lassen. Zum jetztigen Zeitpunkt gibt der Beginn und das Ende der Studie (laut EudraCT-Datenbank, Prüfplan oder Studienende in studienaktiven Zentren, z.B. Comprehensive Cancer Center) Auskunft über die Aktualität der Studie.

ORDER BY: disciplinename,titlealt 

	ID	Kurztitel	EudraCT	Wissenschaftlicher Titel	Phase	Sponsor	Studienstart	Ende
00 ohne Fachgebiet
	1237
	1283
	1290
	1301
	1369		2020-005759-18	A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERATE COVID-19	3		10.05.2021	02.12.2021
	1406					GPOH
	1191	BMC2012	2012-004037-17				01.07.2013	30.09.2014
	1189	CE1145_1001	2008-000654-12	PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY	3	Goethe-Universität Frankfurt	22.09.2008	01.11.2010
	1184	GUF 001	2007-004222-24	Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded read		Goethe-Universität Frankfurt
	1187	HIV-TDM-GT Kids	2010-021624-99	Eine multizentrische, nicht kontrollierte, nicht randomisierte IST zur Evaluation der Plasmaspiegel antiretroviraler Medikamente und des viralen Resistenzprofils und deren Auswirkung auf den Therapieerfolg bei HIV-infizierten Kindern A multi-centre, non-controlled, non-randomised IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected children.	2	Goethe-Universität Frankfurt	14.06.2012	09.05.2022
	1193	JWGKDVAAP0117	2017-000435-13	Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.	4	Goethe-Universität Frankfurt		03.03.2020
	1186	KTvsMM1/09	2009-009909-25	Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial	2	Goethe-Universität Frankfurt		24.10.2012
	1190	Lo-2012-02	2010-021570-11			Goethe-Universität Frankfurt
	1182	M1E-JR-004	2006-006384-24	Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“	3	Goethe-Universität Frankfurt	01.06.2007	01.07.2010
	1194	Pharmasynch	2011-002937-21	Ketamine Dysregulates the Amplitude and Connectivity of High-Frequency Oscillations in Cortical-Subcortical Networks in Humans: Evidence from Resting-State MEG-Recordings		Goethe-Universität Frankfurt		06.01.2014
	1405	SIOP RANDOMET 2017	2018-000533-13	Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumour co	3	GPOH	17.08.2022
	1407	SIOPEATRT01	2018-003335-29	An international prospective umbrella trial for children with Atypical Teratoid/ Rhabdoid Tumours (ATRT) including A randomized	3	Universitätsklinikum Augsburg	06.05.2022
	1418	TED15297	2017-004766-94	A Phase 1 First in Human dose escalation and expansation study for the evaluation of safety, pharmacokinetics,pharmacodynamics and anti-Tumor activity of SAR441000 administered intratumorally in patients with advanced solid tumors	1	Sanofi	12.03.2019
	1416	TTP_IIT		Determinants of Quality of Care in Patients with Thrombocytopenic Purpura (TTP) in Germany and the Influence of Rapid Diagnostics Facilities		Goethe-Universität Frankfurt	22.11.2022
	1417	TTP_IIT		Determinants of Quality of Care in Patients with Thrombocytopenic Purpura (TTP) in Germany and the Influence of Rapid Diagnostics Facilities		Goethe-Universität Frankfurt	22.11.2022
Chir Plastische Chirurgie
	1089	INVERT - Head&Neck 2012		Beobachtungsstudie zur Dokumentation der Ergebnisse einer IMRT-basierten, neoadjuvanten Radiochemotherapie, mit lokaler Dosiseskalation, gefolgt von radikaler Resektion bei Plattenepithelkarzinomen im Kopf-/Halsbereich (INVERT - Head&Neck 2012)		Goethe-Universität Frankfurt	01.05.2013
	1087	PRF-Sinuslift		Klinische, radiologische und histologische Analyse des Einflusses einer Autologen Fibrinmatrix auf die Knochenneubildung bei Sinusbodenaugmenatation mit einem xenogenen Knochenersatzmaterial		Goethe-Universität Frankfurt	01.01.2017	31.12.2020
	1088	Socket Preservation versch. PRF-Var.		Randomisierte, prospektive Studie zur klinischen und funktionellen Untersuchung des Einsatzes verschieden hergestellter PRF-Matrizes bei der Socket-Preservation		Goethe-Universität Frankfurt	01.01.2018	31.12.2020
	1086	Kinesiologisches Training, prospektiv		Verbesserung des Bewegungsumfangs und des subjektiven Wohlbefindens nach Tumoroperationen im Kopf-Hals-Schulter-Bereich durch kinesiologisches Training		Goethe-Universität Frankfurt	01.10.2018
	1084	Mucograft extraoral multizentrisch		Randomised controlled multicenter study to evaluate safety and performance of Geistlich Wound Matrix versus autologous skin graft in the treatment of skin defects		Geistlich Pharma
	1085	Socket Preservation-PRF Kiefernekrose		Untersuchung von autologem Fibrinkonzentrat (Platelet Rich Fibrin, PRF) zur Verbesserung der Wundheilung nach Zahnextraktionen bei Patienten mit Medikamenten-assoziierten und Osteoradionekrosen des Ober- und Unterkiefers		Goethe-Universität Frankfurt	01.06.2019	30.06.2021
Chir Viszeralchirurgie
	1382	ACO/ARO/AIO-18.2	2018-001356-35	ACO/ARO/AIO-18.2: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group	3		30.09.2020
	1402	ARMANI	NCT 04678583	Anatomische Resektion von Lebermetastasen bei Patienten mit RAS-mutiertem kolorektalem Karzinom			16.11.2022
	1068	DANTE/FLOT8	2017-001979-23	Eine randomisierte, offene Phase II Studie zur Wirksamkeit und Sicherheit von Atezolizumab in Kombination mit FLOT versus FLOT alleine bei Patienten mit Magen und Adenokarzinom des ösophagogastralen Übergang (MO30039)	2		14.10.2019
	1383	DISPACT 2	DRKS0014011	Distale Pankreatektomie – eine randomisiert kontrollierte Studie zum Vergleich der minimal invasiven mit der offenen Resektion
	1070	EXPELLIARMUS		Multizentrische, randomisierte, kontrollierte Studie zur Untersuchung postoperativer Komplikationen und Mobilisierung nach großer abdominalchirurgie Operationen mit oder ohne Feedback über einen Fitness-Tracker		Universitätsklinik Heidelberg	04.06.2019
Chirurgie - allg.
	974	Flot 7/RAMES	2015-003118-26	Perioperative Therapie mit Ramucirumabin Kombination mit FLOT vs. FLOT allein bei operablem Magenkarzinom und Adenokarzinom des ösophagogastralen Überganges- eine Phase II/III Studie AIO	2/3	Krankenhaus Nordewst	26.04.2016
	267	A6181122 (SUN)	2007-000325-21	A multicenter, randomized, double-blind, phase 3 study of Sunitinib in metastatic colorectal cancer patients receiving Irinotecan, 5 Fluourouracil and Leucovorin (FOLFIRI) as first line treatment	3	Pfizer	09.08.2007	07.10.2009
	631	ACTICCA-1	2012-005078-70	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma	3	Universitätsklinikum Hamburg Eppendorf	12.05.2014
	1421	ADJUBIL	2021-002389-41	A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer	2	IKF Klinische Krebsforschung GmbH Krankenhau	17.02.2022
	881	ADRESS		A Long-term follow-up of adult kidney and liver allograft recipients previously into a Tacrolimus (Advagraf) Trial. A multicenter non-interventional post authorization study.	4	Astellas	03.03.2014	12.05.2018
	264	AIO-SUP	2009-014725-16	Doppelblinde, Placebo-kontrollierte, randomisierte Phase II Studie zur Untersuchung der Wirksamkeit von Bevacizumab zur Symptomkontrolle bei Patienten mit maligner Aszites aufgrund eines fortgeschrittenen gastrointestinalen Karzinoms	2	AIO-Studien GmbH	14.01.2010	06.01.2014
	1437	ARMANI		Anatomische Resektion von Lebermetastasen bei Patienten mit RAS-mutiertem kolorektalem Karzinom		Medizinische Fakultät Carl Gustav Carus der T	30.10.2020
	265	BO17920 (Avant)	2004-000715-26	A randomized, three arm multinational phase III study to investigate Bevacizumab (q3w or q2w) in combination with either intermittent Capecitabine plus	3	Hoffmann La Roche Ltd.	14.03.2005	29.06.2012
	1297	CELSTAT		Prospektive, randomisierte, kontrollierte Studie zur Evaluierung der Wirksamkeit und der Sicherheit von CELSTAT als ergänzendes Hämostatikum bei Gebwebblutungen im Rahmen von kardiothorax.- allgemein- und gefäßchirurgie Eingriffen		PSI	19.05.2016	11.01.2018
	1248	CIRCULATE	2018-003691-12	Evaluierung der adjuvanten Therapie bei Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung (AIO-KRK-0217)	3	TU Dresden	19.08.2020
	1241	CLARIFY-DROPIZOL		Prospektive Beobachtungsstudie zur Anwendung und zu den Behandlungsergebnissen mit eingestellter Opiumtinktur (DROPIZOL) unter Bedingungen der täglichen Praxis		GWT TUD Gmbh, Dresden
	882	CLIMB	N/A	Eine prospektive Datenbank für kolorektale Lebermetastasen mit einem integrierten Qualitätssicherungsprogramm		EORTC	01.05.2015	24.01.2022
	258	CONKO-005	2007-003813-15	AdjuvanteTherapie des R0 resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte Phase III Studie	3	Charité Berlin	26.11.2007
	259	CONKO-006	2007-000718-35	Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie	2	Charité Berlin	04.04.2008
	1035	CTC Dynamik bei TACE		Kurzzeitige Dynamik von zirkulierender Tumorzellen nach TACE in Leberkarzinompatienten			12.01.2018
	1050	CTC in HCC		Ex vito Nachweis von zirkulierenden Tumormarkern in Leberkarzionompatienten			01.09.2016	31.03.2020
	1036	CTC polarity in HCC		Ex vivo Nachweis der Polarität zirkulierender Tumorzellen in Leberkarzinompatienten		Goethe-Universität Frankfurt
	1051	CTC polarity in HCC		Ex vivo Nachweis der Polarität zirkulierender Tumorzellen in Leberkarzinompatienten			01.04.2018	30.12.2018
	891	DasaHIT	2015-003502-16	Dasatinib Holiday for Improved Tolerability	3	Friedrich-Schiller-Universität	11.08.2016	31.03.2023
	269	DC Bead Studie		Prospektive Randomisierte Studie zur transarteriellen Chemoembolisation(TACE) mit Doxoburicin-Beads vs. Konventioneller TACE bei Pat. Mit HCC auf der Lebertransplantationsliste	3	Charite Universität Berlin	10.11.2009
	1385	DISPACT-2		Distal Pancreatectomy – A randomised controlled trial to compare minimal-invasive distal pancreatectomy to open resection (DISPACT-2 Trial)		Universitätsklinikum Heidelberg
	1358	EnGraft	2020-000796-20	Eine multizentrische, offene, randomisierte, zweiarmige, parallele, Überlegenheitsstudie zur Untersuchung der Bioverfügbarkeit und der Handhabung von Envarsus® im Vergleich zu Advagraf® bei de novo Empfängern von Lebertransplantaten (EnGraft)	4	Regensburg University Medical Center	01.09.2020
	1302	eRADAR		Double-blind evaluation of the diagnosic accuracy of the Ada-App healthcare application in an emergency room-setting eRadar- Trial		Goethe-Universität Frankfurt	31.08.2020	11.09.2021
	1213	ERAS+		Der Effekt einer frühzeitigen Bewegungsintervention und eigenverantwortlichen Mobilisation unter Verwendung eines Mobilisationsbuch auf das postoperative Wohlbefinden und die Mobilität nach chirurgischen Darmeingriffen im Rahmen des ERAS (Enhanced Recovery After Surgery) Konzeptes
	263	Erbitux		Nicht interventionelle Studie zur Effizienz von ERBITUX in der first-line Therapie bei Patienten mit metastasierendem Kolorektalkarzinom mit Wildtyp KRAS-Gen		Merck Serono	25.04.2011
	1436	ESPAC-6	2020-004906-79	An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature	3	Ruprecht-Karls-University Heidelberg, Medical	08.10.2021
	1384	ESSURE		ESSURE - European SIR-Spheres Surgical Registry Eine prospektive Registerstudie zur Leberresektion und Lebertransplantation bei primären und sekundären Lebertumoren nach selektiver interner Radiotherapie (SIRT)		Universitätsklinikum Köln
	963	ESTOIH		Short Stitch Versus Long Stitch Suture Technique Using Monomax® for Abdominal Wall Closure After Primary Median Laparotomy. A Randomized, Controlled, Double-blinded, Multicenter, International Trial		Aesculap AG	09.09.2016
	1037	Exsosomei HCC		Es vivo Nachweis von Exosome in Leberkarzionompatienten			26.09.2016	31.03.2020
	676	FC-005	2014-000816-32	A Phase 3B, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps and Tachosil in Surgical Hemostasis during Hepatic Resection	3	The Medicines Company	17.10.2014	12.08.2015
	883	Flot 7 (RAMES)	2015-003118-26	Perioperative Therapie mit Ramucirumabin Kombination mit FLOT vs. FLOT allein bei operablem Magenkarzinom und Adenokarzinom des ösophagogastralen Überganges- eine Phase II/III Studie AIO	2/3	IKF GmbH	26.04.2016
	1234	GAIN Studie	2017-004444-38	Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin followed by radical liver resection versus radical liver resection olone in incidentally detected resection of BTC (ICC/ECC)	3	IKF
	257	GAST-05		Therapie des lokal fortgeschrittenen Rektumkarzinoms (UICC II und III) im oberen Rektumdritten (12-16 cm ab Anokutanlinie) mittels qualitätsgesicherter totalter (TME) versus partieller mesorektaler Exzision (PME) gefolgt von adjuvanter Chemotherapie (5-FU + Folinsäure + Oxaliplatin)	2	Universitätsklinik Göttingen	01.01.2009
	1296	Global Surg-COVID		Global Surg-Covid Surg Week: Determining the optimal timing for surgery following SARS-CoV-2 infection		University of Birmingham	23.10.2020	30.11.2020
	890	HCCIS	N /A	Prospektive, multizentrische Studie zur Evaluation des Hepatocellular Carcinoma Immune Score als prognostischen Faktor des Gesamt- und erkrankungsfreien Überleben von Patienten nach Resektion eines hepatozellulären Carcinoms		Universitätsklinikum Regensburg	01.06.2016	28.02.2022
	1381	KOMIGRA_1		Diagnostik des kolorektalen Karzinoms bei Migrantinnen und Migranten in Deutschland: Tumorstadium zum Diagnosezeitpunkt im Vergleich zu Nicht-Migranten		UKF, Institut für Allgemeinmedizin	13.06.2013	21.12.2015
	1239	LEX-209	2016-002649-41	Eine randomisierte , doppelblinde, multizentrische Phase III-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Octaplex einem Prothrombinkomplex-Konzentrat mit 4 Faktoren, im Vergleich zu 4F-PCC Beriplex bezüglich der Aufhebung des gerinnungshemmenden Effekts durch VItamin K - Antagonisten bei Patienten mit dringlichem Operationsbedarf und signifikanten Blutungsrisiko	3	OCTAPHARM	17.07.2017	28.06.2018
	462	LICC	2011-000218-20	LICC: L-BLP25 in Patienten mit kolorektalem Karzinom nach kurativer Lebermetastasenresektion – eine randomisierte, plazebokontrollierte, multizentrische, multinationale, doppelblinde Phase II Studie	2	iOMEDICO	21.09.2011
	262	ML 22011 Studie	2009-013099-38	Erstlinien Therapie beim metastasierten Kolorektalkarzinom	3	Klinikum der Universität München Campus Großh	24.09.2010
	260	MT 201-204	2008-004706-14	A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to standard FOLFOX after R0 resection of colorectal liver metastases	2	Micromet AG	08.12.2008	06.02.2009
	261	Panter Studie	2008-005312-41	Prospektive,randomisierte, 2-armige Multicenterstudie zum Vergleich einer perioperativen Chemotherapie (FOLFOX ggf. plus Cetuximab mit einer adjuvanten Chemotherapie (FOLFOX ggf. plus Cetuximab) bei Patienten mit resektablen kolorektalen Lebermetastasen	2	Charité Berlin	31.05.2011	24.02.2015
	884	PARLIM	2010-023671-26	Panitumab nach Resektion von Lebermetastasen des kolorektalen Karzinoms bei Patienten mit RAS -Wildtyp	2	Universitätsklinikum München	19.08.2011
	1258	Phasix		A Post Market Prospetive, Multicenter Single Arm Clinical Investigation of Phasix Mesh for VHWG Grad 3 Midline Hernia Repair			26.10.2016	27.11.2019
	268	PMR-EC 1106 (Diamond-Studie)	2008-002231-32	Multizentrische, dreiarmige, randomisierte, offene klinische Studie zum Vergleich d. Nierenfunktion bei Lebertransplantierten Pat., die eine immunsuppressive Therapie mit Advagraf und MMF mit oder ohne einem monoklonalen Anti-IL2R Antikörper erhalten.	4	Fa. Astellas	19.06.2009	24.11.2011
	768	POLO	2014-001589-85	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study Mainténance Olaparib Monotherapy in Patients with gBRCA Mutatted Metastatic Pancreatic Cancer whose Diesease Has Not Progressed on First Line Platinum Based Chemotherapy	3	Astra Zeneca	10.02.2015
	1386	PreMAPP		PreMAPP: Prospektive Erhebung des (multi)-resistenten Erregerspektrums bei der akuten Appendizitis
	1374	Protego Maxima		Eine Pilotstudie zur Untersuchung der Gebrauchstauglichkeit, der Validität und der Sicherheit einer interventionellen App-basierten strukturierten Prähabilitation vor großen chirurgischen Eingriffen (PROTEGO MAXIMA)		Goethe-Universität Frankfurt
	668	RELY Trial	N/A	Resection of colorectal liver metastases with or without routine hilar lymphadenectomy		Heidelberg University	01.05.2014
	1309	Schilddrüse		Vergleichende Untersuchung zur Lebensqualität von Patienten mit Schilddrüsenknoten nach Operation oder Radiofrequenzablation		Goethe-Universität Frankfurt	01.03.2017
	266	Silver05	2005-005362-36	A prospective randomised, open-labeled, Trial comparing Sirolimus-containing versus mTOR-Inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma	3	Regensburg University Medical Center	01.01.2006	31.12.2009
	461	Socrates	2007-000730-40	Phase II Studie zur Untersuchung von transarterieller Chemoembolisation (TACE) in Kombination mit Sorafenib zur Behandlung des fortgeschrittenen Leberzellkarzinoms (HCC)	2	Heinrich-Heine Universität, Düsseldorf	18.07.2007	15.09.2010
	1249	TOM		Prospektive, multizentrische, vergleichende Studie des Rekurrenz-freien Überlebens nach Lebertransplantation in zwei Tumorstadium-definierten Gruppen (INOs T2 versus Milan out/ UCSF-in) von Patienten mit hepatozellulärem Karzinom (HCC) in Zirrhose und lokoregionärer Therapie zur Überbrückung der Wartezeit		UKSH. Campus Kiel	17.08.2020	28.02.2021
	1295	TONIG		Total versus "near-total" Thyreoidektomie zur chirurgischen Therapie der Autoimmunthyreopathie Typ Basedow - Eine prospektive randomisierte multizentrische Studie zur Evaluierung des transienten Hypoparathyreoidismus		Uni Marburg	02.03.2016	27.08.2017
	625	TUD-CELIM2-050 (CELIM 2)	2011-003288-31	Cetuximab/FOLFIRI mit oder ohne Oxaliplatin und FOLFOXIRI mit oder ohne Bevacizumab als neoadjuvante Behandlung von nicht-resektablen kolorektalen Lebermetastasen.	2	Technische Universität Dresden	04.06.2012	02.01.2020
Diabetologie
	1181	EMR200109-619	2010-022677-34	nfluence of high dose vitamin D substitution on humoral immunity and lymphocyte function in patients with type 1 diabetes mellitus or Addison´s disease (ViDDA1)		Goethe-Universität Frankfurt	22.09.2011	31.12.2013
	1198	FINNjA-DM	2008-007667-17	Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitus	3	Goethe-Universität Frankfurt	19.02.2009	23.03.2013
	1185	Illivit	2016-004488-38	Iluvit - Eine Investigator-initiierte, monozentrische Pilotstudie zur Untersuchung von Entzündungs- und Wachstumsparametern im Glaskörpermaterial während einer Kortison-Langzeittherapie (Iluvien®) bei Patienten mit chronischem diabetischem Makulaödem Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients with chronic diabetic macular edema	3	Goethe-Universität Frankfurt	01.09.2018	04.10.2019
FA Kinder- und Jugendmed. allg.
	1074	9766-CL-0107	2018-003975-36	A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects	2	Astellas	30.09.2019
	1361	CAR-T-Zell-Studie Frankfurt 2020		Zusammenhang von T-Zell-Funktionsparametern vor CAR-T-Zell-Produktion mit dem anschließenden Herstellungserfolg und immunologisches Monitoring bei pädiatrischen Patienten		Goethe-Universität Frankfurt
	1262	CCTL019G2201J	2017-002116-14	A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy	2	Novartis	04.08.2020
	1216	ET13-002	2013-002766-39	SIOP Ependymoma Program II - An international Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma	2/3	Centre Leon Berard in Lyon (Frankreich)
	1201	FRA.GHAT.2009	2009-015739-34	Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)	4	Goethe-Universität Frankfurt		31.08.2012
	1200	FRA.LOS.2007	2007-004541-15	A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma	4	Goethe-Universität Frankfurt		08.02.2011
	1317	IDUNN-MSC	2019-001462-15	A Randomised, open-label, multicentre, Phase 3 Trial of First-line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid-refractory Acute Graft-versus-host disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)	3	Medac Gesellschaft für klinische Spezialpräpa	24.09.2020
	726	INFORM Register		IN­FORM In­di­vi­dua­li­zed The­ra­py	4	Universitätsklinik Heidelberg	01.02.2015
	1261	JCAR017-BCM-004	2018-001246-34	A Phase 1/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL und B-NHL	1/2		09.09.2020
	1206	MAGIC		Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository
	1072	Micro-RNAs		Micro-RNAs als neue Biomarker für intrakranielle Keimzelltumoren		Universitätsklinikum Bonn	07.11.2019
	1311	ML DS 2018	2018-002988-25	Phase II/III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018	2/3		22.02.2021
	1215	NB with SCI		PROSPECTIVE STUDY REGISTRY OF PERIPHERAL NEUROBLASTIC TUMOURS PRESENTING WITH SPINAL CANAL INVOLVEMENT (SCI)		Associazione Italiana Ematologia Oncologia Pe
	683	NV25719	2012-002633-11	an open label, randomized, adaptive, two-arm, multicenter trial to evaluate Pharmacokinetics and Pharmacodynamics of two doses of oseltamivir (TamifluR ) in immunocompromised children, from 2 weeks to less than 13 years of age, with confirmed influenza infection.	1	Roche	19.09.2014	07.08.2018
	1073	RG_13-277	2014-000259-99	rEECur - International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	2	University of Birmingham
	704	STEP seltene Tumore		Seltene Tumorerkrankungen in der Pädiatrie (STEP) Register zur Erfassung von seltenen Tumoren bei Kindern und Jugendlichen		Deutsche Kinderkrebsstiftung	31.10.2012
	1214	Treosufan-nicht-maligne MC-FludT.16/NM	2013-005508-33	Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases
Gyn SP Onkologie
	952	CLSZ102X2101	2015-004016-38	A PHASE I/IB, OPEN LABEL STUDY OF LSZ102 SINGLE AGENT AND LSZ102 IN COMBINATION WITH EITHER LEE011 (LSZ102 + LEE011) OR BYL719 (LSZ102 + BYL719) IN PATIENTS WITH ADVANCED OR METASTATIC ER+ BREAST CANCER WHO HAVE PROGRESSED AFTER ENDOCRINE THERAPY	1	Novartis	12.04.2016	30.11.2020
	1044	AGO-OP.6 (ECLAT)		Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence		Philipps-Universität Marburg	02.07.2018
	1377	BREVITY-02		RNA Disruption Assay (RDA) - Breast cancer Response EValuation for Individualized TherapY-02 (BREVITY-02)		RNA Diagnostics	26.04.2018
	1042	D081RC00001 (DUO-O)	2017-004632-11	A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients	3	AstraZeneca AB	14.02.2019
	896	DETECT III	2010-024238-46	A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs (DETECT III)	3	Universität Ulm
	1066	GeparDouze	2017-002771-25	Randomisierte, doppelblinde Phase III Studie zur Untersuchung von Atezolizumab oder Placebo in Kombination mit einer neoadjuvanten Chemotherapie gefolgt von einer adjuvanten Monotherapie mit Atezolizumab oder Placebo bei triple-negativem Brustkrebs (TNBC)	3		03.04.2018
	1316	SASCIA	2019-004100-35	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment	3	GBG Forschungs GmbH	27.07.2020
Gyn./Geburtshilfe allg.
	1110
	564	PRESENT	2011-005219-98	Prevention of recurrence in early-stage, node-positive breast cancer with low to intermediate HER2 expression with NeuVax treatment	3	Galena Pharma	27.02.2013
	670	AGO 2.23 SOLO-2	2013-001211-75	Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy	3	AGO Wiesbaden	01.06.2014	27.11.2014
	387	AGO-GYN 8	2011-000299-33	Wirksamkeit, Verträglichkeit und Sicherheit von Temsirolimus beim Platinrefraktären Ovarialkarzinom und beim fortgeschrittenen oder rezidivierten Endometriumkarzinom	2	AGO	12.09.2011	11.03.2015
	465	AGO-GYN-7	2008-000245-55	Eine Phase II Studie zum Einsatz der Kombinationschemotherapie PegLiposomales Doxorubicin (PLD) und Carboplatin bei gynäkologischen Sarkomen und gemischt mesenchymalen Tumoren	2	AGO	24.06.2008	24.11.2011
	464	AGO-GYN5	2007-002663-26	AEZS -108 bei Frauen mit gynäkologischen Tumoren die den LHRH-Rezeptor LHRHRezeptor exprimieren	2	Aeterna Centaris GmbH Frankfurt	05.12.2007	10.08.2011
	466	AGO-OVAR 16	2008-004672-50	Eine Phase III Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Pazopanib-Monotherapie im Vergleich zu Placebo bei Frauen mit einem nach Firstline-Chemotherapie nicht fortgeschrittenen epithelialen Eierstock-, Eileiter- oder primären Bauchfellkarzinom	3	GlaxoSmithKline Research & Development Ltd	10.06.2009	23.10.2017
	584	AGO-OVAR 18 ( TRINOVA-3)	2011-001112-53	A phase 3 randomized,. Double blind, placebo-controlled, multi center study of AMG 386 with paclitaxel and carboplatin as first-line treatment of subjects with FIGO stage III-IV epithelial ovarian, primary peritoneal or fallopian tube cancers	3	Amgen	18.07.2012	02.12.2016
	889	AGO-OVAR 19		Eine prospektive randomisierte multizentrische Studie zur primären radikalen Operation vs. Intervalldebulking Operation bei fortgeschrittenem Ovarialkarzinom mit Erweiterung zur Evaluation von Fragilität und Lebensqualität		AGO Wiesbaden	21.06.2017	24.10.2022
	583	AGO-OVAR 2.19 (TRINOVA-2)	2009-017946-30	A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	3	Amgen	14.11.2011	18.08.2016
	582	AGO-OVAR 2.21	2012-004125-24	Eine prospektive, randomisierte klinische Phase III Studie zur Prüfung von Carboplatin/Gemcitabin/ Bevacizumab vs. Carboplatin/pegyliertes liposomales Doxorubin/ Bevacizumab bei Patientinnen mit platinsensiblen rezidivierendem Ovarialkarzinom.	3	AGO Wiesbaden	10.04.2013
	783	AGO-OVAR 20 PAOLA-1	2014-004027-52	Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance	3	AGO Wiesbaden	30.11.2015
	467	AGO-OVAR-10 (MIMOSA)	2006-002801-30	Eine randomisierte, doppelblinde, Placebo kontrollierte, multizentrische Studie mit Abagovomab als Erhaltungstherapie bei Patientinnen mit epithelialem Ovarialkarzinom und kompletter Remission nach erfolgter Primärchemotherapie.	2	AGO	27.02.2007	30.06.2011
	468	AGO-OVAR-11 (ICON-7)	2005-003929-22	Eine multizentrische randomisierte, zweiarmige Phase-III Studie zum Vergleich von Carboplatin/Paclitaxel und Bevacizumab versus Carboplatin/Paclitaxel in der Primärtherapie von Patientinnen mit epithelialem Ovarialkarzinom.	2	AGO	15.03.2007	28.06.2013
	469	AGO-OVAR-12	2008-006831-10	Randomisierte, multizentrische, doppel-blinde, placebo-kontrollierte Phase III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von BIBF1120 (VargateTM: Triple Angiokinase-Inhibitor: VEGFR, PDGFR, FGFR) in Kombination mit der Standardchemotherapie Carboplatin/Paclitaxel.	3	Boehringer Ingelheim Pharma GmbH & Co. KG	16.09.2009	15.09.2016
	391	AGO-OVAR-17 (Boost)	2011-001015-32	A multi-centre, open labeled, randomised, two-arm Phase III trial to evaluate optimal treatment duration of first-line bevacicumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer	3	Hoffmann La Roche Ltd.	15.11.2011
	393	AGO-OVAR-OP.3 (LION)		Lymphadenektomie in ovariellen Neoplasien		AGO	01.12.2008	06.12.2016
	394	AGO-OVAR-OP.4 (DESKTOP III)		Eine randomisierte, multizentrische Studie zum Vergleich der Wirksamkeit einer zusätzlichen Tumordebulking-Operation gegen eine alleinige Chemotherapie bei Patientinnen mit einem platin-sensiblen Ovarialkarzinom-Rezidiv	3	AGO	23.03.2010
	392	AGO-OVAR2.16 (MITO-8)	2008-001755-22	Pegyliertes liposomales Doxorubicin versus Carboplatin / Paclitaxel bei Patientinnen mit Ovarialkarzinomrezidiv sechs bis zwölf Monate nach Primärtherapie	3	Hoffmann La Roche Ltd.	27.10.2010	20.08.2013
	803	AGO-TR1		INCIDENCE OF BRCA IN PATIENTS WITH PRIMARY OR PLATINUM SENSITIVE RECURRENT OVARIAN CANCER.		AGO Wiesbaden	18.06.2015
	470	AGO-Zervix 1	2006-000349-20	Paclitaxel &Topotecan vs. Topotecan & Cisplatin bei rezidivierten Zervixkarzinom	3	Institut fuer Frauengesundheit GmbH	11.10.2006
	543	Aphinity	2010-022902-41	A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer	3	Roche	18.01.2012
	1394	Aphinity	2010-022902-41	A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer	3	Roche	18.01.2012	19.12.2016
	665	ARIEL-3	2013-000518-39	A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3)	3	Clovis	27.02.2014
	1395	Astefania	2020-003681-40	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy	3	Roche	01.03.2021
	886	BCP - Breast Ca Preg	N/A	Prospektive Registerstudie zur Diagnostik und Therapie des Mammakarzinoms in der Schwangerschaft		N/A
	389	BCP - Breast Cancer in Pregnancy		Prospective and Retrospective Register Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy		GBG Forschungs GmbH	01.04.2003
	586	BELLE-3	2011-005524-17	Randomisierte, doppelblinde, Placebo-kontrollierte Phase-III-Studie von BKM120 in Kombination mit Fulvestrant bei postmenopausalen Frauen mit Hormonrezeptor-positivem, HER2-negativem, AI-behandeltem, lokal fortgeschrittenem oder metastasiertem Brustkrebs mit Progression während oder nach Behandlung mit mTOR-Inhibitoren.	3	Novartis	22.10.2012	09.01.2015
	471	BETH	2007-005182-35	Behandlung von Pat. mit HER2-positivem Mammakarzinom mit Chemotherapie plus Trastuzumab vs Chemotherapie plus Trastuzumab und Bevacizumab	3	NSABP	20.06.2008	17.04.2014
	472	BMS-690514	2008-004691-44	Open-label randomisierte zweiarmige Studie zum Vergleich der Wirksamkeit von BMS-690514 + Letrozol mit Lapatinib + Letrozol bei rezidiviertem oder metastasiertem Mammakarzinom	2	Bristol Myers Squibb	02.02.2010	29.10.2010
	473	BOLERO-3	2008-008697-31	Randomisierte doppelblinde placebokontrollierte Mutizenterstudie zur Wirksamkeit von Everolimus in Kombination mit Tratsuzumab und Vinorelbine bei vorbehandelten Frauen mit Her2neu-positivem metastasierten Mammakarzinom	3	Novartis Pharma Services AG	12.11.2009	11.06.2015
	810	C-Patrol		A Single Arm, Prospective Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population		Astra Zeneca	11.01.2016
	1077	CA209-7A8	2019-001334-34	Randomized, Non-comparative Neoadjvant Phase II Study in postmenopausal women with ER+/Her2- Breast cancer >=2 cm with safety-run in, Asessing Nivolumab + Abemaciclib or Palbociclib + Anastrozol	2	Bristol Myers Squibb	27.01.2020	07.05.2021
	1078	CA209-7FL	2019-002469-37	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer	3	Bristol Myers Squibb	27.01.2020
	1079	Chemobrain in motion		Chemobrain in Bewegung - Zum Einfluss verschiedener Chemotherapie begleitender Bewegungsprogramme auf krebsassozierte kognitive Einschränkungen bein Brustkrebspatientinnen - eine randomisierte Studie	3		14.05.2019	01.05.2021
	869	D-Care	2009-011299-32	A randomized, double blind, placebo-controlled, multi-center phase III study of denosumab as adjuvant treatment for women with early -stage breast cancer at high risk of recurrence (D-Care).	3	Amgen	08.02.2011	30.08.2021
	1282	EURBREAST3 (AXSANA)		European prospective multicenter registry on axillary surgical techniques after neoadjuvant chemotherapy		Axsana
	585	EVELYN (GBG76 )	2012-004937-17	Eine multizentrische, randomisierte doppelblinde, placebokontrollierte Phase-III-Studie zum Vergleich einer alleinigen endokrinen Behandlung mit einer endokrinen Behandlung mit Everolimus bei Patienten mit HR-positivem/HER2-negativem metastasiertem Brustkrebs und einem Fortschreiten der Erkrankung nach einer vorherigen Behandlung mit Exemestan und Everolimus	3	GBG	08.08.2013	16.07.2014
	474	Fabre 308	2009-011118-47	Phase III-Studie zur Wirksamkeit von Vinflunin versus alkylierende Substanzen bei Patientinnen mit metastasiertem mammakarzinom nach Behandlung mit Anthrazyklinen, Taxan, Antimetaboliten und Vincaalkaloid	3	PIERRE FABRE MEDICAMENT	03.09.2009	16.01.2014
	519	GAIN II	2011-005214-11	Adjuvant Phase III Trial to Compare Intense Dose-dense Adjuvant Treatment With EnPC to Dose Dense, Tailored Therapy With dtEC-dtD for Patients With High-risk Early Breast Cancer (GAIN-2)	3	GBG	10.08.2012	07.01.2019
	640	GENEVIEVE	2012-003330-16	Eine randomisierte, offene, Phase II Studie zum Vergleich der Effektivität und Sicherheit von Cabazitaxel mit wöchentlich gegebenem Paclitaxel als neo-adjuvante Behandlung von Patienten mit operablem Triple-Negativem oder Luminal B/HER2 normalem Mammakarzinom (Genevieve)	2	GBG	06.12.2012	31.05.2017
	475	GeparQuinto	2006-005834-19	Ein Phase III Studienprogramm zur Kombination von Bevacizumab, Everolimus (RAD001) oder Lapatinib mit einer neoadjuvanten Chemotherapie bei primärem Mammakarzinom	3	GBG Forschungs GmbH	27.10.2007	15.10.2015
	476	HKI-272 (Wyeth 3004)	2008-007345-31	Randomisierte doppelblinde placebokontrollierte Studie zur Wirksamkeit von Neratinib (HKI-272) nach Trastuzumab bei Frauen mit primärem Her2neu positivem Mammakarzinom	3	Wyeth	10.08.2009	31.05.2012
	478	IBIS-II-DCIS	2004-003992-35	An international multi-centre study of tamoxifen vs anastrozole in postmenopausal women with Ductal Carcinoma in Situ (DCIS)	4	GBG	01.07.2003	31.05.2017
	477	IBIS-II-Prävention		Prävention von Brustkrebs mit Anastrozol bei postmenopausalen Frauen mit erhöhtem Brustkrebsrisiko oder DCIS	4	GBG	01.12.2003	31.05.2017
	901	Impassion 131	2016-004024-29	A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER	3	F. Hoffmann-La Roche Ltd	04.07.2017	15.12.2021
	897	IMPROVE	2013-005329-22	An open label, randomized controlled prospective multicenter two arm phase IV trial to determine Patient preference for everolimus in combination with exemestane or capecitabine in combination with beeacizumab for advanced (inoperable or metastatic) HER2 -negative hormone receptor positive breast cancer	4	iOMEDICO AG	19.08.2014
	807	INSEMA		Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial.		University of Rostock	15.01.2016
	200	Intraoperative Radiotherapie des Tumorbettes beim kleinen Mammakarzinom (Targit)		Targit_1 (Paed.) An international randomised controlled trial to compare targeted intra-operative radiotherapy with conventional post-operative radiotherapy after conservative breast surgery for women with early stage breast cancer	3			31.03.2012
	544	Katherine (TDM-1)	2012-002018-37	A randomized, multicenter, open-label Phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with her2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy.	3	Roche	22.02.2013
	390	LACACYT	2009-012706-39	Multizentrische einarmige Studie mit Lapatinib (oral) in Kombination mit Capecitabin (oral) und intrathekal administriertem liposomalen Cytarabin für die Behandlung von meningeal metastasiertem Mammakarzinom	2	GlaxoSmithKline	09.11.2009	26.11.2013
	587	LILAC	2012-004319-29	Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)	3	Amgen	25.04.2013	24.11.2016
	898	MONALEESA-3	2015-000617-43	A randomized double-blind, placebocontrolled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment	3	Novartis Pharma Services AG	28.05.2015
	844	Myeloconcept	2015-003610-25	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-DESIGN, MULTI-CENTRE STUDY TO INVESTIGATE THE EFFICACY TO REDUCE CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN), EFFECTS ON THE HAEMATOPOIETIC SYSTEM, SAFETY AND PHARMACOKINETICS OF MYELO001 IN PATIENTS RECEIVING ADJUVANT OR NEOADJUVANT CHEMOTHERAPY FOR TREATMENT OF BREAST CANCER	2	Myelo Therapeutics GmbH	09.12.2015	20.11.2017
	666	NIS-BRAWO	N/A	Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women (CRAD001JDE53)		Novartis	15.06.2014	01.04.2019
	621	ONCO-RD 017		Prospektive exploratorische Beobachtungsstudie zur Auswertung spezifischer Biomarker beim primäreninvasiven Brustkrebs und deren Modulation durch eine neoadjuvante Standardtherapie.		GlaxoSmithKline	13.04.2011	09.04.2014
	1339	PERFORM		PERFORM: An EPidEmiological, PRospective Cohort Study to Generate Real-world Evidence in Patients With HR+/HER2- Advanced Breast Cancer Treated in the First-line Setting as per Current Standard Of Care With an EndocRine-based Palbociclib CoMbination Therapy		Pfizer
	724	PIKTAM	2014-000599-24	Moleculary stratified group phase II trial of the phosphoinositide-3-kinase (PI3K) inhibitor BKM 120 in combination with tamoxifen in patients with hormone receptor positive, HER2-negative inoperable (locally advanced or metastatic) breast cancer with prior exposure to antihormonal therapy	2	Universitätsklinikum Essen, Westdeutsches Tum	18.12.2014	18.10.2017
	680	Praegnant (S565)	2014-000854-12	PROSPECTIVE ACADEMIC TRANSLATIONAL RESEARCH NETWORK FOR THE OPTIMIZATION OF THE ONCO-LOGICAL HEALTH CARE QUALITY IN THE ADJUVANT AND ADVANCED/METASTATIC SETTING: HEALTH CARE RESEARCH, PHARMACOGENOMICS, BIOMARKERS, HEALTH ECONOMICS		Universitätsklinikum Tübingen	10.11.2014	04.12.2019
	900	RIBECCA	2016-002556-24	A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole	3	Novartis Pharma GmbH	14.10.2016
	1312	Tesaro Ruby	2019-001576-11	Eine randomisierte, doppelblinde, multizentrische Phase-3-Studie mit Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel im Vergleich zu Placebo plus Carboplatin-Paclitaxel bei Patienten mit rezidivierendem oder primär fortgeschrittenem Endometriumkarzinom (RUBY)	3	Tesaro
	388	TIFFANY	2011-000075-13	Eine multizentrische nicht-randomisierte Phase II Studie zur Bewertung von albumingebundenem Nab-Paclitaxel bei metastasiertem Mammakarzinom und vorausgegangener (neo)-adjuvanter Behandlung mit einem lösungsmittelbasierten Taxan	2	GBG	20.06.2011	20.09.2013
	581	TRIO-022	2012-004601-27	A Randomized, Multicenter, Double-Blind Phase 3 Study Of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease	3	Pfizer	17.07.2013	23.05.2014
	1332	WO42633	2020-003681-40	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy	3	Roche	08.02.2021
	1356	WO42633	2020-003681-40	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy	3	Roche	08.02.2021
	408	WT-1	2010-019909-42	Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase I/II zur Beurteilung der Sicherheit, Immunogenität und klinischen Wirksamkeit von WT1-A10 + AS15 ASCI in Kombination mit einer Standardtherapie als neoadjuvante Behandlung bei Patienten mit WT1-positivem Brustkrebs im Stadium II oder III	1/2	GlaxoSmithKline	12.01.2011	09.04.2014
Hämostaseologie
	1438	CT-AMT-060-04	2020-000739-28	A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.	1/2	CSL Behring LLC	19.11.2020
	1413	FORMA-07		Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency	4	OCTAPHARM	17.03.2021
	1439	PRN1008-018	2020-002063-60	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (EFC17093)	3	Principia Biopharma, Inc.	12.11.2020
	1444	TTP_Register_Bern		Thrombotic Thrombocytopenic Purpura Registry - A prospective observational study for patients suffering from hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman Syndrome)		Inselspital, Universitätsklinikum Bern	23.03.2017
Haut- u Geschlechtskrankheiten
	522	MIKIE	2012-003305-10	A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas	2	Roche	03.04.2013	19.07.2016
	1202	APPEAR		A Post Market Prospective Study of FORTIVA® 1mm Porcine Dermis (APPeaR)		RTI Surgical Inc.	14.01.2020
	246	BRAF (MO22515)	2010-023526-21	Zweit-/ Mehrlinientherapie mit Vemurafenib in Patienten mit fortgeschrittenem metastasierten malignen Melanom	3	Roche	13.04.2011	16.02.2015
	521	BRIM-8	2011-004011-24	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence	3	Roche	16.01.2013	05.04.2018
	202	BRIM3	2009-012293-12	BRIM3: Eine randomisierte, offene, kontrollierte, multizentrische Phase III Studie in unbehandelten Patienten mit nicht resezierbarem Melanom (Stadium IIIC oder Stadium IV) mit V600E BRAF Mutation zur Behandlung mit RO5185426 oder Dacarbazin	3	Hoffmann La Roche AG	10.02.2010
	203	c-Kit AB08026	2009-017918-69	Offene Phase III Studie zur Beurteilung der Wirksamkeit und Sicherheit von Masitinib in Patienten mit nicht-resezierbaren Melanom (Stage III/IV) und einer c-Kit Mutation.	3	AB Science	29.09.2010
	452	CA184143		Multinationale, prospektive Beobachtungsstudie an Patienten mit nicht reserzierbaren oder metastasierenden Melanomen	4	Bristol-Myers Squibb	08.11.2012
	718	CA209172	2014-001286-28	A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab(BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody	2	Bristol Myers Squibb	05.11.2014	07.05.2018
	205	ChemoSensMM	2008-001686-28	Kombinationstherapie vs. Monotherapie bei fernmetastasiertem Melanom	2	University of Schleswig-Holstein	24.06.2008	16.10.2008
	757	CLFX453X2201	2014-003613-28	A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis	2	Novartis	06.03.2015	27.01.2016
	575	COLUMBUS	2013-001176-38	A Phase III randomized, 3-arm, partially blinded, placebo controlled, multicenter, study of the Combination of LGX818 plus MEK162 compared with vemurafenib, and of LGX818 compared with vemurafenib for the treatment of patients with unresectable stage IIIB, IIIC or Stage IV melanoma with BRAF V600 mutation	3	Novartis	04.02.2014
	245	DeCOG –MM-PAL11 (Ipilimumab Multibasket )	2010-021946-22	Offene Studie zur Behandlung des metastasierten Melanoms mit Ipilimumab	2	Universitätsklinikum Essen	05.11.2011
	201	DERMA MAGE-A3	2008-002447-16	Adjuvante Immuntherapie im Melanom bei Patienten mit makroskopischer Beteiligung der Lymphknoten	2	GlaxoSmithKline	11.12.2008
	206	H 1005 6002-0702 (Allmirall AK)	2007-003889-18	Studie zur Wirksamkeit von Verrumal verglichen mit Placebo und Solaraze in der Behandlung von aktinischen Keratosen Grad I bis II	3	HERMAL Kurt Herrmann GmbH & Co.OHG	08.05.2008	07.10.2009
	208	H 569 000 – 1004 (Diclo II)	2010-022244-20	Doppelblinde, randomisierte, Placebo- und Vergleichsprodukt kontrollierte Studie zur Behandlung von aktinischen Keratosen mit LAS41007	3	Almirall S.A	07.10.2010	16.07.2012
	207	LEIDA	2007-004884-24	Langzeitwirkung von Aldara 5% Creme und Solaraze 3% Gel bei der Behandlung von aktinischen Keratosen im Gesicht oder auf der Kopfhaut	4	MEDA Pharma GmbH & Co.KG	15.08.2008	20.11.2012
	247	LEIDA II	2010-022054-16	Langzeitwirkung von Aldara 5% Creme und Solaraze 3% Gel bei der Behandlung von aktinischen Keratosen im Gesicht oder auf der Kopfhaut	4	MEDA Pharma GmbH & Co.KG	21.06.2011
	771	LEO AK 0041	2014-003218-98	Efficacy and safety of ingenol mebutate gel 0.015% compared to diclofenac sodium gel 3% in subjects with actinic keratoses on the face or scalp	4	Leo Pharma	26.03.2015
	823	Lipo-MERIT	2013-001646-33	Clinical first-in-human dose escalation study evaluating the safety and tolerability of intravenous administration of a tetravalent RNA-lipoplex cancer vaccine targeting the tumor-associated antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in patients with advanced melanoma	1	BioNTech	24.03.2015
	822	LP0084-1196	2015-002452-27	Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp including 12-month follow-up	3	Leo Pharma	28.12.2015	27.10.2017
	690	MELANIE		Melanoma in Expert Centers		Novartis	14.01.2014	30.09.2014
	719	MK-3475-030		Expanded Access of Pembrolizumab (MK-3475)in Metastatic Melanoma Patients With Limited to No Treatment Options	4	MSD	13.10.2014	01.12.2018
	386	MO25616 (STEVIE)	2011-000195-34	A single arm, open-label, phase II, multicentre study, to assess the safety of vismodegib (GDC-0449) in patient with locally advanced or metastatic basal cell carcinoma (BCC)	2	Hoffmann La Roche Ltd.	21.06.2011
	463	MO25743	2011-000954-46	An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of Vemurafenib in metastatic melanoma patients with brain metastases	2	F. Hoffman-La Roche Ltd.	28.06.2011	05.06.2015
	660	NEMO	2012-003593-51	The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma	3	Novartis	07.06.2013	02.05.2019
	524	PD-1	2012-001828-35	A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigators Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy	3	Bristol Myers Squibb	06.03.2013
	204	Sentinel Studie		Vergleich einer radikalen Lymphadenektomie versus Beobachtung bei Patienten mit malignem Melanom ≥ 1,0 mm Tumordicke und positiver Wächter-Lymphknotenbiopsie	3	Arbeitsgemeinschaft Dermatologische Onkologie	15.01.2006
	750	T-VEC	2013-005552-15	A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec	2	Amgen	12.03.2015	16.12.2020
	1196	Validel / JWGZDVDT0107	2007-006272-11	Validation of Dermatophot for the assessment of steroid induced skin atrophy	4	Goethe-Universität Frankfurt
HNO
	450	FraDySc		Entwicklung und Validierung des Frankfurter Dysphagie Screenings (FraDySc) für Patienten mit Kopf-Hals-Tumor nach Tumorresektion			25.10.2010
	679	KTPLaryLas		Phase III-Studie zu Rezidivfreiheit und Stimmfunktion nach transoraler KTP-Laserbehandlung bei Frühformen des Larynxkarzinoms	3	Klinik für Hals-, Nasen-, Ohrenheilkunde	25.02.2010	28.02.2014
	197	Paradigm-Studie	2006-007076-15	A Randomized Phase III Trial Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatin-Based Chemoradiotherapy with Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced Squamous Cell Cancer of the Head and Neck	3	Noblewell Sp. Z.o.o (Hauptsponsor)	01.02.2008
	249	Tisoc-1-Studie	2009-011902-41	Phase I/II Studie zum Einsatz einer Split-dose TPF-Induktions- Chemotherapie vor Operation eines Oropharynx- oder Mundhoehlen- Tumors	1/2	Universitätsklinikum Jena	05.08.2009
	405	Tumor-Nachsorge		Erfassung von erkrankungs- und therapiebedingten funktionellen Beeinträchtigungen im Rahmen der Tumornachsorge bei Kopf-Hals-Tumoren		Klinik für Hals-, Nasen-, Ohrenheilkunde	01.07.2012
	248	Zalutumumab GEN205	2008-000582-39	An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinooma of the Head and Neck who Failed Standard Platinum-based Chemotherapy.	2	ICON Clinical Researsh Limited	25.11.2008	07.04.2011
Infektiologie
	1368		2021-002387-50	A Phase II, open-label, rollover trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 in	2		22.07.2021
	1146	DUALIS	2015-000360-34	A prospective, multicenter, randomized, open-label trial to assess the safety, tolerability and efficacy of dual therapy with boosted Darunavir + Dolutegravir when switching from standard of care ART in HIV-patients with sustained virological suppression	3	Technische Universität München Fakultät für M	05.06.2015
	1141	100% - Registry122	2011-000945-19	A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection	3	Gilead Sciences, Inc.	01.02.2014	01.02.2017
	1142	100% - Registry123	2011-000946-39	A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection	3	Gilead Sciences, Inc.	01.02.2014	01.02.2017
	1314	200&less Study		Antiretrovirale Initialtherapie bei Patienten mit geringer CD4+-Zellzahl und/oder AIDS-definierenden Erkrankungen		Universitätsklinikum Frankfurt, Zentrum für I
	1153	208132	2018-002208-15	A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults	2	ViiV Healthcare, S.L.	24.01.2019	26.02.2020
	1226	Adaptive COVID-19 Treatment Trial (ACTT)	2020-001052-18	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19	3	University of Minnesota	25.03.2020	28.12.2020
	1281	AEGON		Assessing the Impact of Antimicrobial Exposure and Infection Control Measures on the Spread of Vancomycin-resistant Enterococcus faecium (VREf) – A Prospective Study		DZIF
	1133	AI444-043	2011-003067-30	A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV).	3	Bristol Myers Squibb International Corporatio	01.01.2012	01.01.2014
	1137	Alere-Schnelltest		Evaluation of the Clinical Performance of Alere HIV Combo		Alere Medical Co., Ltd.	01.05.2013	01.06.2014
	1478	ALL POC-US TB		Abdominal and thoracic ultrasound for the diagnosis of pulmonary and extra-pulmonary tuberculosis. Assessing the accuracy of point-of-care ultrasound for the diagnosis and therapy monitoring in patients with presumed tuberculosis in India and Germany		Universität Heidelberg	01.03.2022
	1150	ATLAS	2016-001647-39	A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed	3	ViiV Healthcare UK Limited	28.10.2016
	1152	ATLAS2M	2017-002946-62	A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed	3	ViiV Healthcare UK Limited	22.12.2017
	1165	BESIDE		Evaluierung der Anwendung von Begleitmedikation und der Prävalenz von Begleiterkrankungen: Eine Querschnittsstudie bei HIV-Infizierten in Deutschland		Merck Sharp & Dohme Corp.
	1170	BICSTAR		Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF)		Gilead Sciences Europe Ltd
	1269	BNT162-01	2020-001038-36	A multi-site, Phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults	1/2	BioNTech RNA Pharmaceuticals GmbH	03.02.2021
	1298	BODEGA		Use of Bezlotoxumab for the Prevention Clostridium Difficile Infections within the German Health Care System – An Observational Post-authorization Study		Universitätsklinikum Frankfurt, Zentrum für I
	1470	BOOSTAVAC	2021-004889-35	An international Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timinig of and immunogenicity of administering a 4th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years alreadz vaccinated against SARS-CoV-2)	2	Universitätsklinikum Köln
	1304	BRAVA		Bridging Roche Antigen, Viral Load (PCR), and Antibody Tests: A Prospective Enrollment, Multi-Visit, Observational study		Roche Molecular Systems, Inc., USA	01.06.2021
	1148	BRIGHTE study	2014-002111-41	A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1	3	GlaxoSmithKline Research & Development Ltd	23.06.2015
	1467	C2C		COMBINE-2 for Cabotegravir + Rilpivirine LA Regimen - A prospective cohort study to monitor effectiveness, adherence and resistence	4	ViiV Healthecare	15.11.2022
	1238	CALAVI	2020-001644-25	A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19	2	Acerta Pharma B.V.	06.05.2020	17.11.2020
	1227	CALVID-1	2020-001264-28	A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19	2	Immunic AG	04.05.2020	23.02.2021
	1166	CAPNETZ		Epidemiologische Studie zur ambulant erworbenen Pneumonie		CAPNETZ STIFTUNG
	1279	CAPSID	2020-001310-38	A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19	2	DRK-Blutspendedienst Baden-Württemberg-Hessen
	1158	CAPSTONE 2	2016-002688-32	A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications	3	Shionogi Inc.	07.11.2017	20.04.2018
	1177	CASABI		Cefazolin versus flucloxacillin in bloodstream infections caused by methicillin-susceptible Staphylococcus aureus (MSSA): a quasi-randomized prospective observational study		Uniklinik Köln	01.10.2019
	1477	CELESTIAL		Clinical experience with letermovir for CMV-Prohhylaxis in Hemato-onocological Patients undergoing Allogeneic Stem Cell Transplantation: An Observational Study		Medical Affais	01.08.2028	12.12.2018
	1468	ClinSurv					01.04.2021
	1462	COVIC-19	2021-006621-22	A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen.	3	DRK-Blutspendedienst Baden-Wüttemberg-Hessen	02.09.2022
	1280	CRIT-COV-U01		Prospektive Validierung (Verlaufsbeobachtung) eines Urintests zur		Klinikum St. Georg gGmbH	01.08.2020
	1270	DAV132-CL-3001		A multicenter, randomized, placebo-controlled, parallel-arm clinical trial to evaluate the efficacy of DAV132 in preventing Clostridioides difficile infection in patients with newly diagnosed Acute Myeloid Leukemia or high-risk Myelodysplastic Syndrome treated with intensive chemotherapy.		Da Volterra
	1271	DZIF-10c Infusion	2020-003503-34	A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals	1/2	University of Cologne	01.12.2020	11.08.2021
	1272	DZIF-10c Inhalation	2020-004448-27	A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals	1/2	University of Cologne	01.12.2020	11.08.2021
	1307	EAGLE-1	2018-001780-23	Randomisierte, multizentrische, offene Phase-III-Studie mit jugendlichen und erwachsenen Teilnehmern zum Vergleich der Wirksamkeit und Sicherheit von Gepotidacin zu Ceftriaxon plus Azithromycin bei der Behandlung von durch Neisseria gonorrhoeae verursachter unkomplizierter urogenitaler Gonorrhoe	3	GlaxoSmithKline Research & Development Ltd	12.04.2021
	1117	ESPRIT	2004-00702-46	An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy	3	National Institute of Allergy and Infectious	01.03.2000	01.12.2008
	1366	EU-COVAT-1	2021-004526-29	A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines administration in older adults (>=75) already vaccinated against SARS-COV-2 (EU-COVAT-1_AGED)	2	Universität Köln	02.02.2022
	1370	EU-COVAT-1 AGED	2021-004526-29	A multinational, phase 2, randomised, adaptive protocol to assess immune response and side effects of different COVID-19 vaccines given in older adults (75 years and older) already vaccinated against SARS-CoV-2	2	University of Cologne	28.09.2021
	1164	EUROSIDA		HIV-Kohorte Europa		Rigshospitalet - University of Copenhagen	01.07.2014
	1176	FindHIV		Frühzeitige Identifikation mittels normierter Diagnosekriterien für die HIV-Infektion		Deutsche Arbeitsgemeinschaft niedergelassener	25.01.2019
	1151	FLAIR	2016-001646-25	A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants	3	ViiV Healthcare UK Limited	28.10.2016
	1132	Flamingo	2011-003629-86	A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects.	3	Viiv Healthcare	01.02.2012	01.02.2015
	1118	FLU002 Plus		An International Observational Study to Characterize Adults with Influenza or Other Targeted Respiratory Viruses		INSIGHT	01.01.2010	25.11.2016
	1120	FLU003 Plus		An International Observational Study to Characterize Adults Who Are Hospitalized with Influenza or Other Targeted Respiratory Viruses		INSIGHT	01.09.2009
	1157	FURI	2017-000381-29	Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment	3	SCYNEXIS, Inc.	05.07.2017
	1149	Gemini 2	2016-000459-28	A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults	3	ViiV Healthcare UK Limited	24.08.2016
	1464	GeoSentinel		Register study on diseases in returning travellers			31.10.2022
	1273	GI-COVID	2020-001654-21	Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia	2	Justus Liebig University Gießen	16.09.2020
	1138	GS-US-104-0423	2011-004420-35	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	3/4	Gilead Sciences, Inc.	01.10.2013	01.10.2014
	1122	GS-US-216-0114	2009-016759-22	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of	3	Gilead Sciences, Inc.	01.07.2010	01.07.2012
	1291	GS-US-216-0114	2009-016759-22	A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of	3	Gilead Sciences, Inc.	28.06.2010	16.04.2015
	1294	GS-US-236-0118	2011-000488-29	A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment	3	Gilead Sciences	02.08.2011	16.02.2015
	1139	GS-US-292-0109	2012-005114-20	A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects	3	Gilead Sciences, Inc.	01.03.2014	01.03.2016
	1140	GS-US-292-0117	2013-002830-19	A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults	3	Gilead Sciences, Inc.	27.11.2013	31.07.2017
	1161	GS-US-380-1489	2015-004024-54	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults	3	Gilead Sciences, Inc.	04.04.2016
	1163	GS-US-380-1490	2015-003988-10	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults	3	Gilead Sciences, Inc.	18.02.2016
	1147	GS-US-380-1878	2015-004011-20	A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults	3	Gilead Sciences, Inc.	01.03.2016	01.04.2019
	1162	GS-US-380-4030	2017-000308-17	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed	3	Gilead Sciences, Inc.	05.07.2017
	1457	Gut microbiome correlates of serious AIDS and non-AIDS events		MISTRAL (EuroSIDA)
	1458	Gut microbiome correlates of serious AIDS and non-AIDS events		MISTRAL (EuroSIDA)
	1129	HARNESS	2009-017032-41	An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on their Present Treatment Regimen	4	Bristol Myers Squibb International Corporatio	01.11.2011	01.11.2014
	1472	HDM-FUN -Candidemia	2020-003204-13	Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standar Therapy in Patients With Candedemia	2	Radboudumc University Medical Centre	14.09.2023
	1175	IBIS		Prospektive und retrospektive Studie zu Chlostridium diff. Infektionen		University Hospital Cologne	01.01.2019
	1127	IDEAL	2010-022413-26	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (I	4	University Medical Center Hamburg-Eppendorf	01.08.2011	01.01.2014
	1173	IFI-ADHEM		Invasive fungal infections in adult hematologic patients
	1460	IXION (COVend)	2021-005059-35	Potential of FX06 to improve disease severity in ARDS Patients.	2		01.12.2021
	1289	KIN001-203	2020-005849-16	An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)	2	Kinarus AG	09.03.2021
	1167	LAPTOP	2018-003481-13	An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late Presenter Treatment Optimisation Study	3/4	NEAT-ID Foundation	15.01.2019
	1134	MARCH	2011-002107-15	A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART)	4	Kirby Institute, University of New South Wa	01.02.2012	01.12.2015
	1463	MARIO	2022-000648-32	A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp vs Intravenous Echinocandin followed bz Oral Fluconazole	3	SCYNEXIS, Inc.
	1473	mEXTB		Multicentric cohort and biomarker study for improved care of patients with extrapulmornary tuberculosis.		Universitätsklinikum Köln
	1459	MISTRAL (EuroSIDA)		Gut microbiome correlates of serious AIDS and non-AIDS events
	1204	MK1439A-021	2014-003382-17	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects	3	Merck Sharp & Dohme Corp.	12.08.2015
	1205	MK1439A-030	2015-003616-20	A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations.	2	Merck Sharp & Dohme Corp.	11.02.2016	23.05.2017
	1276	MK4482-002	2020-003368-24	Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19	2/3	Merck Sharp & Dohme Corp.	07.12.2020
	1128	MODERN	2010-021785-30	Multicenter, randomized, double-blind, comparative trial of Maraviroc + Darunavir/Ritonavir vs. Emtricitabine/Tenofovir + Darunavir/Ritonavir	3	ViiV Healthcare UK Limited	01.12.2011	01.12.2013
	1278	NAPKON-HAP		Analysis of pathophysiology and pathology of coronavirus disease 2019 (COVID-19), including chronic morbidity		Charité Klinik m. S. Infektiologie und Pneumo	01.11.2020	31.03.2024
	1293	NAPKON-SÜP		Erkennung, Behandlung und Vorbeugung von der SARS-CoV-2 Infektion und der COVID-19 Erkrankung sowie zukünftiger Pandemien		Universitätsklinikum Frankfurt, ZIM II	01.11.2020	31.12.2023
	1246	NEAT 001 Long Term		NEAT 001/ANRS143		University Hospital of Nantes	13.06.2018
	1125	NEAT001	2009-015113-44	An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir	3	Inserm-ANRS (Agence nationale de recherche su	01.03.2011	01.10.2013
	1144	NEAT22/SSAT060	2013-003704-39	An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression	3	St Stephens AIDS Trust	01.01.2014	01.12.2017
	1461	NECTAR	2022-000715-31	CONNECTS Master Protocol for Clinical Trials targeting macro-, micro-immuno-thrombosis, vascular hyperinflammation, and hypercoagulability and renin-angiotension-aldosterone system (RAAS) in hospitalized patients with COVID-19 (ACTIV-4 Host Tissue)		NEAT-ID	02.03.2023	26.09.2023
	1466	NEURAL (GeoSentinel)		Prospective Evaluation of Neurocognitive Outcome in Travellers Presenting with Malaria
	1174	OPINION		Verlauf der Menopause bei Frauen, die mit HIV leben		Universitätsklinikum Frankfurt, HIVCenter	13.03.2019	06.02.2020
	1476	ORGANGE		HIV-Patients from Ukraine - Continuum of care in Germany -		HIVCENTER FFM	12.10.2022	01.12.2023
	1124	PANNA	2008-006158-16	Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women )	3/4	Radboud University Medical Center	01.01.2011
	1130	PEPDar	2011-001303-13	HIV postexposure prophylaxis with Darunavir/r (PEPDar)	3	Janssen Cilag	01.09.2011	28.09.2013
	1136	PHOTON 2	2012-004154-28	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and	3	Gilead Sciences Inc	01.03.2013	10.07.2014
	1159	PILGRIM		Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens		University Hospital Cologne	29.04.2020
	1465	PRESERVERE (GeoSentinel)		Predictors of severe infections and diagnosis in travelers and migrants			03.08.2023
	1475	PRISMA		Patterns of Real-World savuconazole use, Effectiveness, Safety, and Healthcare Resource Utilization- a Retrospective Chart Review Studz of Patients With Mucomycosis or Invasive Aspergilosis		Pfizer	22.10.2021	01.05.2022
	1169	PROPHET		Prospective clinical and pharmacoeconomic outcomes study of different first-line antiretroviral treatment strategies		dagnä	01.08.2014	01.10.2015
	1131	PROTEA	2011-001635-23	PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects	3	Janssen Cilag International N.V.	14.11.2011	18.03.2015
	1474	Pulmocide	2021-004554-32	A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis	3	Pulmocide Ltd.	25.10.2023
	1121	Quad	2009-016758-42	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults	3	Gilead Sciences	01.07.2010	01.07.2012
	1303	RECOVER	2020-001632-10	A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease	2	Ruprecht-Karls-Universität Heidelberg, Medica	05.04.2020
	1277	RES-Q HR	2020-004695-18	Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals	2	Heinrich-Heine University Düsseldorf	12.01.2020	29.10.2021
	1154	RESPOND		International Cohort Consortium of Infectious Diseases		Rigshospitalet - University of Copenhagen	02.12.2019
	1308	Rocinante		Adult Kidney Transplant Recipients at Risk of CMV Infection and Disease:		MSD Sharp & Dohm	10.05.2021
	1143	SABATO	2013-000577-77	EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION	3	University of Düsseldorf	01.11.2013	01.10.2018
	1172	SANDER		Diagnostische Strategien bei Krebspatienten mit respiratorischen Infektionen			01.04.2016	01.04.2019
	1155	Serokonverter		Untersuchungen zum Verlauf der HIV-Infektion bei Patienten mit bekanntem Infektionszeitpunkt.		RKI	01.06.2016
	1274	SILVER		Impact of different silymarin dosages to decrease elevated liver enzymes due to drug-induced hepatocellular liver injury compared to placebo in a prospective controlled dose-finding phase IIb trial	2	Fraunhofer Institut
	1126	SINGLE	2010-020983-39	A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects.	3	ViiV Healthcare UK Limited	01.02.2011	01.04.2014
	1287	SMART	2004-000441-38	Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy	3/4	National Institute of Allergy and Infectious	12.05.2004	11.07.2007
	1156	SPECTRA		Studie zu den Verordnungsschemata und der Wirksamkeit von Ceftolozan/Tazobactam: Analyse unter Alltagsbedingungen		Merck Sharp & Dohme Corp
	1171	START	2008-006439-12	Strategic Timing of AntiRetroviral Treatment	3	University of Minnesota	31.08.2009	22.01.2020
	1275	Summit	2017-001642-10	A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI)	3	Summit (Oxford) Limited	05.09.2019
	1145	SWORD-1	2014-005147-40	A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed	3	ViiV Healthcare UK Limited	01.07.2015	01.01.2019
	1305	Therapeutics for Inpatients with COVID-19 (TICO)	2020-003278-37	A Multicenter, Adaptive, Randomized, Blinded	3	University of Minnesota	04.09.2020
	1469	TIARA		The impact of colonization with MDRO in complex surgical patients		Universitätsklinikum Köln		31.12.2025
	1160	TP-HIV/TOP-HIV		Translationalen Plattform HIV		DZIF	01.10.2017
	1471	TRIGA-S	CIV-22-10-041187	Clinical performance study of SARS-CoV-2 Antigen Self Test Nasal & SARS-CoV-2 Rapid Antigen Test 2.0 Nasal		SD Biosensor	09.01.2023	25.10.2023
	1123	UKB-2009-MED-I-JKR-01	2009-015904-24	An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection in ART naive subjects with HCV co-infection	4	Rheinische Friedrich-Wilhelms-Universität Bon	01.04.2010	01.04.2011
	1135	VX-950HPC3005	2011-003593-85	Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis	3	Janssen-Cilag International NV	01.05.2012	01.03.2015
	1313	WHAT – Study		Why Doctors Choose Which Antiretroviral Therapy in Patients with Low CD4 Count And/or AIDS-defining Disease		Universitätsklinikum Frankfurt, Zentrum für I	01.03.2018
	1168	WISARD	2017-004040-38	The effect of switching to Dolutegravir and Rilpivirine combination therapy in patients with HIV-1 and the K103N mutation.	3/4	St. Stephen´s Clinical Research & NEAT-ID	09.04.2019
	1228	XPORT-CoV-1001	2020-001411-25	A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe Covid-19 Infection (XPORT-CoV-1001)	2	Karyopharm Therapeutics Inc.	14.04.2020	13.10.2021
Innere Gastroenterol.
	410	AIO-LQ-0111, PROCAPP		A randomized, open-label phase III trial of Mapisal® versus urea hand-foot cream as prophylaxis for capecitabine-induced handfoot syndrome in patients with gastrointestinal tumors or breast cancer	3	AIO Studien GmbH	26.06.2012
	1103	CA209-9DX	2017-002755-29	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation	3	Bristol Myers Squibb
	1097	GFT-505-315-1	2015-005385-38	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.	3	Genfit	20.12.2016	14.04.2021
	411	GM-IMAB-001-04; PILOT	2011-005509-64	Multicenter, open-label, exploratory phase I pilot study to investigate safety, pharmacodynamics and pharmacokinetics of immunological effects and activity of combining multiple doses of IMAB362 with immunomodulation (zoledronic acid, interleukin-2) in patients with advanced adenocarcinoma of the stomach, the lower esophagus or the gastro-esophageal junction (PILOT)	1	Ganymed Pharmaceuticals AG	11.10.2012	14.07.2015
	1099	NUC-5/PSC	2016-003367-19	Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis	3	Falk
	510	AFLIBCO6097	2011-005724-17	A multicenter, single arm, open label clinical trail to evaluate the safety and health-related quality of life of Aflibercept in patients with metastatic colorectal cancer (mCRC) previously treated with an Oxaliplatin-containing regimen	3	Sanofi-Aventis	24.08.2012	26.09.2014
	657	AI444-052	2011-004237-14	A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C	3	Bristol Myers Squibb	09.02.2012	18.02.2014
	766	AI444-062	2012-000070-28	A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Null-Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy or PegIFN/RBV Ineligible/Intolerant/Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C	2	Bristol Myers Squibb	29.08.2012	21.11.2013
	765	AI447-028	2011-005446-35	A Phase 3, Open-Label Study with BMS-650032 and BMS-790052 (DUAL) for Null- /Partial-responders to Peginterferon Alfa-2a and Ribavirin (P/R) Therapy, Intolerant/Ineligible-naive Subjects and Unwilling-naive Subjecs with Chronic Hepatitis C Genotype 1b or 4 Infection	3	Bristol Myers Squibb	07.08.2012	27.11.2013
	767	AI447-029	2011-005422-21	A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa- 2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null/Partial Responders to P/R with Chronic Hepatitis C Genotypes 1a, 1b and 4 Infection	3	Bristol Myers Squibb	14.06.2012	13.11.2013
	717	AIO-LQ-0110	2010-022938-85	Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with kras-wildtype colorectal cancer	2	AIO Studien GmbH	27.04.2011	01.03.2016
	838	AIO-PAK-0114 ALPACA	2014-004086-24	Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study	2	AIO-Studien-gGmbH	18.11.2015
	686	AIO-STO-0110	2010-024111-13	Explorative trial to investigate catumaxomab (anti-EpCAM x anti-DC3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy (AM IIT_CAT 003)“	2	AIO Studien GmbH	18.04.2011	29.07.2016
	629	AIO-STO-0111 (CRAD001RDE35T)	2009-018092-14	A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen	3	Krankenhaus Nordwest	15.07.2011	07.10.2019
	1114	AIO-STO-0217	2017-000624-10	Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma	2	AIO-StudiengGmbH	09.09.2019	05.03.2022
	703	AIO-YMO-0111	2013-002742-37	Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer	2	AIO-StudienGgmbH	12.08.2014	08.10.2020
	614	Al444-011	2010-193783-34	A Phase 2B Study of BMS-790052 in Combination with Peginterferon alfa-2a (Pegasys) and Ribavirin in Chronic Hepatitis C Infected Subjects with a Prior Non-Response to Interferon-Based Therapy	2	Bristol Myers Squibb	27.08.2010	18.02.2013
	620	Amg20101120	N/A	Protocol Medical Records Review to describe the patterns of KRAS testing and Vectibix use in Europe		Amgen	08.10.2013	01.09.2015
	753	Amg386	2008-006212-38	Open-label single-arm, multi-center study to evaluate the efficacy and safety of AMG386 and sorafenib as fisrt line therapy for subjects with advanced or inoperable hepatocellular carcinoma	2	Amgen	22.09.2009	24.03.2015
	706	APACT	2013-003398-91	A PHASE 3, MULTICENTER, OPEN-LABEL,RANDOMIZED STUDY OF nab®-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE AS ADJUVANT THERAPY IN SUBJECTS WITH SURGICALLY RESECTED PANCREATIC ADENOCARCINOMA	3	Celgene	01.03.2014	27.11.2018
	530	Arq197-A-U303	2012-003308-10	A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY	3	Arqule	16.05.2013	02.03.2017
	566	ASTER	2011-005603-32	Use of Acetylsalicylic Acid (ASA) for enhanced early detection of colorectal neoplasms	3	DKFZ	17.09.2012	27.01.2017
	770	BA2011/03/04	2011-002843-92	Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.	3	Onxeo	28.11.2013	08.02.2019
	623	BAY 73-4506 / 16674	2013-003613-18	A Phase I, multi-center, non-randomized, open label, drug-drug-interaction study to determine the effect of multiple doses of regorafenib (BAY 73-4506) on the pharmacokinetics of probe substrates of transport proteins P-gp (digoxin; Group A) and BCRP (sulfasalazine; Group B) in patients with advanced solid malignant tumors	1	Bayer Healthcare AG	16.04.2014
	656	Bayer 15983	2012-004369-42	A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases	3	Bayer Healthcare AG	13.01.2014	05.03.2015
	568	Bayer15982	2012-003649-14	A randomized, double blind, placebo-controlled, multicenter phase 3 study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib	3	Bayer Healthcare AG	30.01.2013	26.04.2019
	591	BAyer16728	2013-000241-39	A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocellular Carcinoma (HCC)	2	Bayer Healthcare AG	30.10.2013	30.04.2015
	734	BBI608-336	2014-000774-18	A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma	3	Boston Biomedical Inc.	25.11.2014	19.09.2017
	514	BI1241.20	2012-003533-41	A Phase III, Randomised, Partially Double-Blind and Placebo- Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infection	3	Böhringer Ingelheim	04.12.2012	11.12.2014
	531	BI1241.30	2012-003534-17	A multi-staged, phase II/III randomised, double-blind and placebo-controlled study to evaluate pharmacokintetics, saftey and efficacy of BI 207127 in combination with BI201335 and patients with moderate hepatic impairment (Child-Pugh B) with genotype 1 chronic hepatitis C infection	2/3	Böhringer Ingelheim	11.04.2013	08.09.2014
	579	BO27798 (S498)	2011-001526-19	A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer	3	Roche	28.12.2011	04.12.2012
	595	CabaGast	2012-001271-37	Multizentrische, Phase II Studie mit Cabazitaxel bei vorbehandelten Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des ösophagogastralen Übergangs und des Magens	2	KHNW	25.09.2013	04.04.2018
	712	Carma		Nicht interventionelle Studie zur Anwendung von Removab bei Patienten mit maligner Aszites bei EpCAM-positiven Tumoren		Fresenius Kabi Deutschland GmbH	01.01.2011	31.01.2013
	214	CRAD00102301	2009-010196-25	A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment	3	Novartis	06.04.2010	08.10.2013
	1095	CRAD001C24100	2007-005422-76	Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001	2	Klinikum Zollernalb	28.08.2008	08.12.2010
	418	CRAD001HDE13 (HEPHAISTOS)	2011-003118-17	A 12 month, multi-center, open-label, randomized, controlled study to evaluate efficacy/safety and evolution of renal function of everolimus in co-exposure with tacrolimus in de novo liver transplant recipients	3	Novartis	29.12.2011	27.11.2017
	758	CRAD001T2302	2011-002887-26	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD) plus best supportive care versus placebo plus best	3	Novartis	26.03.2012	22.07.2020
	540	CSOM230B2406	2010-024165-44	An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushings disease(Seascape)	3	Novartis	05.08.2011	15.08.2013
	549	CSOM230D2203	2008-007348-32	An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin	2	Novartis	12.08.2009	16.01.2014
	689	Delcath	2014-001585-98	An International Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for use with the Hepatic Delivery System Treatment in Patients with Unresectable HCC	2	Delcath Systems Inc.	27.06.2014	24.10.2017
	692	Delcath IIT	N/A	Evaluation of radiological response after Melphalan Chemosaturation - Percutaneous Hepatic Perfusion in patients with Hepatocellular Carcinoma (HCC) and evaluation of the acute effects of the treatment on hemodynamic and coagulatory systems		Institut für Diagnostische und Interventionel	11.04.2014	31.12.2016
	805	E-VITA	2010-021940-16	A Double Blind Placebo Controlled Randomized Phase II Study Evaluating the Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream in First Line mCRC Patients Treated with Erbitux® and FOLFIRI. E-VITA Study	2	Uniklinik Mannheim	01.09.2011	08.12.2015
	738	EMR200095-005	2013-002053-30	A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment	1/2	Merck KGaA	16.05.2014	21.12.2017
	632	EMR200592-001 (MAESTRO)	2012-002957-42	Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)	3	Merck KGaA	17.10.2013	04.05.2016
	743	EMR200637-002	2013-003829-29	Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies	2	Symphogen	27.10.2014	26.04.2017
	713	FERINJECT	2014-000246-30	Intravenöse Eisencarboxymaltose versus orale Eisensubstitution bei Patienten mit metastasiertem kolorektalem Karzinom (CRC) und Eisenmangelanämie: eine randomisiert, multizentrische Therapieoptimierungsstudie.	2	Institut für Klinisch-Onkologische Forschung	01.04.2015	08.05.2020
	599	FLOT 3	2007-005143-17	Prospektive, multizentrische Studie mit 5-FU, Leucovorin, Oxaliplatin, Docetaxel (FLOT) bei Patienten mit primär operablen, limitiert metastasierten oder diffus metastasierten Adenokarzinom des Magens oder des ösophagastralen Überganges - FLOT3		KH Nordwest, Frankfurt	01.05.2009	30.09.2012
	598	FLOT 4	2010-018754-13	Multizentrische, randomisierte Phase II/III Studie mit 5-FU, Leucovorin, Oxaliplatin und Docetaxel (FLOT) versus Epirubicin, Cisplatin und 5-FU (ECF) bei Patienten mit lokal fortgeschrittenem, resektablem Adenokarzinom des ösophagalen Übergangs und des Magens	2/3	KH Nordwest, Frankfurt	01.06.2010	15.05.2019
	748	FLOT 65+	2006-006936-24	"Multizentrische randomisierte Phase II Studie zur Therapie des fortgeschrittenen Magenkarzinoms oder Adenokarzinoms des Ösophagogastralen Überganges bei Patienten über 65 Jahre unter besonderer Beachtung der Lebensqualität und des pharmakogenetischen Risikoprofils"	2	KH Nordwest, Frankfurt	17.07.2007	12.09.2012
	833	FLOT5	2014-002665-30	Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of AIO/CAO-V/CAOGI.	3	KHNW	11.01.2016
	834	FLOT6	2014-002695-86	FLOT vs. FLOT/Herceptin/Perjeta for perioperative therapy of adenocarcinoma of the stomach and gastroesophageal junction expressing HER-2. A phase II/III trial of the AIO	2/3	KHNW	15.03.2016	14.05.2020
	1096	Future	2006-000685-36	A randomized. Open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic cancer	2	Merck Serono	10.03.2008	10.09.2010
	557	GM-IMAB-001-02	2009-017365-36	International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus	2	Ganymed Pharmaceuticals AG	11.08.2010	12.12.2013
	412	GM-IMAB-001-03) FAST, S534	2011-005285-38	A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) as First-Line Treatment of Patients With CLDN18.2-positive Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction	2	Ganymed Pharmaceuticals AG	09.05.2012
	808	GmbH-Sto-0114	2014-004116-11	Multicenter Phase I/II Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction	1/2	AIO Studien GmbH	30.11.2015	01.01.2021
	764	GS-US-174-0149	2010-024586-45	A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon a-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon a-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)	4	Gilead	08.07.2011	09.07.2015
	597	GS-US-256-0148	2011-000456-42	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 or GS-9256 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection	2	Gilead	04.10.2011	14.06.2013
	532	GS-US-337-0102	2012-003387-43	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection	3	GlaxoSmithKline	08.02.2013	17.07.2014
	763	GSUS-334-0133	2012-001942-16	A Phase 3, multicenter, randomized, double-blin, Placebo controlled study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 weeks in Treatment-naive and Treatment-experienced subjects with chronic genotype 2 or 3 HCV infection.	3	Gilead	20.09.2012	19.12.2013
	427	H9H-MC-JBAJ	2011-000211-64	A phase 1b/2 study with Gemcitabine and LY2157299 for patients with metastatic cancer (phase 1b) and advanced or metastatic unresectable pancreatic cancer (phase 2)	2	Lilly Deutschland GmbH	08.06.2012	26.12.2016
	755	HGS-1012-C1103	2010-020798-17	"A Randomized, Multi-Center, Blinded, Placebo-Controlled Study of Mapatumumab ([HGS1012], a Fully-Human Monoclonal Antibody to TRAIL-R1) in Combination with Sorafenib as a First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma. "	2	Human Genome Sciences	30.06.2011	29.08.2014
	606	I4T-MC-JVBB (S535)	2010-021037-32	A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine	3	Lilly	22.08.2011	22.01.2014
	784	I4T-MC-JVDE	2014-005068-13	Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib	3	Lilly	07.08.2015	14.09.2021
	1211	IMMULAB	2018-001381-42	A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)	2	IKF Klinische Krebsforschung GmbH
	775	Keynote 164	2015-001852-32	A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with preiviously treated locally advanced unresectable or metastatic (Stage IV) Microsatellite Instability-High Colorectal Carcinoma	2	MSD	11.12.2015
	628	Komigra		Diagnostik des kolorektalen Karzinoms bei Migrantinnen und Migranten in Deutschland: Tumorstadium zum Diagnosezeitpunkt im Vergleich zu Nicht-Migranten		Institut für Allgemeinmedizin	13.06.2013	10.03.2015
	215	Lilly I2I-MC-JMMC	2008-006209-17	A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer	1/2	Lilly	05.07.2011	28.02.2013
	513	M11-646	2012-002019-25	A Randomized, Double-blind, Placebo-controlledStudy to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)	3	Abbott	25.02.2013	09.10.2014
	762	M11-652	2010-022455-31	A Randomized, open label, Multi-center Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in combination with ABT-267 and/or ABT- 333 with and without Ribavirin (RBV) for 8, 12 or 24 weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection	2	Abbott	16.12.2011	19.09.2013
	511	M13-098	2012-002035-29	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)	2	Abbott	24.01.2013	23.10.2014
	512	M13-099	2012-003088-23	A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)	3	Abbott	25.02.2013	31.12.2013
	596	MGN1703-C02	2009-017432-40	A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)	2	Mologen	13.04.2010	27.02.2013
	702	MGN1703-C06	2014-000834-50	Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer with tumor reduction during induction treatment.	3	Mologen AG	11.11.2014	29.08.2019
	673	MicOryx	2011-000765-12	Phase I/IIa study of immunization with frameshift peptides administered with Montanide® ISA-51 VG in patients with advanced MSI-H colorectal cancer	1/2	Oryx GmbH	22.08.2011	30.05.2015
	751	MK-3475	2014-005241-45	A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who progressed after First-Line Therapy with Platinum and Fluoropyrimide	3	Merck Sharp & Dohme Corp.	24.07.2015
	830	MK-3475-177	2015-002024-89	A Phase III Study of Pembrolizumab (MK-3475) vs Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Carcinoma	3	Merck Serono	15.02.2016
	1104	MK-7902-002	2018-002983-26	Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)	3	MSD
	588	ML22011	2009-013099-38	Sequenzielle Erstlinientherapie des metastasierten kolorektalen Karzinoms mit Capecitabin, Irinotecan und Bevacizumab - Capecitabin plus Bevacizumab versus Capecitabin plus Irinotecan plus Bevacizumab als Erstlinientherapie beim metastasierten kolorektalen Karzinom	3	Klinikum der Universität München Campus Großh	24.09.2010
	732	MO29112	2014-001017-61	A Multi-centre Randomised Clinical Trial of Biomarker-driven Maintenance Treatment for First-line Metastatic Colorectal Cancer (MODUL)	2	Roche	31.03.2015
	1115	MS200647_0047	2018-003707-19	A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy	2		26.09.2019
	1098	MYR301	2019-001213-17	A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta	3	Myr GmbH Deutschland
	1292	NAPKON SÜP		Sektorenübergreifende Plattform des Nationalen Pandemie Kohorten Netz		NAPKON
	684	Nepafox	2013-003972-11	Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma	2/3	KHNW	13.05.2014	13.05.2020
	449	NP27884	2011-003574-84	A randomized, placebo-controlled, double-blind, multicenter phase 2 trial of intravenous GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC)	2	Roche	15.05.2012	19.02.2014
	761	NP28266	2012-000638-21	A Randomized, Multi-Center Study of Interferon-free Treatment with a Combination of an HCV non-nucleoside Polymerase Inhibitor (setrobuvir, RO5466731, STV), a Ritonavir boosted HCV Protease Inhibitor (danoprevir and ritonavir, RO5190591/r, DNV/r), and Copegus® (RBV) with or without an HCV nucleoside Polymerase inhibitor (mericitabine, RO5024048, MCB) in Treatment Naïve HCV Genotype 1 Infected Patients and in HCV Genotype 1 Infected Patients who failed to achieve sustained viral response from previous treatment with an Interferon-containing treatment regimen	2	Roche	06.07.2012	09.10.2013
	523	NV22688	2009-016560-36	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment resistant mutations or the durability of sustained virologic response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC)		Roche	27.07.2010	31.03.2015
	526	P06086	2009-012782-63	Boceprevir/Peginterferon/Ribavarin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavarin Dose Reduction for the Management of Anemia	3	Essex/Sheringh Plough	02.02.2010	26.10.2011
	674	Panusco_S468	2008-004696-22	An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution versus Best Supportive Nutritional Care in Subjects with Pancreatic Adenocarcinoma receiving 5-FU plus Oxaliplatin as 2nd or Higher Line Chemotherapy Regarding Clinical Benefit	3	Universitätsklinik Heidelberg	22.09.2009	21.08.2014
	630	PCI A202/12	2012-002888-10	A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex-induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy in Patients with Locally Advanced Inoperable Cholangiocarcinomas	1/2	PCI Biotech	19.02.2013	21.02.2019
	1116	PCIA_203/18	2018-002647-29	A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma	2		26.08.2019	06.05.2022
	562	PETACC-6	2006-006532-21	Präoperative Radiochemotherapie und postoperative Chemotherapie mit Capecitabin und Oxaliplatin vs. Capecitabin beim lokal fortgeschrittenem Rektumkarzinom	3	EORTC	23.03.2009
	572	PETACC-6 Amote		Use of a pretherapeutic and postoperative assessment in elderly patients with locally advanced rectal cancer and decision making progress regarding participation in clinical trials - motivations of members of the study team and patients (Deutsche Krebshilfe e.V.)		Krankenhaus Nordwest, IKF	01.06.2011	19.11.2012
	790	Pi-01/2010		Differentielle Mikro RNA-Muster in Seren von Patienten mit Leberzirrhose hepatozellulärem Karzinom (HCC)		Piiper	01.01.2010	31.12.2017
	801	PIN-PHO1201	2014-000688-42	Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma	3	Concordia Laboratories	20.04.2015	21.12.2016
	675	QoliXane	N/A	Nicht-interventionelle Studie zur Erfassung der Lebensqualität, Wirksamkeit und Verträglichkeit bei Patienten mit metastasiertem Pankreaskarzinom unter Erstlinientherapie mit NabPaclitaxel und Gemcitabin.		Krankenhaus Nordwest	18.09.2014
	610	RASH (S522)	2011-005471-17	Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances	2	Klinikum der Universität München Campus Großh	07.05.2012
	736	SCOOP		Internationale Beobachtungsstudie zum Einsatz von Teysuno (S-1) bei Patienten mit fortgeschrittenem Magenkarzinom im klinischen Alltag		NORDIC PHARMA	17.06.2015
	1266	SSGXXII - GIST	2014-000898-39	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.	3
	776	STELLA		Studie zur Evaluation der Lebensqualität und Liegedauer durch Aufklärung. Klinische Studie zur Evaluation der Lebensqualität, Liegedauer und Komplikationsraten von Patientinnen/-en mit Enterostoma mit spezieller präoperativer Aufklärung und Schulung vs. standardisierter präoperativer Aufklärung	3	IKF	25.11.2015
	385	Synchronous		Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV) - A randomised controlled multicentre trial	3	University of Heidelberg	09.11.2011
	608	TAS-102	2012-000109-66	Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies	3	Taiho Pharma USA	09.10.2012	09.01.2014
	843	TES10897 (QUTIE)	2008-006796-80	A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel	2	Sanofi-Aventis	23.04.2009	08.11.2010
	730	TIDE 13-22	2014-000998-39	Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-ba	2	Helsinn Healthcare	30.10.2014	28.12.2015
	691	TKI258A2124	2011-000103-41	A multi-center, open-label study of assess pharmacokinetics of TKI258 in adult cancer patients with normal and impaired hepatic funktion	1	Novartis	25.10.2011	23.07.2015
	525	VX-950-TiDP24-C219	2009-012613-21	An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) an ribavarin (Copegus) for subjects from contrl group of the VX-950-TiDP24-C216 trial who failes therapy for virologic reasons	3	Tibotec	06.04.2010	21.03.2012
	701	XL184-309	2013-001001-91	A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib	3	Exelixis	19.09.2013	27.08.2018
Innere Hämatol./Onkol.
	927	20140286	2016-002034-76	A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma	1	Amgen	11.11.2016
	951	20150136		An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices		Amgen	18.08.2017
	935	AC220-A-U302	2015-004856-24	A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia	3	Daiichi Sanky Development	08.11.2016
	944	AIO-TRK-0114 (MARBLE)	2014-001983-36	Eine randomisierte, offene Phase II-Studie zur Förderung der pan-ERBB Blockade nach einer platinbasierten Induktionschemotherapie bei Patienten mit metastasiertem, EGFR mutiertm, nicht-kleinzelligen Lungenkarzinom mit Progress nach Behandlung mit Afatinib als erster gegen EGFR gerichteter Therapie.	2	AIO-Studien-gGmbH	02.07.2015	01.12.2017
	923	ARMY-1	2014-002433-59	First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid Leukemia	1	Menarini Ricerche S.p.A.	01.12.2014
	1027	B1371012/ BRIGHT	2014-001345-24	AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA	1	Pfizer	26.01.2015
	934	BI1230.4	2008-003617-27	An open phase I/II trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intravenous BI 6727 as immunotherapy or in combination with subcutaneous Cytarabine in patients with AML.	1/2	Böhringer Ingelheim	18.09.2008	19.05.2021
	1030	BLU-285-1303	2017-003497-14	An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)	3	Blueprint Medicines	28.08.2018	15.09.2021
	936	BO29561	2015-004845-25	A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and rituximab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma	1/2	F. Hoffmann-La Roche Ltd	23.08.2016	08.05.2019
	928	CA209-580		A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy		Bristol Myers Squibb	22.04.2016
	942	CA209-653 (NORA)		A national, prospective, non-interventional study (NIS) of Nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after Prior therapy.		Bristol Myers Squibb	21.11.2016
	937	CABL001A2301	2016-002461-66	A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors	3	Novartis	07.09.2017
	975	CINC424D2301/REACH 3	2016-004432-38	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation	3	Novartis	24.07.2017
	938	CLXH254X2102	2016-004293-18	A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer	1	Novartis	28.11.2016
	899	CONKO-011	2015-001478-16	Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III Study	3	AIO-Studien-gGmbH	26.10.2015
	931	CV-9202-006	2012-004230-41	An exploratory, open-label phase Ib study of RNActive®-derived cancer vaccine and local radiation as consolidation and maintenance treatment in patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor	1	CureVac GmbH	05.04.2013	31.12.2017
	1029	DKMS-16-01/HAMLET	2015-005399-12	A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor	2/3	DKMS gemeinnützige GmbH	02.08.2017
	1008	DSMM XV	2014-001757-16	Pomalidomid, Ixazomib, und Dexamethason (PId) mit oder ohne Intensivierung durch Cyclophosphamid (PICd): Phase II Studie bei refraktärem oder rezidivierendem Multiplen Myelom	2	GWT TUD Gmbh, Dresden	02.07.2015
	976	E7080-G000-307/ CLEAR	2016-000916-14	A Multicenter, Randomized, Open-Label, Phase3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(CLEAR)	3	Eisai Ltd. UK	17.03.2017
	943	EFC12522	2017-002238-21	A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant	3	Sanofi-Aventis	22.01.2018
	929	ETAL-4 / HOVON-145	2017-000764-15	European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS (ETAL-4 / HOVON-145)	3	Goethe-Universität Frankfurt	11.12.2017
	924	EWALL-BOLD	2017-002853-13	Phase II Studie für die Behandlung von älteren Patienten mit neu diagnostizierter CD19 positiver, Ph/BCR-ABL negativer B-Vorläufer akuter lymphatischer Leukämie mit sequenzieller dosisreduzierter Chemotherapie und Blinatumomab	2	Goethe-Universität Frankfurt	01.03.2018
	948	EWING2008 (Register)		Register zur internationalen, randomisierten Phase 3 Studie für Patienten mit lokalisiertem oder metastasiertem Ewing-Sarkom	3	Uniklinik Münster
	953	GEM333-01	2017-001707-77	A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia	1	GEMoaB Monoclonals GmbH	04.05.2018	23.09.2022
	946	INITIAL-1	2016-004836-39	An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In patients aged 56 years and older with Acute Lymphoblastic leukemia (ALL) (INITIAL-1)	2	Goethe-Universität Frankfurt	21.06.2017
	930	KESTREL	2015-003589-10	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients	3	Astra Zeneca	04.01.2016
	1010	KTE-C19-103/ Zuma-3	2015-005009-35	A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)	1/2	Kite Pharma Inc.	17.08.2016	05.07.2023
	933	M15-656	2016-001466-28	A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy	3	AbbVie	07.08.2017
	939	MK3475-689	2017-001139-38	A Phase 3, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	3	MSD	06.02.2015
	950	NAPOLEON		National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup		Uniklinik Dresden	17.07.2014
	922	OReO	2016-003346-90	A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy	3	Astra Zeneca	05.06.2017	12.07.2023
	925	P001317	2016-001628-72	Altersadaptierte Hochdosistherapie gefolgt von autologer Stammzelltransplantation bei fitten älteren Patienten mit Erstdiagnose eines primär zerebralen Lymphoms	2	Universitätsklinikum Freiburg	18.07.2017
	962	PROSa - A (PROSA)		Krankheitslast und Versorgungssituation bei Sarkomen: Eine nationale Studie zu Einflussfaktoren patientenberichteter Krankheitsfolgen bei Menschen mit Sarkomerkrankungen		TU Dresden	18.10.2018	30.06.2021
	1011	SAKK96/12	2014-001189-87	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial	3	Sakk Swiss Group	03.04.2017
	907	SUNNIFORECAST	2016-000706-12	A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma	2	Goethe-Universität Frankfurt	23.01.2017
	926	TUD-APOLLO-064	2015-001151-68	A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia	3	TU Dresden	19.05.2016
	1031	UKM17_0023/LBL 2018	2017-001691-39	LBL 2018 - International cooperative Treatment protocol for children and adolescents with lymphoblastic lymphoma	3	Uniklinik Münster	21.12.2018
	956	Uni-Koeln-1762 (HD 21)	2014-005130-55	HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD	3	Uniklinik Köln	18.05.2016
	1007	VL2397-201	2017-003435-11	A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients	2	Vical Incorporated	14.08.2018	21.02.2019
	988	20090482	2010-020454-34	Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma	3
	987	2011-003	2012-000128-16	Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)	3
	1224	20180138	2019-001575-37	Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311			17.04.2020	04.06.2020
	1379	20190288	2021-002638-18	A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreaK 201)	2	Amgen	17.12.2021
	1286	20190294		A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)		Amgen Inc.	31.08.2020	11.08.2021
	1340	208887	2019-001138-32	A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)–DREAMM5	1/2	GlaxoSmithKline
	1321	213410	2020-003433-37	A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)	2/3		10.03.2021
	905	2215-CL-0201	2015-001790-41	A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy	2/3	Astellas	02.08.2016	01.03.2023
	996	4EVER	2011-006111-62	4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer	3
	1396	61186372NSC3002	2021-001825-33	A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure	3	Janssen
	1250	64619178EDI1001	2018-000067-87	A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects With Advanced Cancers	1	Janssen Research & Development
	1343	73841937NSC1001	2020-000747-31	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	1	Janssen		04.07.2023
	1410	9766-CL-0107	2018-003975-36	A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects	2	Astellas	30.09.2019
	456	A 536-03	2012-002523-14	A phase 2, open-label, ascending dose study of ACE-536 for the treatment of anemia in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) Protocol Number: A536-03	2	Acceleron Pharma	20.12.2012	22.10.2018
	699	A 536-05	2014-001280-13	An Open Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03.	2	Acceleron Pharma	03.09.2014	19.03.2020
	1016	A6181112		Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors	3
	98	A8851009	2007-002445-20	A Prospective, randomized trial comparing the efficacy of Anidulafungin and Voriconazole in combination to that of Voriconazole alone when used for primary therapy of proven or probable invasive Aspergillosis	3	Pfizer	25.06.2008	01.03.2011
	1454	AA-BMF-Register		Zentrale Registrierung von Patientendaten und Biomaterialbank bei Aplastischen Anämien und Bone Marrow Failure Syndromen		RWTH AAchen	07.03.2023
	175	AC220-002	2009-013093-41	A Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients with Acute Myeloid Leukemia (AML) with and without FLT3-ITD Activating Mutations	2	Ambit Biosciences	19.05.2010	13.01.2014
	700	AC220-007	2013-004890-28	A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220) MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) CONSOLIDATION	3	Ambit Bioscences Corporation	25.08.2014	16.02.2021
	594	ACACIA DN10016	2013-001635-51	Randomised, double-blind, dose-finding phase II study to assess the efficacy of APD403 in the prevention of nausea and vomiting caused by cisplantin- or anthracycline/cyclophosephamide (AC)- based chemotherapy	2	CESAR	06.11.2013	12.02.2015
	1451	ACT16482 Master	2020-003024-16	Phase 1/2 UMBRE LLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol	1/2	Sanofi-Aventis
	1179	ADAM	2018-004329-10	A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy	2	Westfälische Wilhelms-Universität Münster
	876	AG-221-AML-005	2015-003951-23	A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)	1/2	Celgene	08.07.2016
	1180	AGO-OVAR 2.29	2017-000202-37	Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial	3
	1428	AGO-OVAR 2.34	2018-004207-39	A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy.	2	AGO Research GmbH	07.06.2023
	1415	AHA-EMI	2019-004430-42	Emicizumab in Acquired Hemophilia A	2	GWT TUD Gmbh, Dresden	30.11.2020
	1414	AHA_IIT		Langzeitbeobachtung von Therapie und Outcome der erworbenen Hämophilie A		Goethe-Universität Frankfurt	08.10.2021
	423	AIDA2009	NA	Empfehlung zur risikoadaptierten Behandlung der akuten Promyelozytenleukämie (APL) im Rahmen der AML-SAL-Studiengruppe (AIDA2009)- eine Beobcahtungsstudie-			25.09.2012	31.01.2014
	155	AIO-KRK-0109	2009-017731-17	An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and k-ras wildtype (VOLFI)	2	AIO	01.02.2011
	999	AIO-MAM-0110		Vinorelbine In Combination with the mTOR Inhibitor Everolimus vs Vinorelbine monotherapy in Advanced breast cancer	2
	864	AIO-TRK-0114	2014-001983-36	Eine randomisierte, offene Phase II-Studie zur Förderung der pan-ERBB Blockade nach einer platinbasierten Induktionschemotherapie bei Patienten mit metastasiertem, EGFR mutiertm, nicht-kleinzelligen Lungenkarzinom mit Progress nach Behandlung mit Afatinib als erster gegen EGFR gerichteter Therapie.	2	AIO-Studien-GmbH
	1372	AIO-YMO/TRK-0120	2020-003512-27	Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study	2		08.12.2021
	993	AIOKRK0306	2006-004030-32	Randomisierte Studie zur Wirksamkeit von FOLFIRI in Kombination mit Cetuximab vs. Bevacizumab in der Erstlinien-Behandlung des metastasierten kolorektalen Karzinoms	2
	601	ALCANTARA	2013-000706-36	A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)	2	Amgen	24.10.2013	27.05.2017
	1331	ALCL-VBL	2017-002935-40	International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine	3	GPOH gemeinnützige GmbH	17.08.2020
	415	ALL GIMEMA 0201	NA	Glivec (Imatinib mesylate formerly known as STI 571) in the treatment of Philadelphia-chromosome positive and/or BCR/ABL rearranged adult Acute Lymphoblastic Leukemia	2	GIMEMA Foundation	25.11.2005
	414	ALL GIMEMA 0904	2004-001738-17	Intensification of post-remissional treatment of high-risk acute lymphoblastic leukemia in adults and minimal residual disease monitoring	2	GIMEMA Foundation	04.07.2005
	505	ALLIVE		Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in MDS or AML Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial		GWT TUD Gmbh, Dresden	03.04.2014	01.12.2016
	69	Allo-KMT-Studie		Allogene Blutstammzell-Transplantation mit dosisreduzierter Konditionierung bei Patienten mit fortgeschrittenem follikulären und Mantelzell-Lymphom (MCL)	2	Uniklinik	01.03.2007
	95	Allo-SCT-Treo-VP16-Cycle		Allogene Stammzelltransplantation nach Konditionierung mit Treosulfan, VP-16 und Cyclophosphamid bei Patienten mit akuter lymphatischer Leukämie(ALL), für die ein Konditionierungsregime mit Ganzkörperbestrahlung nicht in Frage kommt:Eine Phase II-Studie	2		27.06.2007	01.03.2011
	1412	AlloRelapseMM	2021-001005-67	Allogene Stammzelltransplantation im Vergleich zur konventionellen Therapie als Salvage-Therapie für Patienten mit rezidiviertem / progredientem multiplen Myelom nach einer Erstlinientherapie (AlloRelapseMMStudy)	3		02.03.2021
	90	AmBiGuard	2010-019562-91	A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)	3	Gilead	20.12.2010	16.01.2014
	1259	AMG 20180257	2019-004780-52	A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)	1	Amgen
	1265	AMG 404 20190177	2019-004304-36	A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)	1	Amgen	06.01.2021	13.07.2022
	1354	AMG103 (20190360)	2020-004498-29	Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)	3	Amgen
	82	AML 2003		Randomisierter Vergleich zwischen Standard- und intensivierter Therapiestrategie der akuten myeloischen Leukämie des Erwachsenen im Alter von < 60 Jahren. (AML2003)	3	Uniklinik Dresden
	362	AML 2004 OSHO #069 (Elderly)		Verbesserung der Behandlungsergebnisse bei älteren Patienten mit akuter myeloischer Leukämie durch Intensivierung der Konsolidierungschemotherapie sowie durch den Einsatz der allogenen Transplantation nach dosisreduzierter Konditionierung	3	Universitätsklinikum Leipzig
	23	AML-AZA	2008-004583-40	A randomized, multicenter phase II trial to assess the efficacy of 5-Azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML.	2	Universitätsklinikum Münster	25.03.2009	08.12.2012
	361	AML-CG 2008	2007-003103-12	A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia	3	Klinikum der Ludwig-Maximilians-Universität M	10.03.2009
	26	AMLSG 08-07	2007-006638-33	Open-Label, Multi-Center Phase I Dose-Escalation Study With Lenalidomide In Patients With Acute Myeloid Leukemia.	1	Uniklinik Ulm	24.11.2008	30.11.2015
	363	AMLSG 14-09 (DECIDER)	2009-009916-33	Prospektive, randomisierte, multizentrische Phase II Studie mit niedrig-dosiertem Decitabine (DAC) alleine oder in Kombination mit dem Histon- Deacetylase Inhibitor Valproat (VPA) und All- Transretinsäure (ATRA) bei Patienten über 60 Jahre mit akuter myeloischer Leukämie, bei denen eine Standard-Induktions- Chemotherapie nicht geeignet ist	2	Uniklinik Freiburg	13.05.2011	21.07.2016
	364	AMLSG 17-10 (CIARA)	2010-021719-18	Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML	1/2	Medizinische Hochschule Hannover (MHH)	02.12.2011
	504	AMLSG 18-12		Erhaltungstherapie mit Histamindihydrochlorid und Interleukin-2 bei erwachsenen AML Patienten mit messbarer minimaler Resterkrankung(MRD) - eine nicht-interventionelle Beobachtungsstudie			01.02.2013
	1047	AMPLIFY-NEOVAC (NOA-21)	2017-000587-15	AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial to assess safety, tolerability and immunogenicity of IDH1R132H specific peptide vaccine in combination with checkpoint inhibitor Avelumab	1
	1310	Amplyx APX001-202	2019-001386-33	A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds	2	Amplyx Pharmaceuticals	22.04.2021	04.07.2023
	101	AP24534-10-201	2010-020414-28	A Pivotal Phase 2 Trial of AP24534 in Patients with Refractory Chronic Myeloid Leukemia an Ph+ Acute Lymphoblastic Leukemia	2	ARIAD	20.01.2011	31.05.2016
	135	APL-C-001-09 (ADMYRE)	2009-016138-29	RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF PLiTIDEPSIN IN COMBINATION WITH DEXAMETHASONE VS. DEXAMETHASONE ALONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	3	PharmaMar	07.07.2010	15.11.2017
	42	APL0406	2006-006188-22	A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute promyelocytic leukemia	3	Deutsche StudienInitiative Leukämie (DSIL)	04.08.2008	01.11.2018
	503	ARCADE	2009-016522-14	Multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie zur Behandlung von anämischen Patienten mit myelodysplastischem Syndrom (MDS) mit niedrigem oder intermediär-1 Risiko mit Darbepoetin alfa	3	Amgen Inc.	29.12.2012
	177	ARD12042	2011-001847-58	A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who ar resistant or intolerant to hydroxyurea	2	Sanofi-Aventis	26.04.2012	20.09.2013
	176	ARD12130	2011-001616-57	A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma	2	Sanofi-Aventis	29.09.2011	20.02.2015
	383	ARD12181	2011-005226-21	A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	2	Sanofi-aventis Recherche & Développement	17.04.2012	18.03.2014
	1220	ARO-013	2017-001600-29	Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects <= 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia	3	Arog Pharmaceuticals, Inc.	02.04.2020
	78	AS703569		A Phase 1, dose-escalation study of AS703569 given orally to subjects with haematological malignancies	1	Merck Serono	29.11.2006	18.02.2010
	636	ASPIRE		A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)	2	Glaxo	08.03.2012
	720	ATLANTIC	2013-005427-16	Eine nicht vergleichende, offene, multizentrische, internationale Phase-II-Studie bzgl. MEDI4736 bei Patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom (Stadium IIIB-IV),die mindestens zwei vorangegangene systemische Behandlungen, eischließlich einer Platin-basierten Chemotherapie, erhalten haben. (D4191C00003)	2	Astra Zeneca	19.06.2014
	1022	ATTRACT-2		A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer (ATTRACT-2)	3
	79	Aura 6202-003	2005-002591-15	A Phase I Dose-Escalation Study of PHA-739358 Administered as a 3-hour Infusion Daily for 3 Consecutive Days in a 14-day Cycle in Adult Patients with Relapsed/Refactory Acute Leukamia	1	Nerviano Medical Science	02.05.2007	29.07.2010
	178	Aura 6202-004	2005-004217-15	A Phase I Dose-Escalation Study of PHA-739358 Administered as a 3-hour Infusion in a 14-day Cycle with relapser/Refractory Hematological Malignancies	1	Nerviano Medical Science	02.05.2007	29.07.2010
	45	AURA-6202-009		Aura 6202-009, A Phase I Study with the Multikinase Inhibitor PHA-739358	1		26.06.2008
	697	AURA3	2014-000594-39	A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Lokally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3)	3	Astra Zeneca	19.08.2014
	991	Auto-Allo TSCT in MM		Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma	3
	802	AVALTE	2011-002009-31	Eine einarmige, offene, multizentrische Verlängerungsstudie mit Bevacizumab bei Patienten mit soliden Tumoren unter Studienbehandlung mit Bevacizumab am Ende einer von F. Hoffmann-La Roche / Genentech gesponserten Studie	4	Roche	01.04.2015
	49	AVD-Revlimid Studie	2008-008737-11	Phase I Dosisfindungsstudie mit Lenalidomid (Revlimid®) in Kombination mit AVD bei älteren Hodgkin Lymphom Patienten in mittleren und fortgeschrittenen Stadien	1	GHSG	02.09.2010	31.03.2015
	865	AVEO-AV-951-15-303	2015-003607-30	Eine randomisierte, kontrollierte, multizentrische, offene Phase III Studie zum Vergleich von Tivozanibhydrochlorid mit Sorafenib bei Patienten mit therapiefraktärem fortgeschrittenem Nierenzellkarzinom.	3	AVEO Pharmaceuticals, Inc.	21.04.2016	02.06.2021
	156	Axtinib	2008-007786-23	Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer	2	Pfizer	27.05.2009	15.08.2012
	502	AZA-MDS-003	2012-002471-34	A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes	3	Celgene	29.04.2013
	80	Azarela	2007-004860-37 (laut Sponsor)	Phase-II trial to assess the efficacy and toxicity of 5-Azacitidine in addition to standard donor lymphocyte infusions for the treatment of patients with AML or MDS relapsing after allogeneic stem cell transplantation	2	Uniklinikum Düsseldorf	01.01.2008	21.11.2012
	669	B1371003	2012-000684-24	A phase 1B/2 study to evaluate the safety and efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose Ara-C or Decitabine in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.	1/2	Pfizer	23.05.2013	04.03.2019
	546	B1931022 (Inotuzumab)	2011-005491-41	An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigators Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)	3	Pfizer	07.09.2012	02.05.2017
	842	BAY18239	2015-003483-37	An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated or recommended Phase II dose of oral mutant IDH1 inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacokinetics and preliminary pharmacodynamic and anti-tumor activity in patients with IDH1-R132Xmutant advanced solid tumors	1	Bayer Healthcare AG	15.06.2016	28.06.2022
	1251	BAY19781	2018-003704-39	An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer	1/2	Bayer Healthcare AG
	715	Bayer 16520	2014-000410-57	An open-Label Phase I dose-escalation study characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY1143572 given in a once-daily or intermittent dosing schedule in subjects with advanced acute leukemia.	1	Bayer Healthcare AG	27.01.2015	30.07.2017
	68	BERT	2009-013351-30	A phase I/II trial to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular lymphomaor mantle cell lymphoma in first to third relapse	2	Uniklinik Mainz	07.01.2010	31.10.2016
	395	BEZ 235	2011-005050-61	A phase I, dose-finding study of the oral, dual PI3-Kinase / mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.	1	Dekan der Universität Frankfurt	18.06.2012	07.02.2020
	797	BGBC003	2014-000165-46	A Phase I multicenter open-Label study of BGB324 as a single Agent and in combination with cytarabine in patients with acute myeloid leukemia	1	BerGenBio AS	15.01.2016	04.04.2023
	39	BI 1230.4	2008-003617-27	An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intravenous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with AML.	1/2	Böhringer Ingelheim	07.11.2008
	560	BI 1270.1	2010-021488-34	A Phase I, open, dose escalation trial with BI 836826 in patients with advanced chronic lymphocytic leukaemia	1	Böhringer Ingelheim	02.12.2013	01.03.2014
	384	BI 1270.2	2010-024456-29 (laut Sponsor)	A phase I , open label, Dose escalation Trial with BI 836826 in patients with Relapsed or refractory non – Hodkin Lymphoma of B- cell origin	1	Boehringer Ingelheim	08.02.2012	31.12.2016
	1422	BI 1403-0002	2019-001173-84	A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors	1	Boehringer Ingelheim
	1252	BI 1432-0001	2018-004757-24	A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With Trametinib in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours	1	Böhringer Ingelheim	17.09.2020
	32	BI 811283	2007-005684-10	An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Efficacy and Pharmacokinetics of BI 811283 in Combination With Cytarabine in Patients With Previously Untreated Acute Myeloid Leukaemia Ineligible for Intensive Treatment	1	Boehringer Ingelheim Pharmaceuticals	01.05.2008	01.03.2014
	548	BI1230.33	2013-001290-24	An open label Phase I dose escalation trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intravenous volasertib in combination with subcutaneous azacitidine in patients with previously untreated high-risk myelodysplastic syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) ineligible for high-intensity therapy	1	Böhringer Ingelheim	01.10.2013	16.12.2016
	33	BI1247.3	2007-005684-10	An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatment	1	Boehringer Ingelheim Pharmaceuticals	17.03.2008	05.03.2014
	906	BIBF 1120	2011-001086-41	Eine randomisierte, Placebo-kontrollierte, multizentrische Studie zur Erfassung der Effektivität von Nintedanib (BIBF 1120) in Kombination mit niedrig-dosiertem Cytarabin bei älteren Patienten mit nicht intensiv behandelbarer AML	1/2	Uniklinik Münster	01.09.2017	27.07.2021
	515	BIBF1120 in AML	2011-001086-41	Eine einarmige, offene, multizentrische Phase I/II Studie zur Addition von BIBF1120 zu LDAC bei älteren Patienten mit neudiagnostizierter AML, welche sich nicht für eine intensive Induktionstherapie oder hypomethylierende Therapie qualifizieren	1/2	Universitätsklinikum Münster	28.02.2012
	1009	BIOLUMA/ Uni-Koeln-2785	2016-003334-25	Eine Phase II-Studie mit Nivolumab in Kombination mit Ipilimumab zur Evaluierung der Sicherheit und Wirksamkeit im rezidivierten Lungenkrebs und zur Evaluierung von prädiktiven Biomarkern	2	Universität zu Köln	26.01.2017
	863	BIRMA	2014-004597-42	LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E or BRAFV600K mutation	2	Universitätsklinik Heidelberg	01.06.2016
	772	BLAST	2014-002702-21	A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to conSo	2	Martin-Luther Universität Halle Wittenberg	14.07.2015	15.10.2021
	1376	BLIVEN	2021-001384-25	Eine offene Phase I/II - Studie mit Venetoclax in Kombination mit Blinatumomab Immuntherapie bei erwachsenen Patienten mit rezidivierter/refraktärer akuter B-lymphobastischer Vorläufer-Leukämie	1/2	Goethe-Universität Frankfurt	28.09.2021
	1192	BMC2012-Phasell	2015-001820-51	Zellbasierte Therapie mit bone marrow-derived mononuclear cells (BMC) zur Knochenaugmentation bei der Osteosynthese proximaler Humerusfrakturen - eine randomisierte, offene, multizentrische Phase IIa Studie Cell based therapy by implanted bone marrow-derived mononuclear cells (BMC) for bone augmentation of plate-stabilized proximal humeral fractures - a randomized, open, multicentric study - phase IIa		Goethe-Universität Frankfurt	02.07.2016	07.01.2020
	1432	BMS 052-002	2021-001188-26	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors	1/2	Bristol Myers Squibb	20.03.2023
	102	BMS CA180-035	2005-001169-32	A Randomized Two-Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70mg Twice Daily or 140mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib Mesylate (Gleevec) CA 180-035 Rekrutierung beendet	3		26.07.2005	30.06.2013
	103	BMS CA180-323		Dasatinib (BMS-354825) plus SMO inhibitor (BMS-833923; XL139) in patients with CML resistant to imatinib or nilotinib, or with suboptimal response to nilotinib or dasatinib	1		01.01.2011	29.11.2012
	238	BMS CA216-002	2010-022727-29	Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	1	BMS	01.10.2011	31.12.2015
	592	BO20603 MAIN	2006-005520-16	An international, multi center phase III study of R-CHOP vs R-CHOP + Bevacicumab (RA-CHOP) in patients with previously untreated diffuse large cell B-cell Non Hodgkin´s lymphoma	3	Roche	06.11.2007	30.11.2011
	979	BPV	2013-005485-19	Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma (BPV)	2
	992	BRENDA	2010-024004-98	Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients("slow go") with Aggressive CD-20-positive B-cell Lymphoma Short tiltle: BRENDA	2
	652	BT989	2013-003252-20	An open lable, two stage, phase I/IIa dose escalation study of BT062 in metastasic triple receptor-negative breast cancer and in metastasic transitional cell carcinoma of the urinary bladder.	1/2	Inc. Research	25.03.2014	04.08.2017
	243	BUM-5/GVHD	2008-004562-10	Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD	3	Dr. Falk Pharma GmbH	29.07.2009	01.08.2014
	179	C AMN107 Y 2101	2011-000282-12	A single-arm dose-finding phase Ib multicenter study of the oral Smoothened antagonist LDE225 in combination with nilotinib 400 mg b.i.d. in chronic phase chronic myeloid leukemia patients who have failed prior therapy with other BCR-ABL tyrosine-kinase inhibitors	1	Novartis	28.12.2011	01.02.2014
	158	C-II-004	2007-005022-71	First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer	1/2	CESAR	17.01.2008	08.11.2011
	159	C-II-006	2009-010143-13	Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib	3	CESAR	03.06.2009	02.07.2014
	516	C-II-008 (Berat)	2011-005939-78	Eine prospektive, offene, multizentrische, randomisierte Phase-II-Studie: Sequenztherapie mit BEvacizumab, RAd001 (Everolimus) und Tyrosinekinase-inhibitoren (TKI) im metastasierten Nierenzellkarzinom (mRCC) (BERAT study)	2	CESAR	25.06.2012	22.08.2016
	611	C16010	2011-005496-17	A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma	3	Millennium Pharmaceuticals	10.10.2012
	986	C16011	2011-005468-10	Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis	3
	985	C16019	2013-002076-41	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant	3
	837	CA 209-498	2015-003739-37	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methylatransferase) Glioblastoma	3	Bristol Myers Squibb	29.02.2016
	618	CA180-373	2013-002156-33	A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination of Dasatinib (BMS-354825) plus Nivolumab (BMS-936558) in Patients with Chronic Myeloid Leukemia (CML)	1	Bristol Myers Squibb	01.04.2014	28.11.2018
	517	CA184156	2011-000850-48	CA184156 Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)	3	Bristol Myers Squibb	08.05.2012	23.02.2017
	989	CA204-004	2010-020347-12	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma	3
	727	CA209-214	2014-001750-42	A Phase 3, Randomizid, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previosuly Untreated, Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214; CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 2014)	3	Bristol Myers Squibb	18.12.2014
	1082	CA209-580		A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy		Bristol Myers Squibb
	731	CA209032	2013-002844-10	A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors	1/2	Bristol Myers Squibb	03.12.2013
	1409	CABL001A2001B	2021-000602-17	An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment	3
	1355	CABL001A2302	2020-006057-21	A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors	3	Novartis	23.08.2021
	1360	CABL001J12301 A	2021-000678-27	A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase	3	Novartis Pharma AG	10.08.2021
	1427	CABL001J12302	2022-000995-21	A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinibin patients with newly diagnosed Philadelphia Chromosome Positive Chronic MyelogenousLeukemia in Chronic Phase	3	Novartis Pharma GmbH	20.10.2022
	619	CABL001X2101	2013-004491-36	A phase I, multicenter, open-label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic leukemia	1	Novartis	15.04.2014
	1106	CACZ885V2301	2018-002480-26	A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2)	3	Novartis
	44	CAMN107 A 2128		Offen, zweiphasige, Erstsequenzstudie zur Beurteilung der Wirkung mehrerer Dosen Nilotinib auf die Pharmakokinetik von Midazolam bei CML-Patienten mit Resistenz und/oder Intoleranz gegen mindestens eine frühere Therapie mit einem BCR-ABL-Tryosinkinase-Inhibitor	1	NOVARTIS Pharma Services AG	19.10.2010	31.12.2014
	100	CAMN107 Y 2101		A single-arm dose-finding phase Ib multicenter study of the oral Smoothened antagonist LDE225 in combination with nilotinib 400 mg b.i.d. in chronic phase chronic myeloid leukemia patients who have failed prior therapy with other BCR-ABL tyrosine-kinase inhibitors	1		01.01.2012	11.12.2013
	382	CAMN107A2101	2004-001483-51	A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies	1/2	Novartis	12.07.2005
	25	CAMN107ADE01 (NiloRAD)	2007-000502-70	An open-label phase I/II (proof of concept) trial of a combination of Nilotinib (AMN107) and RAD001 in patients with acute myeloid leukemia	2/3	Dekan Technische Universität München	10.12.2007	29.06.2012
	242	CAMN107ADE04(Target)		Nicht-interventionelle Studie zur Sicherheit und Wirksamkeit von Tasigna sowe zur Therapietreue der Patienten in der Behandlung der Philadelphia-Chromosom-positiven chronischen myeloischen Leukämie in chronischer Phase bei Patienten mit Resistenz oder Unverträglichkeit gegenüber einer Vorbehandlung einschließlich Glivec	4	Novartis	01.06.2007
	1393	CAMN107EDE13T (TIGER)	2010-024262-22	Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy	3	Universitätsklinikum Jena	07.12.2012
	104	CAMN107EIC01	2009-017775-19	A phase III multicenter study of nilotinib in adult patients with newly diagnosed CML in chronic phase using molecular endpoints	3	Novartis	21.06.2010	26.03.2014
	725	CAMN107YDE19	2014-000831-18	A Phase Ib single-arm, open-label, multicenter study to assess the safety and tolerability of combined treatment with nilotinib 300mg BID and ruxolitinib increasing dose in CML patients in CP and in AP/BC or relapsed/refractory Ph+ ALL	1	Novartis	01.03.2015
	1054	CANFOUR (CAN04CLIN001)	2017-001111-36	An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors	1/2		19.07.2019
	1434	CAPTOR-BC	2022-000637-16	Comprehensive Analysis Of Spatial, Temporal And Molecular Patterns Of Ribociclib Efficacy And Resistance In Advanced Breast Cancer Patients	4	IFG Erlangen	11.07.2022
	867	CAPTURE Trial	2015-001035-20	Phase III, randomized, double-blind, multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the THERAFLEX UV-Platelets procedure in comparison to conventional platelet components (CAPTURE)	3	DRK-Blutspendedienst NSTOB	13.01.2016	18.07.2019
	60	CAUY922 A2103	2007-006279-35	Eine offene, multizentrische, Phase I-Ib/II Studie zur Beurteilung von AUY922 als Monotherapie oder in Kombination mit Bortezomib, mit oder ohne Dexamethason, bei erwachsenen Patienten mit rezidiviertem oder refraktärem Multiplen Myelom	1/2	NOVARTIS Pharma Services AG	17.09.2008	18.02.2011
	1342	CB103-C-101	2017-001491-35	A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway	1/2	Cellestia Biotech		16.06.2022
	480	CBKM120 Z2402	2012-002208-41	An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follikular lymphoma	2	Novartis	05.03.2013	20.08.2014
	547	CBKM120D2205	2013-000833-11	A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer	1/2	Novartis	18.11.2013	04.08.2015
	1450	CC-220-MM-002	2020-000431-49	A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)	3	Celgene
	81	CC-5013-MM20/IFM-07/01	2007-004823-39	A Phase III, Randomized, Open-Label, 3-Arm Study To Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation	3	Celgene Corporation	26.06.2008	14.07.2016
	1076	CD-TCR-001	2017-000440-18	A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms	1/2	Medigene AG	28.11.2019
	360	CD3/CD19 EBMT-Haplo-Studie	2007-006016-33	Multizentrische Phase II Studie zur haploidenten Stammzelltransplantation mit einem CD3/CD19 depletierten Transplantat nach einer dosisreduzierten Konditionierung bei Erwachsenen mit einer akuten Leukämie	2	Uniklinikum Tuebingen	30.09.2008
	1018	CDR0000459685	2005-00521738	Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkins Lymphoma
	1264	CETB115JDE01	2019-002658-21	A Phase II, randomized (1:1) open-label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone, as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia (XPAG-ITP)	2	Novartis Pharma AG	28.01.2021
	157	CHANGE		Charakterisierung von Afinitor Nach Gezielter Ersttherapie		Novartis	17.08.2008	31.12.2012
	914	CHARLY	2015-003920-30	Eine Studie zum Stellenwert von Cyclophosphamid nach Thiotepa-Basierter Haplo-identer Stammzelltransplantation für refraktäre non-Hodgkin Lymphome	2	Universität Heidelberg	20.09.2016
	745	CHDM201X2101	2013-003521-28	A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and hematological tumors characterized by wild-type TP53	1	Novartis	15.10.2015
	637	CHOICES	2009-014373-41	A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR)	2	NHS Greater Glasgow and Clyde	27.01.2012
	108	CHOP R-ESC		2-wöchentliche CHOP-Chemotherapie mit intensiviertem Rituximab zur Behandlung von Patienten im Alter von 61 bis 80 Jahren mit aggressivem CD20-positivem B-Zell-Lymphom: Eine Phase-II- und pharmakokinetische Studie	2		30.06.2007
	70	CICL670ADE02	2006-003970-89	A One-Year, Open-Label, Single Arm, Multi-Center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present	4	NOVARTIS Pharma Services AG	21.12.2007	25.03.2013
	53	CICL670ADE03	2006-003971-11	A One-Year, Open-Label, Single Arm, Multi-Center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-Dependent Iron Overload	4	NOVARTIS Pharma Services AG	10.04.2007	06.09.2010
	857	CIDH305X2102	2015-005737-50	A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia	1	Novartis	01.08.2016
	781	CINC280A2201	2014-003850-15	A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease	2	Novartis	24.07.2015
	777	CINC280X2102	2010-024101-12	A Phase I open-Label dose escalation study with Expansion to assess the safety and tolerability of INC280 in patients with c-met dependent advanced solid tumors	1	Novartis	05.03.2015	26.10.2017
	756	CINC280X2202	2011-002569-39	A phaseIB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progressed after EGFR inhibitor treatment	1/2	Novartis	29.09.2014	07.05.2017
	180	CINC424 A2401	2010-024473-39	An open-label, multicenter, expanded access study of INC 424 for patients with primary myelofirosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrisis (PET-MF).	3	Novartis	11.08.2011	13.05.2013
	40	CLBH589B2116	2008-002986-30	A Phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukaemia. (CLBH589B2116)	1	NOVARTIS Pharma Services AG	08.01.2010	27.07.2012
	109	CLBH589B2201	2006-000880-27	A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma	3	Novartis	12.02.2007	24.06.2013
	34	CLBH589B2213	2008-002983-32	A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous leukemia(AML).	2	NOVARTIS Pharma Services AG	13.08.2009	29.05.2013
	54	CLBH589BDE04	2009-010403-84	Einjährige, offene multizentrische Studie von LBH589 allein oder in Kombination mit ESA bei Erythrozytentransfusionsabhängigen LOW und INT-1 MDS Patienten, die entweder refraktär oder mit einer niedrigen Wahrscheinlichkeit auf ESA ansprechen	2	NOVARTIS Pharma Services AG	09.11.2009	18.07.2012
	61	CLBH589D2308	2009-015507-52	A multicenter,randomized,double-blind,placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma	3	NOVARTIS Pharma Services AG	08.12.2009	14.07.2015
	85	CLBH589E2214	2008-003016-35	A Phase IA/II study of oral Panobinostat in adult patients with relapsed/refractory classical Hodgkins’s Lymphoma after high dose chemotherapy with autologous stem cell transplant (CLBH589E2214)	1/2	Novartis	26.09.2008	07.04.2010
	111	CLBH589G2101	2009-016809-42	A phase Ib, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine-based consolidation therapy in adult patients less than or equal to 65 years old with acute myeloid leukaemia (AML)	1	Novartis	29.11.2010	01.05.2014
	35	CLBH589H2101	2009-010548-32	A phase I/b, open-label, multi-centre, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) or acute myeloid leukaemia (AML) (CLBH589H2101)	1	NOVARTIS Pharma Services AG	08.09.2009	13.11.2014
	634	CLDE225X2116	2011-005016-28	A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis	1/2	Novartis Pharma AG	01.05.2013
	542	CLDE225X2203	2012-004022-21	Eine multizentrische, offene, randomisierte Phase II-Studie zur Beurteilung der Sicherheit und Wirksamkeit zweier unterschiedlicher Schemata mit oralem LDE225 bei erwachsenen Patienten mit rezidivierter/refraktärer akuter Leukämie oder bei unbehandelten älteren Patienten mit akuter Leukämie.	2	Novartis	03.06.2013	12.06.2015
	858	CLDK378A2103	2014-003741-95	A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)	1	Novartis	01.10.2015	11.01.2018
	593	CLDK378A2303	2012-005637-36	A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib	3	Novartis	30.09.2013	15.06.2016
	160	CLL 11 (B021004)	2009-012476-28	An open-label, multi-center, three-arm randomized, phase-III study to compare the efficacy and safety of R05072759 + chlorambucil (GClb), rituximab and chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities	3	Hoffmann la Roche	24.02.2010	21.03.2013
	43	CLL-10	2007-007587-21	Prospektive randomisierte Phase III Studie mit Fludarabin, Cyclophosphamid and Rituximab (FCR) gegenüber Bendamustin and Rituximab (BR) bei Patienten mit primär unbehandelter chronisch lymphatischer Leukämie	3	DCLLSG	05.09.2008	01.01.2018
	782	CLL14/BO 25323	2014-001810-24	A prospective, open-label, multicenter randomized Phase III Trial to compare the efficacy and safty of a combined regimen of OBINUTUZUMAB and VENETOCLAX versus OBINUTUZUMAB and CHLORAMBUCIL in previously untreated patients with CLL and coexisting medical conditions.	3	Roche	17.12.2014
	1299	CMBG453B12301	2019-002089-11	A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)	3	Novartis	25.03.2021
	856	CMCS110Z2102	2016-000210-29	A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies	1/2	Novartis	27.09.2016	04.06.2020
	932	CMCS110Z2102	2016-000210-29	A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies	2	Novartis	27.09.2016	04.06.2020
	1452	CMGY825A12101	2021-006793-22	An Open label, Phase I, dose escalatio, expansion study of MGY825 in adult patients with advanced NSCLC	1	Novartis Pharmaceuticals	11.03.2022
	639	CML VI		CML Register Studie		Universität Heidelberg	01.08.2013
	708	CO-1686-19	2013-005532-23	TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation	2	Clovis	11.08.2014
	1253	CodeBreak200	2019-003582-18	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CodeBreak200)	3	Amgen Inc.	31.08.2020
	379	COSS-EURAMOS 1	2004-000242-20	A randomized trial of the European and American Osteosarcoma Study Group		SSG	05.04.2005
	56	CP4055-106	2006-000868-83	A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies	3	Clavis Pharma	28.05.2008	17.06.2009
	365	CP4055-205	2008-008518-38	A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia	2		30.09.2009	07.05.2013
	1058	CR-AIR-009 (HATCY)	2016-004672-21	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy	3	Kiadis Pharma Netherlands B.V.	29.11.2017	12.11.2019
	984	CR103995	2014-000255-85	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	3
	1004	CR108193		A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	3
	1005	CR108193	2016-001737-27	A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
	162	CRAD001N2301-PILLAR	2008-000498-40	Prospektive randomisierte doppelblinde placebokontrollierte Phase III Studie zur adjuvanten Therapie bei Hochrisikopatienten mit diffusem großzelligen B-NHL (DLBCL) mit RAD001 gegen Placebo nach kompletter Remission nach einer Erstlinientherapie mit R-CHOP	3	Novartis	27.11.2009	06.06.2016
	366	Crescendo	2010-018339-16	Phase IV Compliance Studie bei Ph-positiver CML unter Imatinib Langzeittherapie	4	Gesellschaft fur Medizinische Innovation – Ha	19.07.2010	03.07.2013
	903	Crisp		CLINICAL RESEARCH PLATFORM INTO MOLECULAR TESTING, TREATMENT AND OUTCOME OF NON-SMALL CELL LUNG CARCINOMA PATIENTS AIO-TRK-0315		AIO Studien GmbH	15.11.2016
	181	CSTI571 JDE 74	2008-003883-20	An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection	3	Novartis	30.09.2008	02.12.2009
	182	CU-INC424-2011-1		Compassionate Use Program for patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV		Novartis	22.06.2011	31.12.2014
	555	CV-9202-006	2012-004230-41	An exploratory, open-label phase Ib study of RNActive®-derived cancer vaccine and local radiation as consolidation and maintenance treatment in patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor	1	CureVac GmbH	19.12.2013	31.12.2017
	1425	CVAY736I12301	2022-001672-34	A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1)	3	Novartis	18.05.2022
	1424	CVAY736O12301	2022-001773-31	A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)	3	Novartis	13.12.2022
	112	CYTAVIS	2008-005536-32	Phase II Double-blind Placebo-controlled Trial fo CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Caner	2	Cytavis	30.04.2009	28.06.2011
	1433	CYTB323A12101	2018-004336-30	Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL, DLBCL and ALL	1	Novartis Pharmaceuticals	23.05.2019
	651	D2610C00001	2009-012922-35	A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies	1	AstraZeneca	01.11.2011	26.06.2014
	1449	D8241C00001	2020-005106-25	A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies	1/2	Astra Zeneca	15.11.2021	24.07.2023
	635	DASPERSE (CA180-400)	2011-006180-21	A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib	4	Bristol-Myers Squibb	29.05.2013
	1195	DELIcu	2012-004082-41	Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine	3	Goethe-Universität Frankfurt	22.10.2013	28.02.2021
	1435	Destiny-B05	2020-003982-20	A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy	3	Daiichi Sankyo, Inc.	16.03.2021
	105	DJCLS R 07/33		Carreras-Folgeprojekt: Lebensqualität und medizinische Spätfolgen bei Langzeitüberlebenden nach akuter lymphatischer Leukämie des Erwachsenen		DJCLS	01.10.2007	30.04.2011
	244	DJCLS R 07/33 - Retro		Carreras-Folgeprojekt: Lebensqualität und medizinische Spätfolgen bei Langzeitüberlebenden nach akuter lymphatischer Leukämie des Erwachsenen, retrospektive Erhebung			01.10.2007	30.04.2011
	813	DKTK maligne Gliome		DKTK Joint Funding Project Next generation molecular diagnostics of malignant gliomas		DKFZ	25.02.2013
	746	DKTK-Master		Molecularly aided stratification for tumor eradication research		DKFZ	05.05.2015
	1351	DKTK_PMO_1605	2019-000238-20	First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration resistant prostate carcinoma	1	Universitätsklinikum Tübingen
	1446	DNPM Evaluation		Quantitative Evaluation als Teil des Projektes DNPM		Universität Tübingen	15.02.2023
	1080	DS8201-A-U105	2018-000371-32	A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer	1/2	Daiichi Sankyo, Inc.
	63	DSHNHL 2004-2 (FLYER)	2005-005217-38	Randomisierte Studie zum Vergleich einer Immuntherapie mit 6 Zyklen des monoklonalen anti-CD20-Antikörpers Rituximab in Kombination mit 6 oder 4 Zyklen einer Chemotherapie mit CHOP (Cyclophosphamid, Doxorubicin, Vincristin und Prednison) in 21-tägigen Intervallen bei Patienten mit aggressiven CD20-positiven B-Zell-Lymphomen im Alter von 18-60 Jahren ohne Risikofaktor (altersadaptierter IPI=0) und ohne große Tumormassen (Durchmesser <7,5 cm)	3	German High Grade Non-Hodgkins Lymphoma group	25.07.2008
	173	DSHNHL 2004-3 (UNFOLDER-Studie)	2005-005218-19	Randomised Study Comparing an Immuno-Chemotherapy with 6 Cycles of the Monoclonal anti-CD20 Antibody Rituximab in Combination with 6 Cycles of Chemotherapy with CHOP	2	DSHNHL	12.10.2007	01.02.2018
	169	DSHNHL 2009-1 (Optimal > 60 Jahre)	2010-019587-36	Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-Cell Lymphoma by an optimised schedule of the monoclonal antibody Rituximab, substitution of conventional by liposomal Vincristine and FDG-PET based reduction of therapy	3	Universität Saarland	03.07.2012
	552	DSMM XIII	2008-004083-39	The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the Treatment of multiple myeloma DSMM XIII	3	GMIHO	19.10.2009	31.01.2020
	1256	DSMM XVII	2017-001616-11	Elotuzumab (E), in Kombination mit Carfilzomib, Lenalidomid und Dexamethason (E-KRd) gegen KRd vor und nach autologer Stammzelltransplantation bei neu diagnostiziertem Multiplen Myelom und mit nachfolgender Erhaltungstherapie mit Elotuzumab und Lenalidomid gegen Lenalidomid Monotherapie. Eine Phase III Studie der Deutschen Studiengruppe Multiples Myelom	3	UK Würzburg	25.09.2020
	1411	DSMMXIV	2009-016616-21	Lenalidomide, Adriamycin, Dexamethasone (RAD) versus Lenalidomide, Bortezomib, Dexamethasone (VRD).For Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomid Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)	3	Universitätsklinik Würzburg	20.10.2011
	183	EFC 12153	2011-001897-25	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myeolofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Splenomegaly	3	Sanofi-Aventis	17.11.2011	19.09.2012
	994	EGF108919	2007-004568-27	Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer	3
	1254	Elevate	2019-002808-41	An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia	1	Janssen Research & Development	17.09.2020
	1399	ELVN-001	2022-000052-11	A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia	1	ENLIVEN Therapeutics
	1380	EMCL-Registry		The Registry of the European Mantle Cell Lymphoma study group – MCL: Disease pattern, treatment algorithms and mechanisms of relapse		Universitätsmedizin Mainz
	919	ENDURE-CML-IX	2016-001030-94	Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase II, Multicenter Trial With Post-study Follow-up	2	Philipps-Universität Marburg	16.01.2018
	509	ENESTFreedom (CAMN107I2201)	2012-004092-40	A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment	2	Novartis Pharma GmbH	03.01.2013
	642	ENESTop	2012-003186-18	A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)	2	Novartis Pharma AG	15.01.2013
	638	ENESTPath	2012-005124-15	A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID	3	Novartis Pharma AG	16.05.2013
	533	EPAZ	2011-004168-30	A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma	2	GlaxoSmithKline	07.08.2012	25.11.2015
	422	EPIC	2012-001355-38	A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	3	Ariad Pharmaceuticals	17.09.2012
	371	EPOANE	2010-022884-36	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes	3		04.07.2011
	714	ERTUSO_S497	2011-003201-14	Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/neu Expressing (1+/SISH positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy	1	KH Nordwest, Frankfurt	02.03.2012	02.05.2016
	1397	EsPhALL2017/COGAALL1631	2017-000705-20	International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones	3		05.11.2018
	1333	ET13-002	2013-002766-39	SIOP Ependymoma Program II - An international Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma	2/3	Centre Leon Berard in Lyon (Frankreich)
	92	ETAL-1-045	2010-019377-15	Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von <= 60 Jahren mit AML intermediären Risikos (Standardrisiko) und HLA-kompatiblem Geschwister- oder Fremdspender (ETAL-1).	2	Technische Universität Dresden	04.11.2010	30.04.2020
	819	ETAL3-ASAP	2014-003124-44	Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML (ETAL3-ASAP)	3	TU Dresden	28.05.2015
	687	EUCROSS	2013-002737-38	A phase II trial to evaluate efficancy and safety of Crizotinib treatment in advance adenocarcinoma of the lung harbouring ROS1 translocations	2	Uniklinik Köln	13.05.2014
	380	Euro-BOSS 1	N/A	A European treatment protocol for bonesarcoma in patients older than 40 years			19.10.2011	31.12.2016
	507	EuroTarget NIS		European collaborative project on TArgeted therapy in Renal cell cancer: GEnetic and Tumour-related biomarkers for response and toxicity		CESAR	17.10.2012	30.06.2016
	508	EuroTarget Phase IV	2012-001415-23	European collaborative project on TArgeted therapy in Renal cell cancer: GEnetic and Tumour-related biomarkers for response and toxicity	1	CESAR	17.10.2012	30.06.2016
	554	EVER PRO (CRAD001LDE51)	N/A	Evaluierung der Lebensqualität unter Zweitlinientherapie des met. NierenzellKarzinomss mit Affinitor	3	Novartis	04.10.2012	22.09.2017
	113	EWALL-PH-02	2010-022855-46	An open label phase II study to evaluate the efficacy and safety of induction and consolidation therapy with Nilotinib in combination with chemotherapy in patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL).	2	Dekan der Univiersitätsklinik Frankfurt	13.07.2011
	444	Ewing 2008	2008-003658-13	Randomisierte klinische Studie zur Therapieoptimierung bei Patienten mit lokalisiertem oder metastasiertem Ewing-Sarkom	3	Uniklinik Münster	01.01.2009
	747	ExAblate		International Registry: ExAblate Treatment of Bone Tumours and Pain Palliation		Insightec	20.08.2015	01.04.2017
	1065	Fascination (CMLXI)	2018-002256-33	Frontline Asciminib Combination in Chronic Phase CML	2
	185	Fasturtec Studie		Multizentrische randomisierte Phase-III-Studie zur Bestimmung von Effektivität und Sicherheit von Rasburicase (Fasturtec®) im Vergleich zu Allopurinol zur Behandlung der Hyperurikämie bei Patienten mit akuter lymphatischer Leukämie oder hochmalignem Non-Hodgkin-Lymphom mit hohem Risiko eines Tumorlyse-Syndroms (ab 15 Jahren) Fasturtec® bei ALL und B-ALL/NHL	3		01.04.2004	30.10.2008
	1019	FIRE 3		5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
	893	FIRE-4	2014-003787-21	Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab	3	Klinikum der Ludwig-Maximilians-Universität	11.03.2015
	1000	FL-OSHO/GLSG-M3-2005-01	2005-005473-29	Primärtherapie fortgeschrittener FL mit einer Induktion durch Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung	3
	1453	FLAMSACLAX	2022-002435-66	Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAML	1/2	Uniklinik Düsseldorf	07.02.2023
	737	FLAVIA		Prospektive Studie zur Bewertung der frühen Integration Palliativ-medizinscher Versorgung in die onkologische Therapie.		Institut für Klinisch-Onkologische Forschung	18.06.2015
	163	FLIPPER	2011-001138-40	Einarmige, multizentrische Studie zur Bewertung von Pazopanib als Erstlinientherapie in Hochrisikopatienten mit fortgeschrittenem oder metastasierendem Nierenzellkarzinom (First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma)	4	iOMEDICO	17.11.2011	31.07.2017
	1111	FPA144-004	2017-003507-22	A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase	3	Five Prime Therapeutics	12.08.2019
	1244	FREEDOM2	2018-003411-21	An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)	3	Celgene
	115	Freiburger ZNS-NHL Studie	2005-000615-99	Freiburger ZNS-NHL Studie	2	vertreten durch Prof. Dr. Dr. h. c. M. Brandt	28.12.2006
	237	GALLIUM (BBO21223)	2010-024132-41	A multicenter phase III open label randomized study in nmpreviously untreated patients with advanced indolent Non-Hodgkin-Lymphom evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab + chemotherapy followed by GA101 or Rituximab maintenance therapy in responders	3	Roche	30.11.2011	05.11.2021
	240	Geron CP14B015	2010-023076-10	Phase-II-Studie zur Beurteilung der Aktivität von Imetelstat (GRN163L) bei Patienten mit essentieller Thrombozythämie, die eine zytoreduktive Therapie benötigen und bei denen eine Vorbehandlung unwirksam bzw. unverträglich war oder die eine Standardtherapie ablehnen	2	Geron Corporation	28.02.2011	06.01.2015
	416	GIMEMA LAL1308	2009-016075-30	Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment	2	GIMEMA Foundation	01.04.2010
	417	GIMEMA LLC0606	2006-006185-42	A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients	1/2	GIMEMA Foundation	01.01.2009
	9	GMALL 07/03	n.a.	Multizentrische Therapieoptimierungsstudie der akuten lymphatischen Leukämie bei Erwachsenen und Adoleszenten ab 18 Jahren (GMALL 07/2003) - Therapieoptimierung durch Evaluation der minimalen Resterkrankung (Amendment IV)	4	verantwortliche Studiengruppe: GMALL	01.04.2003
	848	GMALL 08/2013	2013-003466-13	Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL)durch individualisierte, gezielte und intensivierte Therapie - Eine Phase IV-Studie mit einem Phase III-Teil zur Evaluation der Sicherheit und Wirksamkeit von Nelarabin bei T-ALL	3	Dekan der Universität Frankfurt	15.09.2015
	64	GMALL B-ALL/NHL 2002		Multizentrische Therapieoptimierungsstudie für die Therapie der B-ALL und hochmaligner Non-Hodgkin-Lymphome bei Erwachsenen (ab 18 Jahre) (Amendment VIII)	4		15.08.2002
	12	GMALL Elderly 01/2003		Therapieoptimierungsstudie für ältere Patienten (> 55 Jahre, ohne obere Altersgrenze) mit akuter lymphatischer Leukämie (Amendment II)	4	verantwortliche Studiengruppe: GMALL	01.04.2003
	14	GMALL Lebensqualität und Therapiefolgen nach ALL		Lebensqualität und Therapiefolgen - retro- und prospektive Begleitstudie für GMALL 07/03 und Elderly		verantwortliche Studiengruppe: GMALL	01.01.2008
	83	GMALL Register		GMALL-Register und Biomaterialbank: Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen			01.08.2009
	13	GMALL STI571/SCT2004		Eine randomisierte, multizentrische Phase III Studie zum Vergleich der Effektivität und Sicherheit einer frühzeitigen präemptiven und einer bei Nachweis minimaler Resterkrankung (MRD) begonnenen Behandlung mit Imatinib Mesylate (STI571, Glivec) nach Stammzelltransplantation bei Philadelphia Chromosom positiver akuter lymphoblastischer Leukämie (Ph+ALL) (GMALL STI571/SCT2004) (CSTI571ADE39)	3	verantwortliche Studiengruppe: Prof. Ottmann	01.06.2004	31.05.2015
	17	GMALL T-LBL		Multizentrische Therapieoptimierungsstudie für T-lymphoblastische Lymphome bei Erwachsenen und Adoleszenten ab 18 Jahren	4	verantwortliche Studiengruppe: GMALL	21.05.2004
	501	GMALL Therapieempfehlung: Rezidivtherapie (keine Studie)		Konsensus - Empfehlung der German Multicenter Study Group for Adult ALL (GMALL) für die Therapie von erwachsenen Patienten mit Rezidiv einer akuten lymphatischen Leukämie			01.01.2013
	1364	GMALL-BLIVEN	2021-001384-25	An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)	1/2	Goethe-Universität Frankfurt
	1387	GMALL-EVOLVE	2022-000760-21	A multicentre, randomized trial in adults with de novo Philadel-phiaChromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with Blina-tumomab and chemotherapy in optimal responders and to evalu-ate Blinatumomab before SCT in suboptimal responders	2	Goethe-Universität Frankfurt
	873	GMALL-MOLACT1-BLINA	2015-000733-76	A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial)	2	Dekan der Universität Frankfurt	28.07.2016
	1365	GMALL-MOLACT2-PONA	2019-004491-19	A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia		Goethe-Universität Frankfurt
	1375	GMALL-MOLACT2-PONA	2019-004491-19	Eine multizentrische, einarmige Studie zur Bestimmung der Wirksamkeit, Sicherheit und Verträglichkeit des Tyrosinkinaseinhibitors Ponatinib bei erwachsenen Patienten mit minimaler Resterkrankung (MRD) einer Philadelphia-Chromosom-positiven akuten lymphatischen Leukämie.	2	Goethe-Universität Frankfurt
	116	GMALL-PH-01	2010-022854-18	Open label phase II study to evaluate the safety of standard induction and consolidation therapy in combination with dasatinib in newly diagnosed adult patients with philadelphia chromosome positive acute lymphoblastic leukemia (PH+ALL)	2	Dekan der Univiersitätsklinik Frankfurt	23.02.2011	30.09.2015
	983	GMMG HD6		A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)	3
	86	GMMG-HD 4		Phase III Studie zum randomisierten Vergleich einer Hochdosistherapie und autologen Stammzelltransplantation gefolgt von einer Thalidomid-Erhaltungstherapie vs. Bortezomib plus Hochdosistherapie und autologer Stammzelltransplantation gefolgt von einer Bortezomib- Erhaltungstherapie.	3	Universitätsklinikum Heidelberg		03.02.2011
	1033	GMMG-HD7	2017-004768-37	Randomisierte Phase III-Studie für Patienten mit neu diagnostiziertem Multiplem Myelom zur Untersuchung des Nutzens der Hinzunahme von Isatuximab zu einer Induktionstherapie mit Lenalidomid / Bortezomib / Dexamethason (RVd) sowie einer Erhaltungstherapie mit Lenalidomid	3	Universität Heidelberg	11.10.2018
	1326	GO41944	2020-001021-31	A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (StarGlo)	3		22.01.2021
	1336	Goal II	2019-002373-59	A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Mor208 for patients with relapsed/refractory aggressive lymphoma	2	Universitätsmedizin Mainz
	76	GRAALLPHAG06	2006-005694-21	EWALL, Eine offene Phase II Studie zur Bestimmung der Wirksamkeit und Sicherheit der Induktions – und Intensivierungstherapie mit Dasatinib in Kombination mit Chemotherapie bei Patienten ≥ 55 Jahre und Philadelphia Chromosom-positiver (Ph+ oder bcr-abl+) akuter lymphatischer Leukämie (ALL	2	Hospiteaux Paris	26.03.2008	30.06.2015
	710	GRASPA-AML 2012-01	2012-002026-78	A Multicenter, open, randomized, controlled phase IIb trial evaluating efficacy and tolerability of GRASPA (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy.	2	Erytech Pharma	16.06.2014	15.12.2016
	879	GS-US-339-1559	2016-003353-16	A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)	1/2	Gilead	18.04.2017	21.02.2019
	854	GS-US-339-1560	2015-002768-18	A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)	1	Gilead Science	18.03.2016	27.02.2018
	912	GS-US-406-1840	2015-004572-30	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)		Gilead Sciences, Inc.	26.07.2016	31.01.2018
	1448	GS-US-546-5857	2020-003949-11	A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia	3	Gilead Sciences, Inc.
	1420	GS-US-576-6220 (EVOKE-02)	2021-004280-27	An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations (EVOKE-02)	2	Gilead Sciences Inc	15.02.2022
	1419	GS-US-590-6154	2021-003434-36	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy	3	Gilead Sciences Inc	22.02.2023
	117	H3E-EW S124	2008-002155-24	A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer	3	Lilly	01.10.2008	17.12.2014
	1017	H6Q-MC-S039		Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Patients With Newly Diagnosed Glioblastoma	2
	1328	HaploMUD	2017-002331-41	Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with identical GVHD Prophylaxis – A Randomized, Prospective European Trial	2	University Medical Center Hamburg - Eppendorf	27.09.2019
	499	HCT vs CT	2007-003514-34	Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission	3		26.03.2009
	96	HD 13		Qualitätssicherungsprotokoll zur Toxizitätsreduktion in der Primärtherapie des frühen Morbus Hodgkin (2x ABVD+IF vs 2x AVD+IF)	2		15.01.2003	30.10.2008
	84	HD 14		HD14 für intermediäre Stadien Qualitätssicherungsprotokoll zur Effektivitätssteigerung in der Primärtherapie des intermediären Morbus Hodgkin (4 x ABVD + IF vs. 2 x BEACOPP eskaliert + 2 x ABVD + IF)	3	GHSG	15.01.2003	30.12.2009
	118	HD 15		Qualitätssicherungsprotokoll zur Toxizitätsreduktion und zur prognostischen Bedeutung der FDG-PET in der Primärtherapie des fortgeschrittenen Morbus Hodgkin (8 x BEACOPP eskaliert vs. 6 x BEACOPP eskaliert vs. 8 x BEACOPP-14, gefolgt von RT auf PET positive PR)	3			30.04.2008
	50	HD 16	2007-004474-24	HD 16, Therapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET	3	Uniklinik Köln	09.07.2009	29.12.2020
	119	HD 17	2007-005920-34	HD17 für intermediäre Stadien; Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET	3	GHSG	14.10.2011
	51	HD 18	2007-003187-22	Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET	3	GHSG	17.04.2008	18.07.2018
	862	HD 6	2014-003079-40	A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma	3	Universitätsklinik Heidelberg	16.06.2015
	1023	HECTOR		Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse (HECTOR)	3
	97	High/CHOP21		Eine Randomisierte Studie zum Vergleich einer Chemotherapie mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid und Prednison) in 21-tägigen Intervallen in Standarddosis und eskalierter Dosis bei Patienten mit aggressiven Non-Hodgkin-Lymphomen	3		01.07.2000	13.04.2005
	752	HIIT		Evaluation der Durchführbarkeit, immunologischer Auswirkungen und der sujektiven Bewertung eines (hoch-)intensiver Intervallprotokolls mit onkologischen Patienten während Therapie und in der Nachsorge		Institut für klinische Forschung am Krankenh	01.03.2015	23.04.2018
	234	HOMB 114242	2010-023066-52	An open-label, multi-center study investigating the safety and efficacy of Ofatumumab therapy versus physicians choice in patients with bulky Fludarabine refractory chronic lymphocytic leukaemia (CLL)	3	GSK	04.04.2011	15.08.2013
	413	HOVON 89 MDS	2008-002195-10	A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome	2	Hovon	01.06.2009
	545	I2I-MC-JMMG	2010-020408-31	A Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer	2	Lilly	10.11.2010	07.11.2013
	378	IAWS 1/2-2006	N/A	A cooperative investigation of the Interdisciplinary German Sarcoma group			01.04.2009
	1300	IDH2-Post-Allo	2019-001416-30	IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation	2	Uniklinik Düsseldorf	08.03.2021
	817	IDHentify	2015-000344-42	A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation	3	Celgene	21.01.2016
	453	IELSG PCNSL	2009-012432-32	Randomisierte Phase II Studie mit primärer Chemotherapie mit hoch dosiertem Methotrexat und hoch dosiertem Cytarabin mit oder ohne Thiotepa und mit oder ohne Rituximab, gefolgt von Ganzhirnbestrahlung oder Hochdosischemotherapie mit autologer Stammzelltransplantation für immunkompetente Patienten mit neu diagnostiziertem primären ZNS-Lymphom - Freiburg IELSG PCNSL-Studie	2	IELSG-International Extranodal Lymphoma Study	12.07.2010	08.10.2016
	120	IMA901	2006-006370-25	IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (IMA901-202)	3	Immatics	07.05.2007	24.08.2009
	165	IMA901-301	2010-022459-45	IMA901 in patients recieving sunitinib for advanced/metastatic RCC	3	Immatics	15.12.2010	28.02.2013
	787	IMBARK	2015-000946-41	A randomized, single-blind, multicenter, phase 2 study to evaluate the activity of 2 dose levels of Imetelstst (GRN163L) in subjects with Intermediate-2 or high-risk Myelofibrosis (MF) previously treated with Janus Kinase (JAK) Inhibitor (63935937MYF2001)	2	Janssen-Cilag	03.08.2015	07.02.2020
	739	IMPULSE MGN1703-C03	2013-003503-19	Randomized Clinical Study of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy	2	Mologen AG	26.06.2014
	121	INCB 18424-352 (comfort-II trial)	2009-009858-24	A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)	3	Novartis	11.08.2009	24.02.2015
	847	INSPIRE	2015-001476-22	A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physicians Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent	3	Onconova	16.02.2016	23.08.2021
	1255	intrigue		A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib		Deciphera Pharmaceuticals, LLC
	1048	IOM-060331 (MYRIAM)		Clinical research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma		iOMEDICO AG	25.09.2017
	1455	ITP-Register		Multizentrisches nationales ITP-Register und begleitende Bioproben-Sammlung		Universität Jena	07.03.2023
	809	JANUS-1	2014-000293-20	A randomized, double blind, Phase 3-study of the JAK 1/2 inhibitor, Ruxolitinib or placebo in combination with capecitabine in subject with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapie (JANUS-1 Study)	3	Incyte Coopration	05.03.2015	26.02.2016
	818	JNJ-56022473AML2002	2015-001611-12	A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy	2	Janssen-Cilag	21.12.2015	26.06.2018
	373	JUMP (CINC424A2401)	2010-024473-39	An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)	3	Novartis Pharma AG	11.08.2011
	913	Katherine	2012-002018-37	A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy	2	Roche	22.02.2013
	759	KCP-330-008	2014-000920-26	A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) VERSUS SPECIFIED PHYSICIAN’S CHOICE IN PATIENTS = 60 YEARS OLD WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY AND/OR TRANSPLANTATION	2	Karyopharm Therapeutics	08.09.2014	28.08.2017
	836	KESTREL	2015-003589-10	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients	3	Astra Zeneca	04.01.2016
	1367	Klinisches Myelom-Register Heidelberg		Langzeit-Beobachtung von PatientInnen mit Multiplem Myelom und dessen prämalignen Vorstufenerkrankungen
	1447	KT-US-486-0201	2020-000962-40	A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia	1	Gilead Science
	172	KZ-HD	N/A	Registerstudie zur Salvagetherapie bei Patienten mit refraktären oder rezidivierenden Keimzelltumoren.		Universitätsklinikum Frankfurt	30.04.2010
	997	LEOPARD II	2010-023427-18	Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer	2
	796	Lilly 16F-MC-JJCB	2014-005024-10	A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients	1/2	Lilly	29.07.2015	15.01.2018
	571	LQ S511		Anonyme Patientenbefragung onkologischer und hämatologischer Patienten bezüglich von Symptomen, welche einen Einfluss auf die Lebensqualität haben, und deren Stellenwert im Arzt-Patienten-Gespräch		KH Nordwest, Frankfurt	01.09.2011	01.09.2012
	649	LUD 00-014		Phase 1 study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers	1	Ludwig Institut for Cancer Research	01.01.2001	19.05.2014
	578	LUD 05-003	2006-002015-27	A phase 1 study of Mixed Bacteria Vaccine (MBV) in patients with tumor expressing NY-ESO-1 antigen.	1	Ludwig Institute for Cancer Research	01.05.2007	01.04.2013
	443	LUX-Lung 8	2011-002380-24	A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy	3	Böhringer Ingelheim	29.02.2012	31.01.2015
	66	LYM-3002	2007-005669-37	A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cycloposphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant	3	Johnson&Johnson	10.03.2009
	122	Magrit	2007-001283-73	A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer	3	Glaxo Smith Kline	21.09.2007	23.09.2014
	851	MAIA	2014-002273-11	A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy Protocol 54767414MMY3008	3	Janssen-Cilag	31.08.2015
	167	marC-2	2010-021370-11	An open label, single arm trial to characterize patients with metastatic renal cell cacinoma treated with everolimus after failure of the first VEGF-targeted therapy	4	iOMEDICO	29.12.2010	30.09.2017
	75	Marqibo	2006-006978-20	A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy	2	Hana Biosciences, Inc.	21.11.2007	01.03.2011
	741	MATRix	2012-000620-17	High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial	3	Klinikum Stuttgart	28.04.2014
	18	MC-PEGASP.1/Adults	2010-020613-91	A randomized, multi-centre, parallel-group, open label, Oncaspar controlled dose ranging trial of three doses of pegylated recombinant asparaginase in adult patients with newly diagnosed acute lymphoblastic leukaemia	1/2	Gesellschaft für klinische Spezialpräparate	18.11.2010	22.05.2013
	1479	MCL2005-01 (R-HAD)	2005-005144-62	Wirksamkeit und Sicherheit einer Kombinationstherapie mit Rituximab, hochdosiertem Ara-C und Dexamethason (R-HAD) mit oder ohne Bortezomib bei Patienten mit rezidiviertem oder refraktärem Mantelzell-Lymphom- eine randomisierte Phase III Studie des European MCL Networks.	3	Roche	08.05.2009	02.04.2020
	55	MDS CD34+Fish-Studie		Erst- und Verlaufsuntersuchungen (genetisches Monitoring) von Patienten mit MDS während verschiedener Therapien durch zytogenetische Analyse von zirkulierenden CD34+Zellen.			01.10.2009
	369	MDS LEMON 5		Multizentrische, einarmige, offene Phase II Studie zur Erfassung der Sicherheit und Feststellung von Progressions-Markern einer Monotherapie mit Lenalidomid (Revlimid®) bei Patienten mit MDS (IPSS low oder intermediate-1) und einer isolierten Deletion 5q (Del(5q)	2
	370	MDS VALENA Studie		Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von Valproinsäure und Lenalidomid (Revlimid®) bei Patienten mit Niedrig- Risiko-MDS	2
	372	MDS/AML Eltrombopag		Eltrombopag bei MDS und AML	1
	878	MEDI4736_MDS_001	2015-003596-30	A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)	2	Celgene	07.06.2016
	134	MEK 111759	2009-017376-25	An Open-Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leucemias	1/2	Glaxo Smith Kline	21.03.2011	19.03.2013
	561	METEOR XL184-308	2013-001010-14	Eine randomisierte, kontrollierte Studie der Phase 3 zu Cabozantinib (XL184) gegenüber Everolimus bei Patienten mit metastasiertem Nierenzellkarzinom, das nach vorheriger Therapie mit VEGFRTyrosinkinasehemmer fortgeschritten ist	3	Exelixis	09.10.2013	25.01.2018
	421	Midokit	2011-002567-17	Einarmige Phase-II-Studie zur Wirksamkeit von Midostaurin (PKC 412) in Kombination mit primärer Standard-Chemotherapie bei Patienten mit neudiagnostizierter c-KIT- oder FLT3-ITD-mutierter t(8;21)-AML	2	TU Dresden	15.03.2012
	483	MINDACT	2005-002625-31	Microarray in Node negative and 1 to 3 positive Lymph node Disease may Avoid Chemotherapy - Prospektive randomisierte Studie zum Vergleich der 70-Gen-Signatur mit den allgemeinen klinischen Kriterien zur Selektion der chemotherapie-bedürftigen Patientinnen mit Mammakarzinom	3	EORTC	29.05.2007	26.02.2020
	1334	MK-7902-010	2019-003717-34	A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010)	3	MSD	06.04.2020	28.03.2023
	1046	MK7902-005	2018-003747-37	A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors	2
	1020	ML18147	2006-004634-32	A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.	3
	91	MM5	2010-019173-16	Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment (MM5).	3	Universitätsklinik Heidelberg	08.07.2010	11.03.2017
	1021	MMY3022	2008-003213-27	Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma	3
	978	MO28231	2012-001628-37	A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
	875	MO29499		Alectinib Compassionate Use Programm: CUP0004-1_MO29499- Patients with Anaplastic lymphoma klinase-positive non-small cell lung cancer (ALK+NSCLC)		Roche	31.01.2017	02.05.2017
	1350	MO40599 / GLA 2017-R2 (Pola-R-ICE)	2019-002962-10	An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)	3	GWT-TUD GmbH	02.11.2020
	633	MPN Registerstudie		SAL-MPN-Register und Biomaterialbank der Studienallianz Leukämie (SAL)		Universitätsklinikum Aachen	01.02.2013
	57	MPN-SG 01-09	2009-010738-23	Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage	2	Universitätsklinikum Ulm	12.11.2009
	749	MRT-Biopsie-Studie		Evaluation von Tumorhypoxie und Mikromilieu in malignen Gliomen mittels magnetresonanztomographischer Methoden: Histologische Validierung und tumorbiologische Bedeutung.		Dekan der Universität Frankfurt	20.02.2013	30.01.2019
	74	MT 103-202	2006-006520-19	An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of positive B-precursor acute lymphoblastic leukemia (ALL)	2	Micromet AG	11.10.2007	07.07.2014
	19	MT 103-206	2009-015989-62	An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (ALL)	2	Micromet AG	05.08.2010	14.10.2016
	187	MT 103-211	2011-002257-61	An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)	2	Micromet AG	15.11.2011	25.02.2015
	20	MT103-203	2010-018314-75	A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia	2	Micromet AG	05.08.2010	27.11.2018
	1445	MTB Frankfurt		Evaluation von präzisionsonkologischen Patienten des molekularen Tumorboards Frankfurt		Goethe-Universität Frankfurt	01.01.2023
	89	MTXIFO Depocyte	2009-014300-55	Phase II-Studie zur kombinierten systemischen und intrathekalen Chemotherapie mit Methotrexat, Ifosfamid und liposomalem Cytarabin (DepoCyte®) bei HER-2/neu-negativen Patientinnen mit Mammakarzinom und Meningeosis neoplastica	2	Charité Berlin	14.04.2010	02.03.2012
	1041	MX39795 (CUPISCO)	2017-003040-20	A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapy	2	F. Hoffmann-La Roche Ltd	31.10.2018	28.09.2023
	1055	NCT-2017-0417 (TOP-ART)	2017-001755-31	Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies	2	Ruprecht-Karls-Universität Heidelberg	31.08.2018
	186	Nelarabine Studie		Phase II Studie mit Compound GW506U78 bei Patienten mit refraktärer oder rezidivierter T-ALL oder T-lymphoblastischem Lymphom	3		31.05.2005	31.12.2011
	982	NEOD001-CL002	2014-003865-11	The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)	3
	981	NEOD001-OLE251	2016-004664-18	A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)	2
	1001	NHL 7-2008	2008-005859-16	Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas	4
	941	NintNivo	2017-001723-45	Machbarkeit und Sicherheit von Nintedanib in Kombination mit Nivolumab bei vorbehandelten Patienten mit fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Adenokarzinom-Histologie - Eine AIO-Phase-Ib-Studie	1	AIO-Studien-GmbH	22.05.2018
	940	NIVAHL	2016-002626-37	Nivolumab und AVD für Patienten mit klassischem Hodgkin Lymphom im intermediären Stadium - Eine randomisierte, multizentrische GHSG Phase II Studie	2	Universität zu Köln	18.12.2017	30.12.2022
	877	NIVOSWITSCH	2016-002170-13	A randomized Phase II study with Nivolumab or continuation of therapy as an early SWITSCH Approach in patients with advanced or metastatic renal cell carcinoma(RCC) and disease cotrol after 3 months of Treatment with tyrosine kinase inhibitor	2	AIO Studien GmbH	25.10.2016	18.01.2021
	653	OMB 110918	2008-004177-17	Klinische Studie zu Ofatumumab und Bendamustin bei Patienten mit indolentem, gegen andere Therapien refraktären Non-Hodgkin-Lymphom	3	GlaxoSmithKline	08.06.2010	08.07.2014
	626	ON04-24	2013-001124-19	Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine	3	Onconova	25.09.2013	24.06.2015
	447	Onconova 04-21	2010-019755-21	A Phase III, Multi´-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intorlerant to Azacitidine or Dezitabine	3	Onconova	20.08.2012	12.10.2015
	368	ONO 1910		Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine	3	Onconova Therapeutics, Inc.
	888	Optimal (> 60 Jahre)	2010-019587-36	Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-Cell Lymphoma by an optimised schedule of the monoclonal antibody Rituximab, substitution of conventional by liposomal Vincristine and FDG-PET based reduction of therapy	3	Uni Saarland	03.07.2012
	500	PACE	2012-002523-14	A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)	2	Acceleron Pharma, Inc	20.12.2012
	1346	PACE-LUNG	2019-004757-88	Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment	2	Goethe-Universität Frankfurt
	124	Palette	2008-001307-33	A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy	3	Glaxo Smith Kline	10.12.2008	20.08.2012
	1203	PALOMA	2018-002430-21	Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML	2	GWT TUD Gmbh, Dresden	12.02.2020
	72	PANOBEST	2010-018699-26	Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST)	1/2	Dekan der Uniklinik Frankfurt	25.10.2010	19.06.2020
	484	PANTHER	2007-002061-12	Randomisierte Phase III-Studie zum Vergleich einer 2-wöchentlichen angepassten Chemotherapie mit dtEC-dtT versus FEC-T q21 bei nodal-positivem oder high risk Mammakarzinom	3	ABCSG	05.11.2008	31.05.2017
	1052	PazoQol	2017-003382-10	Lebensqualität bei Patienten mit nicht-adipozytärem Weichgewebssarkom unter palliativer Chemotherapie oder Pazopanib - eine randomisierte, kontrollierte Studie	4		01.04.2019	06.10.2020
	1429	PDC Lung	2018-002382-19	An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)	1/2	PDC*line Pharma SAS	11.11.2020
	1338	PDC-Lung-101	2018-002382-19	An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)	1/2	PDC*line Pharma SAS
	1325	PH-L19TNFDOX2-03/16	2016-003239-38	A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma (Fibrosarc)	3		28.07.2017
	998	PHEREXA		A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer	2
	954	PHITT		Paediatric Hepatic International Tumour Trial	3		11.01.2017
	21	PKC412 Studie (CALGB10603)	2006-006852-37	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in newly diagnosed Patients < 60 years of age with FLT3 Mutated Acute Myeloid Leukemia	2	CALGB (Cancer and Leukemia Group B)	11.07.2008	29.09.2011
	479	POLO-AML-2 (BI 1230.14)	2012-002487-27	A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy	3	Böhringer Ingelheim	04.02.2013	01.07.2021
	539	POMINC (MPN-SG 02-12)	2012-002431-29	Ruxolitinib und Pomalidomid bei primärer und sekundärer Myelofibrose	1/2	Universitätsklinikum Ulm	23.07.2013
	617	Pre-Cam-Q (S525)	N/A	Pretest zur Validierung und Vergleich unterschiedlicher Patientenfragebögen zum Einsatz von komplementären und alternativen Heilverfahren durch Patienten mit hämatologischer oder onkologischer Grunderkrankung.		AIO Studien GmbH	01.05.2012	30.05.2012
	485	PREDICTOR		Diagnostische Genauigkeit von In-vitro-Diagnostika bei Patientinnen mit Ovarialkarzinom: Predictor-study		NOGGO Berlin	01.01.2008	05.09.2011
	486	PREFACE	2008-004874-42	Offene prospektive multizentrische Phase IV Studie zur Untersuchung des Einflusses von pharmakokinetischen Markern auf die Wirksamkeit und NW-Rate bei postmenopausalen, steroidhormonrezeptor-positiven Mammakarzinompatientinnen, die mit Letrozol behandelt werden	4	Uni Erlangen	06.02.2009
	1223	PrevTel	2019-000210-11	Prevention of Paclitaxel-induced neuropathic pain by Telmisartan in patients with planned Paclitaxel chemotherapy due to ovarian or breast cancer (PrevTel)	2	Fraunhofer Gesellschaft	18.09.2019
	1225	PrevTel	2019-000210-11	Prevention of Paclitaxel-induced neuropathic pain by Telmisartan in patients with planned Paclitaxel chemotherapy due to ovarian or breast cancer (PrevTel)	2		18.09.2019
	1423	Primain-00591	2008-007645-31	Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie	2	Universitätsklinikum Freiburg	09.06.2023	02.03.2015
	1069	PROMETCO		Eine evidenzbasierte, prospektive Kohortenstudie zur Behandlung des metastasierten kolorektalen Karzinoms in der Versorgungsrealität: aus klinischer Sicht und Patientenperspektive			07.10.2019
	831	Prospektive Studie zum Einfluss des qualifizierten onkologischen Erstgespräches auf Lebensqualität und Zufriedenheit von Patient		PELOMA		IKF	20.05.2016
	990	PX-171-009		Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma	3
	1257	Q-HAM	2018-002675-17	Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD	2		01.01.2022
	850	R1979-ONC-1504	2015-001697-17	A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 x Anti CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients with B-Cell Malignancies	1	Regeneron	01.12.2015
	1107	R2810-ONC-1620	2016-003122-16	A Phase 2 Study of REG2810, a fully human monoclonal Antibody to Programmed Death-1, in Patients with advanced Basal Cell Carcinoma who experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were intolerant or of prior Hedgehog Pathway Inhibitor Therapy	2	Regeneron	15.10.2017
	1260	RAGNAR	2019-002113-19	A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations	2	Janssen Cilag	30.10.2020	23.03.2023
	127	REACT	2007-005460-28	Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy	3	Novartis Pharmaceuticals	25.06.2008	27.10.2009
	1389	rECCur	2014-000259-99	International Randomised controlled Trial of Chemotherapy for the Treatment of recurrent and primary refractory Ewing sarcoma. Internationale randomisierte klinische Phase II Studie für Patientinnen und Patienten mit rezidiviertem oder nicht auf die Standardbehandlung ansprechendem Ewing-Sarkomen.	2/3
	1352	Reg. Selten. Anämien		Register für Seltene Anämien		Universität Heidelberg
	1081	REGSA Registerstudie		Deutsche Prospektive Registerstudie zur Erfassung der Behandlungspraxis von gynäkologischen Sarkomen in der klinischen Routine		NOGGO Berlin
	1102	Reiseverhalten		Pilotprojekt zur Evaluation des Reiseverhaltens von palliativen Tumorpatienten		Goethe-Universität Frankfurt
	446	ReLApsE	2009-013856-61	Randomisierte, offene, multizentrische Phase III Studie zum Vergleich von Lenalidomid/ Dexamethason versus Lenalidomid/ Dexamethason mit anschließender autologer Blutstammzelltransplantation und Lenalidomid Erhaltungstherapie für Patienten mit rezidiviertem Multiplen Myelom.	3	Universitätsklinikum Heidelberg	14.07.2010	03.07.2019
	874	REMAR		Oncotype DX®-REMAR(Rhein-Main-Register) -Studie		AGAPLESION, Markus Krankenhaus	20.09.2016
	374	RESUME		Phase III Studie mit Pomalidomid bei Myelofibrose und RBC-Transfusionsbedürftigkeit	3	Celgene
	425	Rhodiola-Studie	N/A	Einsatz eines standardisierten Rhodiolaextraktes bei Tumorpatienten mit Fatigue	2	Dekan der Universität Frankfurt	01.07.2011
	129	RV-MDS-PI-409	2008-001866-10 (laut Sponsor)	A multicenter, single-arm, open-label phase II study of the safety of lenalidomide monotherapy and markers for disease progression in patients with IPSS low- or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality (Del 5q)	2	Celgene	01.03.2010
	130	S-TRAC	2006-004024-37	Sunitinib treatment of renal adjuvant cancer (S-TRAC): a randomized double-blinded phase 3 study of adjuvant Sunitinib vs. Placebo in subjects at high risk of recurrent RCC	3	Pfizer Inc	07.08.2007	30.08.2017
	667	SAIL	2014-000526-37	An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML	2	GSO	18.08.2014
	409	SAL.AML Register		AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL)		Uniklinik Dresden	01.05.2012
	1335	SCC215/P002900 OptiMATe	2018-002115-96	Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial	3	Uniklinik Stuttgart
	59	SCT + Thalidomide / DLI		Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age < 55 years: A phase II-study	2		01.03.2009	01.06.2018
	769	SGI-110-04	2014-001233-89	A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy	3	Astex	25.06.2015	29.05.2018
	1327	SHAPE	2019-004536-37	Treatment of MDS/AML patients with an impending Hematological relapse with Azacitidine alone or in combination with PEvonedistat - a randomized phase 2 trial	2	Universität Leipzig	19.10.2021
	487	SOFIA	2007-000124-41	Phase II Studie einer neoadjuvanten Behandlung mit Epirubicin, Cyclophosphamid (EC) und Sorafenib gefolgt von Paclitaxel und Sorafenib bei primärem Brustkrebs von Frauen, die vorher keine andere Behandlung erfahren haben.	4	GBG	28.08.2007	11.01.2011
	377	Sorafinib (Elderly) (KKS/Innere_A/AML2006)	2005-005966-35	Eine doppelblinde, placebokontrollierte, randomisierte, multizentrische Studie zur Erfassung der Effektivität der Gabe von Sorafinib zusätzlich zur Standard-Erstlinientherapie bei Patienten > oder = 61 Jahre mit neu diagnostizierte AML	2	Universitätsklinikum Münster	24.07.2006	07.07.2009
	1337	SoraTram	2018-003237-16	Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity	1	Universitätsklinikum Freiburg
	87	SORMAIN	2010-018539-16	Eine doppelblinde, Placebo-kontrollierte, randomisierte, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Sorafenib Erhaltungstherapie bei Patienten mit FLT3-ITD positiver AML in kompletter hämatologischer Remission (CHR) nach allogener Stammzelltransplantation (allo-SCT).	2	Philipps-Universität Marburg	28.09.2010	31.01.2018
	1306	SPACE (AIO-TKR-0119)	2019-001707-21	Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide	2	AIO-Studien-gGmbH
	171	STAR-TOR		Register zur Bewertung der Sicherheit, Verträglichkeit und Wirksamkeit von Temsirolimus (Torisel®) und Sunitinib (Sutent®) in der Behandlung von Patienten mit fortgeschrittenem Nierenzellkarzinom, Mantelzell-Lymphom und Gastrointestinalem Stromatumor (GIST)		Wyeth	07.04.2010
	600	STORM	2011-001491-20	A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial	2	Uniklinik Freiburg	04.10.2012	02.07.2019
	52	Studie zur Therapieoptimierung des HIV-assoziierten Morbus Hodgking		Studie zur Therapieoptimierung des HIV-assoziierten Morbus Hodgkin	2		09.03.2007
	131	SU011248	2005-002097-30	A SU011248 Treatment Protocol For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols And May Derive Benefit From Treatment With SU011248	3	Pfizer	21.11.2005	10.11.2012
	995	SuccessC-Trial	2008-005453-38	Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies SUCCESS C-Trial	3
	577	SUMA (S 379)	2007-002828-15	An open-label, uncontrolled phase II trial of single agent Sunitinib (SU 11248) for patients with chemo-refractory metastatic melanoma	2	KH Nordwest	13.03.2009	27.05.2013
	1345	TAK-079-1004	2019-004103-12	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia	2	Millennium Pharmaceuticals, Inc.
	812	TARGIT_BQR		TARGeted Intraoperative radioTherapy With the INTRABEAM-System as an Advanced Boost in Patients With Breast Cancer - A Quality Control Registry in Germany (TARGIT BQR)	4	Universitätsklinikum Mannheim	01.02.2013
	779	TAS-2009		"An Open-Label, Multi-Centre Phase I/II Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Advanced Solid Tumors"	1/2	Ergomed	22.10.2009	20.08.2012
	780	TAS-2010	2011-000124-15	An open label, multi-center, Phase I/IIa dose escalation study to investigate the safety and tolerability of multiple doses of oral Tasidotin HCL in Patients with relapsed/refractory aggressive Non-Hodgkin´s Lymphomas	1/2	Ergomed Clinical Research Limited	22.06.2011	27.09.2013
	1217	TEAM	2017-005158-12	TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib: A Multi-centre Matched Threshold Crossing Phase II Approach	2	Universitätsklinikum Heidelberg	12.02.2020
	132	Temsirolimus 3066K1-4407		A randomized trial of Temsirolimus versus Sorafenib as second-line therapy in patients with advanced renal cell carcinoma who have failed first-line Sunitinib therapy		Pfizer, Inc.	01.09.2007
	1329	Tesaro Ruby	2019-001576-11	Eine randomisierte, doppelblinde, multizentrische Phase-3-Studie mit Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel im Vergleich zu Placebo plus Carboplatin-Paclitaxel bei Patienten mit rezidivierendem oder primär fortgeschrittenem Endometriumkarzinom (RUBY)	3	Tesaro
	73	Therapie der Invasiven Aspergillose		A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis	3		01.05.2008
	1344	TIGER-CTL019	2019-002930-35	Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma	2	Uniklinik Köln
	904	TIGER-Optune	N/A	The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care – TIGER Study		Novocure GmbH	30.08.2017
	826	TOGETHER		Prognostische Bedeutung von Stress und körperlicher Bewegung bei Patienten mit neu-diagnostiziertem Glioblastom und ihren nächsten Angehörigen (TOGETHER)		Dr. Senckenbergisches Institut für Neuroonkol	12.04.2016	30.06.2017
	133	TOR-AML	2011-002365-37	A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of Temsirolimus added to standard first line therapy in elderly patients with newly diagnosed AML	2	Dekan der Universitätsklinik Frankfurt	04.04.2012	26.04.2017
	602	TOWER	2013-000536-10	A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)	3	Amgen	12.12.2013	22.08.2016
	1353	TRABTRAP	2020-005858-21	PHASE II/III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS; 2nd LINE)	2/3	Westfälische Wilhelms-Universität Münster
	1324	Trade-hypo (AIO-YMO/TRK-0319)	2019-002192-33	Thoracic radiotherapy plus Durvalumab in Elderly and/ or frail NSCLC stage III patients unfit for chemotherapy -Employing optimized (hypofractionated) radiotherapy for foster Durvalumab eficacy	2		06.02.2020
	832	TRANSATRA	2014-001479-30	Phase I/II study of sensitization of non-M3 acute myeloid leukemia (AML) blasts to all-trans retinoic acid (ATRA) by epigenetic treatment with tranylcypromine (TCP), an inhibitor of the histone lysine demethylase 1 (LSD1).	1/2	Universitätsklinikum Freiburg	04.02.2016
	892	TRICC-C	2010-023050-37	A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)	2	Martin-Luther-Universität Halle-Wittenberg	20.05.2011
	733	TUD-2DAUNO-058	2013-003191-12	Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia = 60 years. Sequential two-part, two-arm unblinded open-Label multicenter randomized-controlled Phase-III Treatment optimization trial	3	TU Dresden	31.01.2014	25.04.2022
	1408	TUD-ALPINE-077	2020-002683-31	A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung	2	Technische Universität Dresden	10.05.2021
	41	TUD-AZALE1-037		A phase I study of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS or relapsed/refractory AML patients with cytogenetic abnormalities including -5 or del (5q)	1	TU Dresden	01.06.2009	01.07.2012
	93	TUD-BRIDGE-046	2010-022584-35	Clofarabine salvage therapy in patients with relapsed or refractory AML. The BRIDGE Trial	2	Technische Universität Dresden	25.11.2011	23.08.2013
	1341	TUD-MOSAIC-075	2019-003863-23	MidOStaurin + Gemtuzumab OzogAmIcin Combination in Firstline Standard Therapy for Acute Myeloid Leukemia (MOSAIC)	2	AML Register	16.12.2021
	576	TUD-RELA02-048	2010-022388-37	Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidin (Vidaza®)	2	Universität Dresden	23.09.2011	12.02.2021
	1207	TUD-RELAX1-070	2018-003025-28	Phase-I/II Studie für Patienten mit rezidivierter oder refraktärer Akuter Myeloischer Leukämie (AML) mit Venetoclax in Kombination mit Cytarabin und Mitoxantron	1/2	TU Dresden
	22	TUD-SORAML-034	2008-004968-40	A double-blind, placebo-controlled, randomized, multicenter phase-II trial to assess the efficacy of Sorafenib2 added to standard primary therapy in patients with newly diagnosed AML ≤60 years of age.	2	Universitätsklinikum Dresden	20.02.2009
	980	Uni-Koeln-1014	2007-005920-34	HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET	4
	1212	Uni-Koeln-3254/FIND	2018-000399-13	A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harboring FGFR genetic alterations after relapse of standard therapy	2	UNI Klinik Köln
	1060	Vedolizumab-3035 (GRAPHITE)	2018-002141-11	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	3	Millennium Pharmaceuticals, Inc.	06.02.2019
	174	VEG113387 (Protect)	2010-020965-26	A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy	3	GSK	27.10.2010	15.04.2019
	1024	VELVET	2011-003308-18	A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cance	2
	709	Venice	N/A	Verträglichkeit von Nivestim unter zytotoxischer Chemotherapie in der Behandlung maligner Erkrankungen		Hospira Deutschland GmbH	30.04.2012	31.07.2014
	672	VicOryx	2011-000948-18	Phase I/II study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers	1/2	Oryx GmbH	25.08.2011	30.05.2015
	742	VICORYX-2	2014-005201-21	Pilot study on concurrent cisplatin-based chemotherapy combined with vaccination therapy with the P16_37-63 peptide in patients with HPV- and p16INK4a-positive cancer	1	Oryx GmbH	25.06.2015	26.06.2017
	241	VidazaAlloStudy	2010-018467-42	Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability	2	Universitätsklinik Hamburg-Eppendorf	30.05.2011
	894	Xilonix 2012-PT023	2012-005287-10	A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer	3	XBiotech Germany GmbH	03.08.2015
	895	YO28322	2012-001402-23	A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic HER2-Negative, MET-Positive Gastroesophageal Cancer	3	F. Hoffmann-La Roche AG	07.09.2012
Innere Kardiologie
	1197	2007-08-16 REPAIR-AC	2007-004874-14	Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem Koronarsyndrom (Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome; REPAIR - ACS)	2	Goethe-Universität Frankfurt	01.10.2008	30.06.2017
	1199	REPEAT	2011-000595-33	Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in patients with chronic post-infarction heart failure	3	Goethe-Universität Frankfurt
Innere Pneumologie
	1090	AIO-YMO/TRK-0416	2016-003963-20	AIO-YMO/TRK-0416 Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC	2	AIO-Studien-gGmbH	15.02.2018
	1092	IO102-012	2018-000139-28	An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer	2	IO Biotech Aps
	1094	MK-7339-008	2018-004721-88	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of metastatic squamous Non-small Cell Lung cancer (NSCLC)	3	Merck Sharp & Dohme GmbH
	1093	MSK 7339-006	2018-004720-11	A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment for Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer	3	Merck Sharp & Dohme GmbH
	716	9090-14	2012-004349-34	GALAXY-2, 9090-14 A Randomized, phase 3 study of Ganetespib in Combination with Docetaxel versus Docetaxel alone in Patients with advanced NSCLC	3	synta pharmaceutical	14.05.2013	21.10.2015
	209	ABC-2006-NSCLC-01 (INNOVATION)		Bevacizumab plus Erlotinib oder Gemcitabin/Cisplatin plus Bevacizumab bei NSCLC	2	Aktion Bronchialkarzinom (ABC) e.V.	01.06.2007
	688	Antiemese		Patientendokumentation zur Leitlinienadhärenz bei der antiemetischen Behandlung von Tumorpatienten		Prof. Hartmut Link	05.11.2014	31.12.2014
	569	ARD 11585	2010-020394-17	Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer	1/2	Sanofi-Aventis	20.12.2011	18.10.2013
	536	AVAdeno		Nichtinterventionelle Studie ML28306 BEVACIZUMAB (Avastin) in der Erstlinien-Behandlung des Adenokarzinoms der Lunge		Roche	28.05.2013	31.10.2015
	254	AVAILABLE		Nicht-Interventionelle Studie Available, Avastin beim Lungenkarzinom		Roche	01.12.2009
	744	c14018	2013-003713-18	a randomized, double-blind, Placebo-controlled, Phase II clinical Trial of alisertib in combination wieth paclictaxel versus Placebo in combination with paclitaxel as second line therapy for SCLC	2	Millennium Pharmaceuticals	13.04.2015	23.04.2016
	406	CA180385 (S513)	2011-003128-11	Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation	2	Bristol-Myers Squibb	09.05.2012	23.07.2014
	451	CA184104 (IDEATE)	2009-017396-19	Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Additin to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV / Recurrent Non-Small Cell Lung Cancer	3	BMS	21.06.2011
	825	CA209-331	2015-001097-18	an open-Label, randomized, Phase 3 study of nivolumab or chemotherapy(Topotecan i.v.) in sujects with relapsed SCLC after platinum-based first line chemotherapy	3	Bristol Myers Squibb	26.10.2015	13.08.2021
	846	CA209227	2014-003630-23	an open-Label, randomized, Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab or Nivolumab plus platinum doublet Chemotherpay versus platinum doublet Chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	3	Bristol Myers Squibb	29.09.2015
	681	CV-9201-003 Curevac	2008-007785-39	Safety and efficacy phase I/IIa trial of an RNActive-derived cancer vaccine in stage IIIB/IV non small cell lung cancer (NSCLC)	1/2	CureVac GmbH	15.04.2009	25.02.2014
	537	ElderTac		Erlotinib in der täglichen Routinebehandlung des NSCLC beim älteren Patienten		Roche	20.12.2012	30.12.2015
	828	EMPRESS		The EMPrint Ablate and RESect Study in Patients with Metastatic Lung Tumors (EMPRESS)		Covidien	03.05.2016	17.05.2017
	707	EMR 63325-001	2006-000579-14	A multi center phase III randomized double blind placebo controlled study of STIMUVAX(BLP25 liposime vaccine) in non small cell lung cancer subjects with unresectable stage III disease	3	EMD Serono	24.07.2007	08.09.2015
	255	FRAME		Oberservational Study		Lilly
	641	GO28915	2013-003331-30	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY	3	Roche	20.03.2014
	840	GO29537	2014-003206-32	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL FOR CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER	3	Roche	09.09.2015
	211	I4T-MC-JVBA (IMCL CP12-1027)	2010-021297-11	Eine randomisierte, doppelblinde Phase-3-Studie mit Docetaxel und Ramucirumab versus Docetaxel und Placebo bei der Behandlung von nichtkleinzelligem Lungenkrebs im Stadium IV nach Krankheitsprogression im Anschluss an eine vorausgegangene platinbasierte Chemotherapie	3	Lilly	09.03.2011	10.04.2014
	424	LUD 2009-007; S508	2009-017885-22	Phase II Study of ADI-PEG 20 in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer	2	Ludwig Institute for Cancer Research	10.08.2012	24.06.2013
	806	LuLife		Tumorregister Lungenkarzinom Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten bei behandlungsbedürftigen Lungenkarzinom		iOMEDICO	30.01.2012	01.11.2014
	210	LUME (1199.13)	2007-004803-36	LUME Lung 1 Randomised Double Blind Phase III Trial of BIBF 1120 Versus Placebo in Addition to Standard Therapy of Docetaxel in Patients With Advanced NSCLC	3	Bristol Myers Squibb	30.03.2009
	256	Medac-Register		Registerstudie zur Erfassung der Versorgungssituation in Deutschland zur systemischen Primärtherapie älterer, chemonaiver NSCLC-Patienten im Stadium IV		medac	01.06.2011
	1091	ML39885		Nicht-interventionelle Studie zum Atezolizumab bei lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom (NSCLC) nach vorheriger Chemotherapie		Roche	15.03.2019	18.02.2020
	839	MM-121-01-02-09	2014-003673-42	A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	2	Merrimarck Pharmaceuticals	19.01.2016
	841	MORAb-009-201	2014-004489-85	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	2	Morphotek	03.11.2015
	835	NeoIntercal	2014-005595-28	Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation - A single arm Phase II trial.	2	AIO-StudienGgmbH	29.09.2015	16.03.2017
	253	NIS-ODE-DUM-2009/1		Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed stage IIIB/IV NSCLC in Germany		Astra Zeneca	01.10.2009
	682	OSI-774-302 Radiant	2005-001747-29	A multi center, randomized, double blind, placebo-controlled, phase III study of single agent Tarceva (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA NSCLC who have EGFR-positive tumors	3	Roche	20.12.2006	25.06.2014
	824	PEARLS	2015-000575-27	a randomized, Phase 3 Trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus Placebo for patients with early st	3	Merck Serono	24.11.2015
	454	PemSplitCisp_03-11	2011-001963-37	Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Nonsquamous Non-small-cell lung cancer (NSCLC) (Cisplatinum/Pemetrexed versus Split-dose Cisplatinum/Pemetrexed In NSCLC)	2	Universitätsklinikum Essen	24.08.2012	07.07.2017
	788	PRIMUS	2015-001123-22	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following Fisrt-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)	2	AIO Studien GmbH	03.11.2015	24.11.2020
	252	QoLiTax		Nicht-interventionelle Studie zur Erfassung der Lebensqualität bei Patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligem Bronchialkarzinom		Sanofi-Aventis
	404	U3-1287-A-U201	2010-021082-74	RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON AT LEAST ONE PRIOR CHEMOTHERAPY	2	DSI	28.01.2011	16.12.2013
	705	U31287-A-U301	2013-004371-12	Randomisierte, placebokontrollierte, doppelblinde, multizentrische, zweiteilige Phase-3-Studie mit Patritumab (U3-1287) in Kombination mit Erlotinib an Patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligen Lungenkarzinom (NSCLC) und EGFR-Wildtyp, bei denen es unter mindestens einer vorherigen systematischen Therapie zu einer Progression gekommen ist.	3	Daiichi Sanky Development	04.12.2014	18.05.2016
	1045	Uni-Koeln-1784 (EATON)	2016-003944-35	An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy	1	Universität zu Köln	08.03.2019
Innere Rheumatologie
	1178	CGD-Version2	2012-001725-26	A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector	1/2	Goethe-Universität Frankfurt	01.12.2012	11.09.2019
	1183	FFM07-Rtx-Lef	2009-015950-39	Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis	3	Goethe-Universität Frankfurt
Kinder SP Hämatol./Onkol.
	918	Metro-NB 2012	2011-004593-29	METRO-NB 2012: PHASE II TRIAL OF METRONOMIC TREATMENT IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR PROGRESSIVE NEUROBLASTOMA	2	Uniklinik Köln
	947	AIEOP-BFM_ALL_2017	2016-001935-12	International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia	3	Universitätsklinikum Schleswig Holstein	02.07.2018
	563	ALL Rez Register	N/A	ALL REZ BFM Beobachtungsstudie und Biobank für Rezidive einer akuten lymphatischen Leukämie im Kindes- und Jugendalter		A. von Stackelberg	01.01.2013
	1025	AMoRe2017	2017-003422-32	International multicenter, open-Label, Phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with azacitine	2	GPOH gemeinnützige GmbH	16.11.2018
	915	B-NHL-2013	2013-003253-21	Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents		Uniklinik Münster	29.05.2017
	1006	CCTL019A2205B	2014-001673-14	Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy	2/3	Novartis	15.05.2015
	921	CIK-Cell Study	2013-005446-11	A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation	1/2	Goethe-Universität Frankfurt	28.05.2015
	958	GPOH SIOP 2001 Register		Studie zur Behandlung von Kindern und Jugendlichen mit einem Nephroblastom wird ab September 2011 als Register geführt		Deutsche Kinderkrebsstiftung		30.09.2011
	960	HIT HGG 2013	2013-004187-56	International cooperative Phase III Trial of the HIT HGG study Group for treament of high grade glioma, diffuse intrinsic pontine glioma and gliomatosis cerebri in children and adolescents <18 years	3		09.08.2017
	916	HLH Registry		A registry for hemophagocytic lymphohistiocytosis (HLH) HLH Registry		Stephan Ehl University Medical Center Freibur
	917	International Registry Relapsed AML 2009		In­ter­na­tio­nal Re­gis­try Re­l­ap­sed AML 2009, Re­gis­try of child­ren and ado­le­scents with re­l­ap­sed or re­frac­to­ry acu­te mye­lo­id leu­ke­mia (AML), AML-BFM-Stu­dy Group
	961	ITCC-059/Erasmus Inotuzumab	2016-000227-71	A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia	1/2	Erasmus MC	11.07.2017
	949	LCH-IV-G-2016	2016-003568-38	Deutsche Therapieoptimierungsstudie für Kinder mit Ersterkrankung oder Reaktivierung einer Langerhanszell-Histiozytose (LCH) als Teil der Internationalen Studie LCH-IV	3	Goethe-Universität Frankfurt	13.10.2016
	1039	LFS-CPS-R01		Li-Fraumeni-Syndrome-Cancer-Predisposition-Syndrome Registry 01 (LFS-CPS-R01)		Medizinische Hochschule Hannover
	945	RB-Registry (Retinoblastom Reg.)		RB-­registry: a clinical registry for prospective data on retinoblastoma epidemiology and clinical course		Universitätsklinikum Essen
	955	Register AML-BFM 2017		Register AML-BFM 2017 zur Erfassung akuter myeloischer Leukämien bei Kinder und Jugendlichen		GPOH
	1032	RG_15-114 / Hepatoblastom	2016-002828-85	Paediatric Hepatic International Tumour Trial	3	Universitätsklinikum München	20.09.2017
	1034	SIOP Ependymoma Program II	2013-002766-39	SIOP Ependymoma Program II - An international Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma	2/3	Centre Leon Berard in Lyon (Frankreich)	16.10.2014
	959	SIOP-LGG-2004-Interim Register		Studie zur Behandlung von Kindern und Jugendlichen mit einem Gliom niedrigen Malignitätsgrades wird ab 01.04.2012 als Interim Register geführt		GPOH gemeinnützige GmbH	15.04.2012	31.12.2018
	957	Uni-Koeln-1495	2011-004593-29	Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma	2	Uniklinik Köln	19.01.2016
	1398	9766-CL-0107	2018-003975-36	A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects	2	Astellas	30.09.2019
	306	A1501080 Vorikonazol	2008-005275-10	A prospektive, open-label, non-randomized, multi-center study to investigate the safety and tolerability of Voriconazole as primary therapy for treatment of invasive aspergillosis and molds such as scedosporium or fusarium species in pediatric patients	3	Pfizer Pharma GmbH	03.08.2009	01.05.2013
	307	A8851008 Anidulafungin	2008-004150-32	A prospective, open-label study to assess the pharmacokinetics, safety and efficacy of Anidulafungin when used to treat children with invasive candidiasis, including candidemia	3	Pfizer Pharma GmbH	01.07.2009	23.01.2012
	123	AIEOP-BFM ALL 2009	2007-004270-43	Internationales kooperatives Behandlungsprotokoll für Kinder und Jugendliche mit akuter lymphoblatischer Leukämie	3	Universität Kiel	01.06.2010
	1323	ALCL-VBL	2017-002935-40	International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine	3		17.08.2020
	137	ALL BFM 2000		Studienprotokoll zur Behandlung von Kindern und Jugendlichen mit akuter lymphoblastischer Leukämie	3	Universitätsklinikum Kiel	01.07.2000	31.05.2010
	868	ALL Register-2017		Im AIEOP-BFM ALL 2009-Register sollen alle ALL-erkrankten Kinder im Alter von 1-17 Jahren in Deutschland erfasst werden, unabhängig davon, welche Art der Therapie sie erhalten.
	138	ALL REZ BFM 2002		Studie zur Behandlung von Kindern und Jugendlichen mit Rezidiv einer akuten lymphoblastischen Leukämie	4		01.01.2002
	871	ALL Rez HR-Blina.	2014-002476-92	A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE¿ Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	3	Amgen	29.06.2015	16.09.2019
	920	ALL Rez HR-Blina.	2014-002476-92	A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE¿ Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	3		29.06.2015
	1440	ALL SCT FORUM Registry 2022		Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia		Goethe-Universität Frankfurt	17.10.2022
	624	ALL SCTped 2012 FORUM	2012-003032-22	ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia	2/3	St. Anna Kinderkrebsforschung	13.11.2013
	1348	ALL SCTped 2012Forum	2012-003032-22	Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia	2/3	St. Anna Kinderkrebsforschung	13.11.2013
	506	ALL SZT BFM 2003		Allogene Stammzell- Transplantation bei Kindern und Jugendlichen mit Akuter Lymphoblastischer Leukämie	4	Dr. C. Peters	03.10.2003	09.09.2011
	139	AML BFM 2004		Studie zur Behandlung von Kindern und Jugendlichen mit akuter myeloischer Leukämie	2/3	Uniklinik Münster, Uniklinik Hannover	22.07.2004
	140	AML REZ 2001/01		Studie zur Behandlung von Kindern und Jugendlichen mit einer refraktären oder rezidivierten akuten myeloischen Leukämie	3
	435	AML SCT- BFM 2007	2007-004517-34	Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML	3/4	Hannover Clinical Trial Center GmbH	13.01.2010
	789	AML-BFM 2012	2013-000018-39	AML-BFM 2012 Klinische Prüfung zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen	3	GPOH gemeinnützige GmbH	21.11.2014
	309	AP23573	2007-003462-18	A pivotal trial to determine the efficacy and safety of AP23573 when administered as maintenance therapy to patients with soft-tissue or bone sarcomas	2	Kendle	03.06.2008	01.06.2010
	310	ATRT-ZNS 2004		Pilotstudie zur Behandlung von atypischen teratoiden/rhabdoiden Tumoren des zentralen Nervensystems im Kindes- und Jugendalter	4	Deutsche Kinderkrebsstiftung	05.05.2004	31.12.2012
	793	AZA AML004	2014-002172-92	A Randomized, Multicenter open-label, Phase 2 STUDY, with a safety run-in Part To evaluate safety, pharmacodynamics and Efficacy of azacitidine compared to no ANTI-CANCER treatment in children and young adults with acute myeloid leukemia in molecular relapse after first complete remission	2	Celgene	04.02.2016	16.01.2019
	794	AZA JMML001	2014-002388-13	A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND ACTIVITY OF AZACITIDINE AND TO COMPARE AZACITIDINE TO HISTORICAL CONTROLS IN PEDIATRIC SUBJECTS WITH NEWLY DIAGNOSED ADVANCED MYELODYSPLASTIC SYNDROME OR JUVENILE MYELOMONOCYTIC LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION	2	Celgene	04.02.2016	13.05.2019
	311	B-NHL Rituximab		B-NHL BFM Rituximab: Multizentrische Therapiestu­die mit einem Rituximab-Window vor anschließender Chemotherapie zur Behandlung von Kindern und Jugendlichen mit reifem B-Zell Non-Hodgkin-Lymphom oder B-ALL	2		01.01.2004	14.04.2011
	438	Blinatumomab	2010-024264-18	A Single- Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE(R) Antibody Blinatunomab (MT 103)in Pediatric and Adolescent Patients with Relapsed/ Refractory B- Precursor Acute Lymphoblastic Leukemia	1/2	Amgen	23.11.2011	24.05.2016
	774	Blinatumomab-Rialto	2014-001700-21	An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Rialto Study)	3/4	Amgen Inc.	11.02.2015	25.07.2018
	437	Bortezomib ITCC 021	2009-014037-25	A feasibility and phase II study in childhood relapsed ALL	2	Erasmus MC	15.12.2011	04.02.2015
	436	Brentuximab C25002	2011-001240-29	A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in pediatric patients with relapsed or refractory systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma	1/2	Millennium Pharmaceuticals, Inc.	24.04.2012	18.06.2018
	141	BXC 1777-108 Forodesine	2008-002219-42	Pharmacokinetic study of intrevenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor acute lymphoblastic leukaemia or T-cell Non-Hodgkin’s lypmphoma	1/2	Mundipharma	26.01.2009	14.10.2010
	1188	C2T	2010-021622-35	Eine monozentrische, nicht kontrollierte, nicht randomisierte IST zur vergleichenden Bioverfügbarkeit von Kaletra®-Softgelkapseln oder –Lösung und Kaletra®-Tabletten in pädiatrischen Patienten“ – „C2T“ A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T	1	Goethe-Universität Frankfurt	12.08.2011	07.05.2014
	144	CA180-018	2005-002882-35	Phase I study of Scr/Abl tyrosine kinase inhibitor dasatinib in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005	1	BMS	02.03.2006	11.11.2014
	148	CA180-226	2008-002260-33	A Phase II study of Dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia or with Ph+ Leukemias resistant or intolerant to Imatinib	2	BMS	17.03.2011
	902	CCTL019B2001X	2016-001991-31	Expanded treatment protocol for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019	2	Novartis	26.07.2017	13.10.2020
	804	CCTL019B2202	2013-003205-25	A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia	2	Novartis	03.02.2016	07.10.2022
	853	CIK-Cell Study	2013-005446-11	A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation	1/2	Dekan der Universität Frankfurt	28.05.2015
	142	CML - päd 95/96		Protokoll zur Behandlung von Kindern und Jugendlichem mit chron. myeloischer Leukämie
	143	CML - päd II	2007-001339-69	Mul­ti­zen­tri­sche The­ra­pie­op­ti­mie­rungs­stu­die zur Be­hand­lung von Kin­dern und Ju­gend­li­chen mit chro­nisch mye­loi­scher Leuk­ämie	4		01.01.2007	31.01.2017
	1028	CMLpädII Register		Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML)		Universitätsklinikum Erlangen
	431	COSS Register	N/A	COSS Register		N/A	30.06.2005
	887	CPT SIOP Register	N/A	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients with Choroid Plexus Tumors.		GPOH	11.11.2014
	149	CWS 2002 P		Multizentrische Therapiestudie zur Behandlung von Kindern und Jugendlichen mit Weichteilsarkomen, Cooperatiove Weichteilsarkom Studie CWS-2002 P	4		01.01.2003
	150	CWS DOK IV 2002		Multizentrische Therapieoptimierungsstudie: zur Behandlung von Kindern und Jugendlichen mit Stadium IV eines Weichteilsarkoms	2
	314	CWS DOK IV 2004		Cooperative - Weichteilsarkomstudie CWS, CWS DOK IV 2004			11.02.2005
	313	CWS-2007-HR	2007-001478-10	CWS-2007-HR A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults	3	Universitätsklinikum Tübingen	19.02.2009
	315	CWS-Register SoTiSaR		CWS-Register SoTiSAR A Registry for soft tissue sarcoma and other soft tissue tumours in children, adolescents, an young adults			01.07.2009
	1400	D8850C0006 (TRUST-Studie)	2021-006056-13	Open-label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks Gestational Age to < 18 Years	1	Astra Zeneca	21.03.2022
	316	DBA 2000		Beobachtungsstudie der Erkrankung an Diamond-Blackfan-Anämie	4		01.09.2003
	1373	DKMS-21-01	2021-000853-17	Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG (GRAPPA)	3	DKMS gemeinnützige GmbH	11.11.2021
	911	Eisai E7389-G000-213	2016-003352-67	A phase 1/2 single-arm study evaluating the safety and efficacy of eribuline mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	1	Eisai Ltd. UK	08.05.2017	28.11.2018
	317	EPOC-MS-001-Doxo	2009-011454-17	Phase II pharmacokinetic study to assess the agedependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia	2	Uniklinik Münster	22.02.2010	29.05.2013
	145	EsPHALL	2004-001647-30	Studie zur Behandlung der Philadelphia-positiven ALL mit Imatinib	2/3	Universitätsklinikum Kiel	05.10.2005	31.03.2017
	861	EsPhALL Imatinib Obs		A European observational registry collecting efficacy and safety data in newly diagnosed pediatric Philadelphiapositive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients treated with chemotherapy + imatinib (+/-) hematopoietic stem cell treatment (+/-)HSCT)	4	Novartis	07.03.2016
	605	EsPhALL Register	N/A	EsPhALL Register		Zentrum für Kinder- und Jugendmedizin	01.04.2013
	430	EU-RHAB	N/A	EU­RO­PEAN RHAB­DO­ID RE­GIS­TRY		N/A	01.03.2010
	318	EURAMOS 1	2004-000242-20	EURAMOS 1 A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy
	558	EURO-HIT-HLH	2011-002052-14	EURO-HIT-HLH. Europäische kooperative Pilotstudie zur Untersuchung einer Hybrid-Immunochemotherapie bei hämophagozytischer Lymphohistiozytose (HLH)	2/3	A.O.U. Meyer, Florenz, Italien	30.09.2013	23.02.2016
	319	EuroNet-PHL-C1	2006-000995-33	EuroNet-PHL-C1 First international Inter-Group Study for classical Hodgkin´s Lymphoma in Children and Adolescents	3	Uniklinik Halle/Wittenberg	13.12.2006	15.01.2019
	786	EuroNet-PHL-C2	2012-004053-88	Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	3	Justus Liebig Universität Giessen	01.07.2015
	482	EuroNet-PHL-LP1	2007-004092-19	EuroNet-PHL-LP1 First international Inter-Group Study for nodular lymphocyt-predominant Hodgkin´s Lymphoma in Children and Adolescents.	4	Uniklinik Halle/Wittenberg	22.07.2009
	849	Evoltra-CLO08708 Reg		The Evoltra European Registry Programme: Paediatric Leukaemia Protocol No. CLO08708 (OBS12879)		Sanofi-Aventis	30.08.2010	31.12.2020
	320	Ewing 2008	2008-003658-13	Randomisierte klinische Studie zur Therapieoptimierung bei Patienten mit lokalisiertem oder metastasiertem Ewing-Sarkom	3	Uniklinik Münster	19.03.2009
	441	EWOG- SAA 2010	N/A	EWOG-SAA 2010 Genetic and Immunological Characterization of Acquired Severe Aplastic Anemia (SAA) in Children and Adolescents An open non-randomized multi-center prospective study	3/4	Universitätsklinikum Freiburg	21.05.2012
	146	EWOG-MDS 2006		Protokoll zur Behandlung von Kindern und Jugendlichen mit einem myelodysplastischen Syndrom	4	Uniklinik Freiburg	01.01.2007
	439	EXSEPT CICL670ADE10	N/A	Nicht-interventionelle Studie zur Praktikabilität der Exjade-Behandlung von Patienten mit transfusionsbedingter Eisenüberladung		Novartis	01.06.2012	31.12.2016
	1247	Fanconi Register FAR		Fanconi Anemia Registry 01		Prof. Kraatz
	792	GO29664	2014-004697-41	AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI-PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS	1	Roche	06.10.2015	28.06.2017
	321	GPOH SIOP 2001		Studie zur Behandlung von Kindern und Jugendlichen mit einem Nephroblastom (Wilmstumor)	4	SIOP	01.03.2003	30.09.2011
	419	GPOH-HD Register 2011	NA	Register zur Behandlung von Kindern und Jugendlichen mit einem Hodgkin Lymphom			29.01.2012	18.06.2018
	1315	GPOH-HD Registry	NA	GPOH-HD Registry - Prospective Registry for children and adolescents with classical Hodgkin Lymphoma (cHL), nodular lymphocyte predominant Hodgkin lymphoma (nLPHL) and relapsed/refractory Hodgkin (r/rHL) lymphoma		Justus Liebig Universität Giessen	19.11.2020
	664	GPOH-MET-Register	N/A	GPOH-MET-Register Register zur Erfassung maligner erndokriner Tumoren im Kindes- und Jugendalter			02.07.2014	13.04.2022
	1392	GSK 213406 SCOOP	2020-002359-39	A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours	1	GlaxoSmithKline	05.07.2022
	322	HIT 2000		tudie zur Behandlung von Kindern und Jugendlichen mit tumoren des ZNS - seit 01.01.12 Register	3		01.01.2001	31.12.2014
	323	HIT HGG 2007	2007-000128-42	Studie zur Behandlung von Kindern und Jugendlichen mit Tumoren des ZNS	2	Uniklinik Halle/Wittenberg	19.03.2009	28.03.2018
	455	HIT HGG CilMetro	2009-011898-33	Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Young Adults	2	Uni­ver­si­tät Hal­le - Wit­ten­berg	28.11.2011	21.02.2014
	324	HIT REZ 2005	2005-002618-40	Studie zur Behandlung von Kindern und Jugendlichen mit Tumoren des ZNS	2	Deutsche Kinderkrebsstiftung	13.12.2005	30.01.2016
	845	HIT Rez Register		Multinationales multizentrisches Register für Kinder, Jugendliche und junge Erwachsene mit therapierefraktären oder rezidivierten Medulloblastomen, Pineoblastomen, primitiv neuroektodermalen Tumoren des ZNS (ZNS-PNETs) und Ependymomen		Universitätsklinikum Essen	11.08.2015
	420	HLH-2004	NA	HLH-2004 Treatment Protocol of the Second International HLH Study 2004			01.01.2004	31.12.2011
	795	I-HIT-MED		International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumours		Universitätsklinik Hamburg-Eppendorf	01.01.2015
	1026	I-HIT-MED		International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumours		Universitätsklinik Hamburg-Eppendorf	15.04.2015
	1330	iEwing Register		iEwing Register
	800	Imatinib Register		A European observational registry collecting efficacy and safety data in newly diagnosed pediatric Philadelphiapositive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients treated with chemotherapy + imatinib (+/-) hematopoietic stem cell treatment (+/-)HSCT)	4	Novartis	07.03.2016
	151	Interfant 06	2005-004599-19	Studie zur Behandlung von Säuglingen im ersten Lebensjahr mit ALL	4	Dutch Childhood Oncology Group	19.06.2009	23.02.2011
	852	INTERFANT 06-Register		INTERFANT 06-Register		Universitätsklinikum Kiel	01.10.2008
	152	International Registry Relapsed AML 2009		Register zur Behandlung von Kindern und Jugendlichen mit rezidivierter oder refraktärer akuter myeloischer Leukämie	4	Studienzentrale Hannover	01.06.2009
	1064	IntReALL HR 2010	2012-000810-12	International Study for Treatment of High Risk Childhood Relapsed ALL 2010	2		05.04.2017
	663	IntReALL SR 2010	2012-000793-30	IntReALL SR 2010 International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group	3		29.08.2013
	1456	ISIS 721744-CS7	2022-000757-93	An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)	3	IONIS Pharmaceuticals	01.02.2023
	339	ITCC 020 & I-BFM	2009-009457-13	A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML	1/2	Erasmus MC	01.04.2010	02.04.2014
	325	Kraniopharyngeom		Studie zur Behandlung von Kindern und Jugendlichen mit Tumoren des ZNS	3		01.10.2007
	1071	KranioReg19		Multicenter registry for patient with childhoodonset craniopharyngioma, xanthogranuloma, cysts of Rathke´s pouch, menigioma, pituitaryadenoma, arachnoid cysts		Klinikum Oldenburg	01.10.2019
	166	KZT-HD-Chemo		Sequentielle Hochdosischemotherapie mit 3 Zyklen Carboplatin und Etoposid (CE) und autologer Stammzelltransplantation als Salvagetherapie bei Patienten mit refraktären und rezidivierten Keimzelltumoren
	326	LCH-III		LCH-III Treatment Protocol of the Third International Study for Langerhanscell Histiocytosis	3		14.05.2001
	735	LCH-REG-DE 2013		Deutsches Register für Langerhanszell Histiozytosen im Kindes- und Jugendalter LCH-REG-DE 2013			01.07.2014
	1038	LOGGIC		HIT LOGGIC Register		Universitätsklinikum Heidelberg	18.09.2019
	1040	LOGGIC Core		LOGGIC Core-BioCLinical Databank		Universitätsklinikum Heidelberg	18.09.2019
	433	LTR	N/A	Register für Lebertumoren bei Kindern und Jugendlichen		N/A	01.01.2011
	327	MAHO 98		Ko­ope­ra­ti­ve, pro­spek­ti­ve, nicht ran­do­mi­sier­te The­ra­pie­stu­die für ma­lig­ne Ho­den­tu­mo­ren im Kin­des­al­ter	4		29.10.1998	25.05.2018
	328	Makei 96		Extrakraniale nicht die Hoden betreffende, bösartigeKeimzelltumoren im Kindes- und Jugendalter	3		29.11.1996	25.05.2018
	329	MC-ASP 6/INF	2008-006300-27	Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphblastic leukemia	2	Medac	19.06.2009	23.02.2011
	168	MCL2005-01		Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
	330	MET 97		Therapieoptimierungsstudie zur Behandlung von Kindern und Jugendlichen mit malignen endokrinen Tumoren	3	GPOH	31.12.1997	31.12.2017
	574	Mifamurtide C23003	2009-017204-89	Observational, noninterventional surveillance study of patients with newly diagnosed Osteosarcoma	4	Millennium Pharmaceuticals	29.01.2013
	331	MK-0869 Prot. 134-01	2006-005515-10	A multicenter, open-label, 5-part study to evaluate the pharmacokinetics, safety and tolerability of Aprepitant and Fosaprepitant Dimeglumine in pediatric patients receiving emetogenic chemotherapy	1	MSD	11.02.2009	28.01.2014
	1053	MK-8228-030	2018-001326-25	A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from brith to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell Transplantation (HSCT)	2	Merck Sharp & Dohme Corp	15.04.2019
	1318	MNP Int-R		Internationales Molekulare Neuropathologie Register		DKFZ	01.06.2021
	1057	MO40597 (GAZELLE)	2018-003255-38	A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma	4	Hoffmann-La Roche	26.02.2019
	859	Moleular Neuropathology 2.0 (MNP 2.0)		Molecular Neuropathology 2.0 - Increasing diagnostic accuracy in pediatric neurooncology (Molekulare Neuropathologie 2.0 zur Erhöhung der diagnostischen Genauigkeit bei Hirntumoren im Kindesalter)		DKFZ	22.04.2015	01.10.2020
	445	Mozobil	2010-019340-40	A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoetic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, aged 2 to <18 Years, with Solid Tumours Eligible for Autologous Transplants	1/2	Sanofi-Aventis	04.11.2010	08.05.2017
	1430	Nasal Ag Tests		Clinical performance study of SARS-CoV-2 Antigen Self Test Nasal & SARS-CoV-2 Rapid Antigen Test 2.0 Nasal		SD Biosensor, Inc.	22.03.2023
	341	NB 2004		NB2004 Tri­al Pro­to­col for Risk Ad­ap­ted Tre­at­ment of Child­ren with Neu­ro­b­last­o­ma	3		01.10.2004
	872	NB Registry 2016		Die Behandlung von neuen Neuroblastompatienten sollte grundsätzlich nach der bisherigen Diagnostik und Standardtherapie erfolgen. Auf der Basis der internationalen Datenlage werden aber die folgenden Änderungen empfohlen: •Der Alters-Cut-off für Stadium 4S Patienten verschiebt sich von 12 Monaten auf 18 Monate •Neben der bisherigen Hochdosis-Konditionierung mit Melphalan, Etoposid und Carboplatin (MEC) wird aufgrund der internationalen Datenlage auch die Hochdosis-Konditionierung mit Busulfan und Melphalen (BU/MEL) empfohlen. •Für die Therapie mit Retinolsäure nach Stammzelltransplantation ist die internationale Evidenz nicht mehr gegeben.			01.01.2017
	1112	NB Registry 2016		Registry for neonates, infants, children, adolescents, and adults with newly diagnosed and/or relapsed neuroblastic tumors (NB Registry 2016)		UNI Klinik Köln
	434	NHL-BFM Registry 2012	N/A	Registry of the NHL-BFM study group for all subtypes of Non-Hodgkin lymphoma diagnosed in children and adolescents		N/A	15.05.2012
	332	NPC-2003-GPOH		NPC-2003-GPOH Multizentrische Studie zur Behandlung des Nasopharynxkarzinoms bei Kindern und Jugendlichen			01.08.2003
	1056	NPC-2016		NPC-2016 - A multicenter registry for nasopharyngeal cancer in children, adolescents and young adults			24.08.2017
	333	P03579	2007-004645-15	Phase 1B Study of the safety, tolerance and pharmacokinetics of oral Posaconazole in immunocompromised children with neutropenia	1	Schering-Plough	22.07.2008	10.07.2015
	334	P04720	2007-005341-38	A Study to determine the activity of SCH 717454 in subjects with Osteosarcoma or Ewing’s Sarcoma that has relapsed after standard systemic therapy	2	Schering-Plough	09.06.2008	15.08.2013
	1059	PAED-201601 (MAKAI V)	2016-001784-36	Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin	3	Rheinische Friedrich-Wilhelms-Universität Bon
	1431	PersoMed-I	2020-003063-26	Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)	2	EORTC	03.05.2022
	1441	Pfizer- InOchild	2022-000186-40	A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA	2	Pfizer	28.07.2023
	791	Posa MK5592-097	2014-002807-10	A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole POS) in Immunocompromised Pediatric Subjects with Neutropenia	1	MSD	02.09.2015	03.09.2018
	335	RAD001 Effects	2010-022583-13	An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC).	3	Novartis	13.01.2011	31.10.2011
	426	Register AML-BFM 2012		Register AML-BFM 2012 der akuten myeloischen Leukämien bei Kindern und Jugendlichen		Zentrum für Kinder- und Jugendmedizin	01.04.2012
	308	Relapsed AML 2001/01		A randomised phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia TRIAL Relapsed AML 2001/01	3		31.07.2001	10.01.2020
	655	RIST-rNB2011	2011-004062-15	Pro­s­pec­tive, open la­bel, ran­do­mi­zed pha­se II tri­al to as­sess a mul­ti­modal mo­le­cu­lar tar­ge­ted the­ra­py in child­ren, ado­le­scent and young adults with re­l­ap­sed or re­frac­to­ry high-risk neu­ro­b­last­o­ma	2	Zentrum für Kinder- und Jugendmedizin	06.08.2012	16.04.2022
	1371	RTPS		Familien mit Rhabdoid-Tumor-Dispositions-Syndromen (RTPS1 und 2)			02.03.2021
	336	SARC 011 (NO21157)	2007-003940-30	A phase Ii trial of R1507,a recombinant human monoclonal antibody to the insuline-like growth factor-1 receptor for the treatment of patients with recurrent of refractory Ewingsarkocoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas	2	Hoffmann la Roche AG	21.05.2008	01.06.2010
	432	SAREZ	N/A	SAREZ SArkom REZidivregister für Knochen- und Weichteilsarkomrezidive		N/A	01.01.2010	05.07.2018
	442	SIOP CNS GCT II	2009-018072-33	SIOP CNS GCT II: Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours		N/A	01.08.2011	30.06.2020
	337	SIOP LGG 2004		Studie zur Behandlung von Kindern und Jugendlichen mit einem Gliom niedrigen Malignitätsgrades	3		01.04.2004	30.09.2016
	662	SIOP PNET 5 MB	2011-004868-30	AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)	2	Zentrum für Kinder- und Jugendmedizin	31.10.2013
	1443	SIOP RTSG 2016		Umbrella Protocol SIOP RTSG 2016, Integrated research and guidelines for standardized diagnostics and therapy		Universitätsklinik Saarland	08.02.2023
	860	SIOP-LGG-2004-Interim Register		Studie zur Behandlung von Kindern und Jugendlichen mit einem Gliom niedrigen Malignitätsgrades wird ab 01.04.2012 als Interim Register geführt		N.A.	01.04.2012
	603	Siopen ch14.18	2009-018077-31	A Phase I/II dose schedule finding study for CH14.18/CHO continuos infusion combined with subcutaneous Aldesleukin (=Proleukin) (IL-2) in patients with primary refractory or relapsing Neuroblastoma	1/2	N/A	01.02.2012
	338	SPD422-404 Shire		Multicentre Paediatric Disease Registry in Essential Thrombocythaemia		Shire	16.05.2011	29.02.2016
	1426	T-Haplo for SCD	2018-002652-33	A phase 2 trial to assess haploidentical alpha/beta T-depleted stem cell tranplantation in patients with sickle cell disease with no available sibling donor (T-Haplo for SCD)	2	Universitätsklinikum Regensburg	10.05.2020
	773	TCRalpha/beta-Haplo2010	2011-005562-38	A multi-center phase I/II safety and feasibility study using CliniMACS TCRa/ß and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults	1/2	Miltenyi Biotec GmbH	13.11.2012	21.12.2018
	153	Thrombotect		Studie zur Behandlung von Kindern mit All (Thrombotect)	4	Sanofi Aventis	01.01.2001	01.03.2014
	154	TMD Prävention 2007	2006-002962-20	"Prävention der myeloischen Leukämie bei Kindern mit Down Syndrom und transient myeloproliferativem Syndrom /TMD"		Medizinische Hochschule Hannover	15.03.2007
	698	Treosulfan Maligne	2013-003604-39	Phase II Studie zur Untersuchung der Sicherheit und Wirksamkeit der Treosulfan-basierten Konditionierungstherapie vor allogener Stammzelltransplantation in pädiatrischen Patienten mit malignen hämatologischen Erkrankungen	2	Medac	11.04.2014	20.12.2019
	573	Volasertib 1230.27	2013-001291-38	Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability, and toxicity of volasertib in paediatric patients from 2 years to less than 18 years of age with acute leukaemia or advanced solid tumour, for whom no effective treatment is known	1	Böhringer Ingelheim	14.01.2014	15.11.2017
	799	Volasertib 1230.28	2015-004625-14	Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy regimen with liposomal daunorubicine, fludarabine and cytarabine (DNX-FLA) followed by fludarabine and cytarabine (FLA) in children from 3 months to less than 18 years of age with acute myeloid leukaemia after failure of the front-line therapy	1	Böhringer Ingelheim	01.03.2016	22.11.2016
	340	ZKJ-SCT-Haplo-0106	2006-000393-76	Allogene Stammzelltransplantation mit CD 3/19 depletierten Stammzellen von haploidenten verwandten oder nicht verwandten Spendern bei pädiatrischen Patienten mit malignen und nicht malignen Systemerkrankungen	2	Uniklinik Frankfurt am Main	25.10.2006	18.08.2017
Kindergastroenterol.
	721	2819-CL-0202	2013-000508-40	A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspensio or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhoe	3	Astellas	18.11.2014	07.03.2018
MKG
	250	DCC	2007-007034-18	Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle	2	Charité Universitätsmedizin Berlin – CVK,	26.01.2009	03.12.2012
Neurochirurgie
	909	Car2Brain	2016-000225-39	Monozentrische, offene Phase I-Studie mit intrakranieller Injektion von NK-92/5.28.z (HER2.taNK) Zellen bei Patienten mit rezidiviertem HER2-positivem Glioblastom (CAR2BRAIN)“	1	Goethe-Universität Frankfurt	07.11.2017
	428	Curcumin-1	N/A	Messung der intratumoralen Konzentration des sekundären Pflanzenstoffes Curcumin bei Patienten mit primärem Glioblastom		Klinik für Neurochirurgie	15.10.2012	03.07.2013
	722	FTinMRIguidedTS		nTMS, fMRI and DCS fiber tracking in iMRI guided tumor surgery		Dekan der Universität Frankfurt	01.01.2012	31.12.2014
	403	Galaxy_01		GENERAL ANESTHESIA vs. LOCAL ANESTHESIA in STEREOTAXY, Vollnarkose versus Lokalanästhesie bei stereotaktischen Gehirnoperationen		Dekan der Universität Frankfurt	27.01.2012	31.12.2014
	678	IMAGER-01		Intraoperative MRI and 5-ALA-guidance to improve the extent of resection in brain tumor sugery (IMAGER)		Uniklinik Frankfurt am Main	23.10.2014	31.12.2020
	1222	LogGlio		Multicentric Registry Study on Epidemological and Biological Disease Profile as well as Clinical Outcome in Patients with Low Grade Gliomas		Universitäts-klinikum Ulm
	785	MF-1001		MF 1001: AN OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF NANOTHERM® MONOTHERAPY AND NANOTHERM® IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN RECURRENT / PROGRESSIVE GLIOBLASTOMA		Klinik für Neurochirurgie	10.08.2015	30.11.2016
	1263	RESURGE		Randomized controlled comparative phase II trial on surgery for glioblastoma recurrence		University Hospital Bern	01.04.2020
Neurologie
	1100	EORTC-1709-BTG	2017-003908-50	Eine Phase-III-Studie von Marizomib in Kombination mit Temozolomid-basierter Standard-Radiochemotherapie im Vergleich zur Temozolomid-basierten Standard-Radiochemotherapie allein bei Patienten mit neu diagnostiziertem Glioblastom	3	EORTC
	1014	NCT-2014-0235/N2M2	2015-002752-27	NCT Neuro Master Match (N²M²) Phase I/IIa Studie basierend auf einer molekularen Charakterisierung unter Nutzung zielgerichteter Substanzen in Kombination mit Strahlentherapie zur Behandlung von Glioblastomen mit einem nicht-methyliertem MGMT-Promotor	1	Universitätsklinikum Heidelberg	04.04.2018
	285	AP12009-G005 (Sapphire)	2007-005802-38	Wirksamkeit und Sicherheit von AP 12009 bei volljährigen Patienten mit einem progredienten oder refraktären Anaplastischen Astrozytom im Vergleich zur Standardbehandlung mit Temozolomid oder BCNU. Eine offene randomisierte Studie	2	Antisense Pharma	01.08.2008	10.01.2012
	296	APG101_CD_002_01	2009-013421-42	Randomisierte, offene, multizentrische Phase II Studie mit APG101 (wöchentlich) plus Re-Bestrahlung versus Re-Bestrahlung alleine in der Behandlung von Patienten mit erstem oder zweiten Progress eines Glioblastoms	2	Apogenix, Heidelberg	14.12.2009	09.10.2014
	457	Avastin-Projekt		Beobachtung von Patienten mit Glioblastom während einer Therapie mit Bevacizumab oder alleiniger Chemotherapie			07.07.2009	30.06.2019
	1240	BI 1336-0011	2017-001378-41	An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors	1	Böhringer Ingelheim
	1113	CA 209-498	2015-003739-37	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methylatransferase) Glioblastoma	3	Bristol Myers Squibb
	855	CA209-548	2015-004722-34	Eine randomisierte einfach verblindete Studie der Phase II mit Temozolomid und Strahlentherapie in Kombination mit Nivolumab oder Placebo bei erwachsenen Patienten mit neu diagnostiziertem Glioblastom, welches einen methylierten MGMT-(O-6-Methylguanin-DNA-Methyltransferase)-Promoter aufweist	2	Bristol Myers Squibb	19.05.2016
	1319	CDI-CS-002	2014-003371-34	An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma	1/2	Basilea	10.03.2021
	685	CDX110-04 (ACT IV)	2011-006068-32	An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The ACT IV Study)	3	Celldex	20.09.2013	07.03.2016
	290	CENTRIC-Studie	2007-004344-78	Cilengitide in Kombination mit Standardbehandlung vs. Standardbehandlung alleine	3	Merck Serono	05.08.2008	18.10.2013
	295	CeTeG-Studie	2009-011252-22	Phase III-Studie zur CCNU/Temozolomid Kombinationstherapie vs Standard-Temozolomidtherapie bei neudiagnostizierten Glioblastompatienten mit methyliertem MGMT-Promoter im Tumor(CeTeG)	3	Rheinische Friedrich Wilhelmsuniversität Bonn	11.06.2010	07.04.2017
	677	Checkmate 143 BMS	2013-003738-34	Eine randomisierte offene Phase-3-Studie mit Nivolumab versus Bevacizumab und eine Sicherheitsstudie mit Nivolumab oder Nivolumab in Kombination mit Ipilimumab bei erwachsenen Patienten mit rezidiviertem Glioblastom (GBM)	3	Bristol Myers Squibb	05.06.2014
	291	DIRECTOR	2008-006871-60	Dosisintensivierte Reexposition mit Temozomid im Wochenwechsel versus im Wechsel von drei Wochen Therapie und einer Woche Therapiepause	2	Universitätsklinikum Heidelberg	23.06.2009	30.06.2013
	289	Enzastaurin-Studie (H6Q-MC-S039)	2007-000281-21	Enzastaurin und Strahlentherapie bei Patienten mit neu diagnostiziertem Glioblastom	2	Lilly	05.09.2007	18.12.2013
	870	EORTC 1320	2014-002446-47	Trabectedin für wiederkehrende Meningeome des Grades II oder III: Eine randomisierte Phase-II-Studie der EORTC Brain Tumor Group	2	EORTC	01.01.2017	31.08.2017
	1221	EORTC 1608	2017-001029-42	Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study (STEAM)	1	European Organization for Research and Treatm	11.03.2020	05.05.2022
	293	EORTC 26062	2008-001949-26	A randomized phase III Study of Temozolomide and a short course Radiation versus short course Radiation alone in the treatment of newly diagnosed Glioblastoma multiforme in elderly Patients	3	EORTC	30.11.2009	01.08.2016
	294	EORTC 26091 Studie	2009-017422-39	Randomisierte Studie zur Beurteilung der Signifikanz von Bevacizumab bei rezidivierten Grad II und Grad III Gliomen	2	EORTC	30.05.2011	24.09.2017
	654	EORTC 26101	2010-023218-30	Phase III trial exploring the combination of bevacizumab and Lomustine in patients with first recurrence of a glioblastoma	3	EORTC	22.12.2011	30.04.2018
	1362	EORTC-1419-BTG		Molekulargenetische, patienteneigene und klinische Determinanten für das Langzeitüberleben mit Glioblastom		EORTC
	1363	EORTC1721		Understanding the long-term implications of treatment of rare brain tumours on health-related quality of life: A European cross-sectional study			10.11.2021
	287	ERGO		Ernährungsumstellung bei Patienten mit Rezidiv eines Glioblastoms		Institut für Neuroonkologie	01.12.2007	03.01.2010
	551	ERGO2	N/A	Vorübergehende kalorische Restriktion begleitend zu einer Strahlentherapie bei Patienten mit Rezidiv eines Glioblastoms (ERGO2): eine randomisierte Pilotstudie		Uniklinik Frankfurt am Main	17.05.2013	06.09.2018
	1210	ERGO3		Untersuchung metabolischer Veränderungen im Tumorgewebe durch vorübergehendes Fasten bei Patienten mit einem malignen Gliom: eine Pilotstudie (ERGO3)		Goethe-Universität Frankfurt	25.02.2020
	292	Glarius	2009-010390-21	Radiotherapie +Temozolomide vs Radiotherapie +Bevazizumab und Irinotecan bei nicht methylierten MGMT Promotor	2	Roche	10.02.2010	05.03.2015
	1101	GLIOPT		Gliompatienten in der stationären und ambulanten Versorgung - Optimierung des psychosozialen Screenings bei ambulanten neuroonkologischen Patienten in einer prospektiven multizentrische Längsschnitt-Studie (GLIOPT, Teilprojekt 3)		Universitätsklinikum Tübingen
	458	H9H-MC-JBAI	2010-022160-13	Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma	2	Lilly	21.02.2011	23.01.2017
	459	H9H-MC-JBAL	2011-004418-40	A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma	2	Lilly	29.08.2012	14.07.2015
	288	HELLO-Studie		Levetiracetam bei primären ZNS Tumoren	4	Universitätsklinikum Tübingen	30.01.2008	01.09.2009
	1320	IMPROVE CODEL NOA-18	2018-005027-16	Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial		Universitätsklinik Heidelberg	14.09.2020
	1242	METIS		METIS: Effect of TTFields (150 kHz) in Non- Small Cell Lung Cancer (NSCLC) Patients with 1-10 Brain Metastases Following Radiosurgery	3	Novocure GmbH
	286	MRT-Studie		Intraoperative Resektionskontrolle			01.10.2007	01.02.2011
	1391	NEU-201901	2021-000708-39	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24)	1/2	Universitätsklinikum Bonn	11.05.2022
	728	Next generation sequencing (NGS)		Next generation sequencing (NGS) of gliomas after anti-angiogenic treatment		Prof. Plate	01.01.2015
	282	NOA-05		Chemotherapie und Strahlentherapie der Gliomatosis cerebri	2	NOA		31.07.2014
	283	NOA-08 (Methusalem)		Temozolomid versus Strahlentherapie bei Astrozytom und Glioblastom	3	NOA	01.05.2005	29.04.2011
	729	NOA-16	2014-000503-27	Gezielter Angriff der IDH1R132H-Mutation in Grad III-IV Gliomen mit einem Peptid-Impfstoff - eine Phase I-Studie zur Analyse der Sicherheit, Verträglichkeit und Immunogenität“	1	Universitätsklinik Heidelberg	01.06.2015
	711	NONK3-NOA12	2011-000921-61	Randomisierte, unverblindete, multizentrische klinische Prüfung der PhaseI/II zum Vergleich einer Re-Bestrahlung plus einer Gabe von BIBF1120 gegenüber einer Re-Bestrahlung zur Behandlung von Patienten mit erster oder zweiter Progression eines Glioblastoms	2	Universitätsklinikum Heidelberg	25.04.2012	30.09.2017
	866	Orbus Therapeutics STELLAR	2016-000089-45	STELLAR Studie - Eine randomisierte, offene Phase-III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Eflornithin mit Lomustin im Vergleich zu Lomustin allein bei Patienten mit anaplastischem Astrozytom, das nach Bestrahlung und adjuvanter Temozolomid-Chemotherapie fortschreitet/wiederkehrt	3	Orbus Therapeutics. Inc,	07.11.2016
	284	OSAG 101	2005-003101-85	Vergleich zweier Therapiestrategien beim neu diagnostizierten Glioblastoma multiforme Grad IV	3	Oncoscience AG	14.05.2007	03.05.2012
	1243	Rosalie Studie	2018-002279-16	A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma (Rosalie study)	1/2	Enterome
	1390	TIGER PRO-Active		Use of TTFields in Germany in routine clinical care study PROgram - daily activity, sleep and neurocognitive functioning in newly diagnosed glioblastoma patients Study		Novocure GmbH
	1049	VXM01-AVE-04-INT (VAXIMM)	2017-003076-31	An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery	1/2	VAXIMM GmbH	10.10.2018
	1285	ZNS-Lymphom		NOA 13: Prospektive Beobachtungsstudie zur Chemotherapie bei nicht spezifisch vorbehandelten Patienten mit primärem ZNS-Lymphom (PZNSL)		Universitätsklinikum Knappschaftskrankenhaus
Psychiatrie/Psychother.
	553	CCC-MC		Psychoonkologische Beratung und Behandlung im Rahmen der Comprehensive Cancer Center (CCC): Multizentrische Studie zur Erfassung des Bedarfs, der Indikationsstellung, Inanspruchnahme sowie Evaluation des psychoonkologischen Versorgungsangebots		N/A	15.09.2013	31.12.2013
	609	PO01012011	N/A	PRO-Integra – Integrative Vernetzung von Psychoonkologie und psychosozialen Ressourcen in der Primärintervention bei onkologischen Patienten	3	KH Nordwest, Frankfurt	21.01.2011
	607	Screening Distress	N/A	Distress als 6. Vitalzeichen in der Onkologie: Verbesserung der Patientenversorgung durch die nachhaltige Implementierung eines psychosozialen Screenings in zwei Organzentren des Universitären Centrums für Tumorerkrankungen (UCT) des Universitätsklinikums Frankfurt			15.09.2013	31.12.2018
Radiologie allg.
	279	224/10 (Optibolus)		Evaluation der Bildqualität eines Mehrfasen-Injektionsystems bei der kontrastmittelunterstützten CT		Institut für Diagnostische und Interventionel	15.01.2011	25.09.2013
	275	312041(546)	2008-000583-16	Multizentrische, randomisierte Vergleichsstudie zur Beurteilung der Ergebnisse und des Ressourcenbedarfs bei Bildgebung und Behandlung nach Primovist-verstärkter MRT der Leber im Vergleich zur extrazellulären Kontrastmittelverstärkten (ECCM-) MRT und zur kontrastverstärkten Computertomographie (CT) bei Patienten mit bekannten oder vermuteten Lebermetastasen nach Kolorektalkrebs	4	Bayer Healthcare AG	17.09.2008	31.12.2010
	276	91782 (Gemma 2)	2009-009598-90	An open label, multi-center, phase 3 study with corresponding blinded imagereading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 molar (Gadovist®) in patients with newly diagnosed breast cancer referred for contrast-enhanced breast MRI	3	Bayer Healthcare AG	17.05.2010	15.04.2013
	613	AMO LNS	N/A	PROSPEKTIVE, KONTROLLIERTE, RANDOMISIERTE STUDIE ZUR EVALUATION EINES LASER-NAVIGATIONSSYSTEMS (LNS) BEI CT-GESTEUERTEN INTERVENTIONEN AN THORAX UND ABDOMEN		Institut für Diagnostische und Interventionel	09.12.2010	31.12.2014
	281	DGD-44-050 (Sentio)	2010-020319-34	Safety and efficacy evaluation of DOTREM in magnetic resonance imaging MRI in patients with central nevous system (CHS) lesions	3	Guerbet	30.09.2010	08.07.2011
	627	EU-Star		A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)		DFINE Inc.	15.01.2014	31.12.2016
	518	FAST		FrAnkfurter STudie (FAST): Evaluation des Therapieresponse nach regionaler Chemoembolisation mit Lipiodol oder EmboCept® mittels MR-Diffusion und -Perfusion bei Thirdline-Therapie der Lebermetastasen eines kolorektalen Karzinoms		Institut für Diagnostische und Interventionel	01.05.2013
	565	FAST-II	N/A	FrAnkfurter Studie II (FAST-II: Evaluation des radiologischen Response nach regionaler Chemoembolisation entweder mit Lipiodol oder Lipiodol und EmboCept® im Rahmen der Therapie eines hepatozellulären Karzinoms (HCC)		Institut für Diagnostische und Interventionel	15.10.2013	31.12.2016
	740	FAST-III	N/A	FrAnkfurter Studie-III (FAST-III): Evaluation des Therapieresponse nach regionaler Chemoembolisation mit EmboCept® S oder EmboCept® S und Lipiodol mittels MR-Diffusion und -Perfusion bei Lebermetastasen eines Mammakarzinoms.		Institut für Diagnostische und Interventionel	24.06.2015	01.10.2018
	1401	iEuroEwing	2019-004153-93	International Euro Ewing Trial For Treatment Optimisation In Patients With Ewing Sarcoma	3	Universitätsklinikum Essen	17.06.2022
	820	IMILT		To Evaluate the Safety & Palliative Treatment Effect on Patients with Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)		CLS	13.01.2016	06.06.2018
	280	KKSH-071 (Debiritux)	2009-014728-44	Chemoembolisation der Leber mit Irinotecan-haltigen Beads in Kombination mit intravenös verabreichtem Cetuximab gegenüber einer Therapie mit intravenösem Cetuximab und intravenösem Irinotecan bei Patienten mit refraktärem-metastasiertem kolorektalem Karzinom und k-ras Wild-Typ Tumoren.	2	Martin-Luther Universität Halle Wittenberg	13.01.2010	15.05.2013
	693	MiRa 1	N/A	MiRa-1: Evaluation des Therapieresponse nach CT gesteuerter Mikrowellen- oder Radiofrequenzablation mittels des AMICA™ Dual Ablationssystems bei Lebermetastasen.		Institut für Diagnostische und Interventionel	10.12.2013	31.12.2016
	695	MiRa 2	N/A	MiRa-2: Evaluation des Therapieresponse nach CT gesteuerter Mikrowellen- oder Radiofrequenzablation mittels des AMICA™ Dual Ablationssystems eines primären Leberzellkarzinoms (HCC).		Institut für Diagnostische und Interventionel	10.12.2013	31.12.2016
	277	NEMA-0027-017 (Nemorubicin)	2005-000731-26	Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by dose-escalation.	2	Nerviano Medical Service	13.11.2007	19.04.2012
	460	SORAMIC	2009-012576-27	Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma	2	Medical Faculty, University Magdeburg	09.04.2010
	278	STX0206 (SIRFLOX )	2008-003737-25	RANDOMISED COMPARATIVE STUDY OF FOLFOX6m PLUS SIR-SPHERES® MICROSPHERES VERSUS FOLFOX6m ALONE AS FIRST LINE TREATMENT IN PATIENTS WITH NONRESECTABLE LIVER METASTASES FROM PRIMARY COLORECTAL CARCINOMA	4	Sirtex Technology Pty Ltd	26.11.2008
	274	Vasovist	2007-001802-25	An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular contrast agent Vasovist® vs. the conventional contrast agent Magnevist®	2	Dekan der Universitätsklinik Frankfurt	27.10.2008
Strahlentherapie
	1105
	189	Bev-XelOx-RT	2007-001558-21	Neoadjuvante Radiochemotherapie beim Rektumkarzinom mit Capecitabin und Oxaliplatin plus Bevacizumab	2	Universitätsklinikum Schleswig Holstein Prof.	26.02.2008	20.11.2012
	190	CAO/ARO/AIO-04		Präoperative Radiochemotherapie und adjuvante Chemotherapie mit 5-Fluorouracil plus	3	Prof. Dr. R. Sauer Universitätsklinikum Erlan		31.12.2009
	723	CAOAROAIO-12-Studie	2011-006310-13	Induktionschemotherapie vor und nach präoperativer Radiochemotherapie und Operation bei lokal fortgeschrittenem Rektumkarzinom: eine randomisierte Phase II Studie der German Rectal Cancer Study Group	2	Dekan der Universität Frankfurt	19.01.2015
	616	CONKO-007	2009-014476-21	Randomisierte Phase III-Studie zum Stellenwerk einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom: Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie	3	Universitätsklinikum Erlangen	22.02.2013
	270	DÖSAK - pN1 - Studie		Wirksamkeit einer postoperativen adjuvanten Strahlentherapie bei Patienten mit Plattenepithelkarzinom der Mundhöhle oder des Oropharynx und gleichzeitig histologisch gesicherter solitärer ipsilateraler zervikaler Lymphknotenmetastase (pN1)	4	Deutsche Krebshilfe e.V.	01.10.2009
	192	GC-DOR-2004		Prospektive, offene multizentrische Phase I/II-Studie zur Bestimmung der Sicherheit und Wirksamkeit einer neoadjuvanten Radiochemotherapie mit Docetaxel und Oxaliplatin bei Patienten mit Adenokarzinomen des gastroösophagealen Übergangs	1/2	Prof. Dr. Peter. R. Galle	31.03.2005	30.06.2009
	658	HNPrädBio		Radiobiologisches Profiling für eine biologisch stratifizierte Radiochemotherapie bei Kopf-Hals-Plattenepithelkarzinomen: eine multizentrische prospektive Studie des Deutschen Konsortiums für translationale Krebsforschung DKTK)		Universität Dresden	18.03.2014
	671	Hsp-70-Screeningsstudie	N/A	Gewinnung von Tumormaterial und Blut für die Erforschung der Hsp70 Expression als Tumormarker (HSP70)		TU München	30.06.2014	12.07.2018
	811	HYPOSIB		Adjuvante Strahlentherapie nach brusterhaltender Operation beim Mammakarzinom: Hypofraktionierung mit simultan-integriertem Boost versus Standard-Fraktionierung	3	Universitätsklinikum Schleswig-Holstein	04.06.2015
	550	INVERT_Studie		Beobachtungsstudie zur Dokumentation der Ergebnisse einer IMRT-basierten, neoadjuvanten Radiochemotherapie, mit lokaler Dosiseskalation, gefolgt von radikaler Resektion bei Plattenepithelkarzinomen im Kopf-Hals-Bereich		Uniklinik Frankfurt am Main	01.05.2013	31.03.2017
	193	N-SUP-09-DE		The effect of a new specific enteral formula compared to a standard formula on the tolerability of a combined radio- and chemotherapy in cancer patients	1	Fresenius Kabi Deutschland GmbH	01.10.2006	31.12.2009
	199	NEO-RIT-Panitumumab-Studie	2009-016782-28	NEO-RIT - Panitumumab in combination with radiotherapy in patients with locally advanced KRAS wild-type rectal cancer (clinical stages II and III)	2	GMIHO Gesellschaft für Medizinische Innovatio	15.09.2010	01.01.2014
	659	NK-Immuntherapie-Studie: NSCLC-TKD/IL-2	2008-002130-30	Targeted Natural Killer (NK) cell based adoptive immunotherapy for the Treatment of patients with Non-Small Cells Lung Cancer (NSCLC) after radiochemotherapy (RCT)	2	TU München	15.11.2013
	535	OLGA-Trial	2011-005296-16	Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA Trial)	2	Universitätsklinik Hamburg-Eppendorf	26.02.2013	10.10.2014
	194	PacCis-RCT	2005-003484-23	Randomisierte Phase III-Studie zur Radiochemotherapie lokal weit fortgeschrittener Kopf-Hals-Tumoren der Stadien III und IVA-B: Reduktion der Strahlendosis im Rahmen der Radiochemotherapie (RCT) mit Paclitaxel/Cisplatin im Vergleich zu einer Standard-RCT mit 5-FU/Cisplatin	3	Deutsche Krebshilfe e.V.	14.04.2010
	195	Polyprobe-Studie Kolorektale Malignome		Sensitives Polyprobverfahren zur verbesserten Prädiktion von Therapieresponse und Bestimmung der Prognose von Patienten mit kolorektalem Karzinom		Bundesministerium für Bildung und Forschung	31.03.2010
	198	PROCLAIM-Studie	2008-001170-32	Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology	3	Lilly	25.07.2008	03.09.2012
	271	Radiochemotherapie des Pankreaskopfkarzinoms		Neoadjuvante Radiochemotherapie des Pankreaskopfkarzinoms (AIO, ARO, CAO)	2	Deutsche Krebshilfe e.V.	01.06.2003
	534	SOCCER		Untersuchung zur Symptomkontrolle bei Patienten mit rezidiviertem und / oder metastasiertem SCCHN unter Erstlinientherapie mit Erbitux - SOCCER		Merck Serono	01.02.2013
	272	Targit: Intraoperative Radiotherapie des Tumorbettes beim kleinen Mammakarzinom		An international randomised controlled trial to compare targeted intra-operative radiotherapy with conventional post-operative radiotherapy after conservative breast surgery for women with early stage breast cancer	3	Prof. Wenz;Universitätsklinikum Mannheim
	538	TransValid-B-Studie	2011-004228-37	Translational Validation Trial-B (add-on phase I/II study to the Clinical Research Unit (Klinische Forschergruppe) KFO179-2: Preoperative radiochemotherapy (RCT) combined with 5-fluorouracil (5-FU) and oxaliplatin followed by 3 cycles of FOLFOX chemotherapy (5-FU+folinic acid+oxaliplatin) and total mesorectal excision (TME-surgery) in advanced rectal cancer (clinically staged as UICC stages II, III or IV) accompanied by molecular and cell biological (translational) analysis.	1/2	University of Göttingen	16.10.2012
	615	TransValid_A		Translationale Validierungsstudie (add-on Studie zu zweiten Föderperiode der Klinischen Forschergruppe KFO179-1 Biomarker Scores zur Prädiktion und Prognose fortgeschrittener, primär resektabler Rektumkarzinome der klinischen(c) Tumorstadien cUICC-II bis cUICC-IV, die mit einer 5-FU basierten Standard-Radiochemotherapie (RCT) gefolgt von einer totalen mesorektalen Exzision (TME) behandelt werden.		University of Göttingen	01.05.2013
Urologie
	1015	ALSYMPCA (BC1-06)	2007-006195-11	Alpharadin (Radium 223) beim hormonrefraktären Prostatakarzinom	3	Algeta ASA	01.06.2008	27.02.2014
	908	ATLAS	2015-003007-38	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy	3	Janssen-Cilag	04.02.2016
	1012	CA017-078		A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer	3	Bristol Myers Squibb	22.10.2018
	1013	Propose		PRospective Prostate biOmarker Study (PROPOSe)		Proteomedix
	570	A-94-58150002 (OPTIC III)		prospektive nicht -interventionelle Studie zur Optimierung der photodynamischen TUR-B in der klinischen Praxis		Ipsen Pharma	20.11.2013	03.03.2014
	694	AFU-GETUG 20	2010-022037-29	randomised trial to evaluate the benefit of adjuvant hormonal treatment with leucoprorelin acetate for 24 month after radical prostectomy inpatients with high risk of recurrence	3	UNICANCER	14.05.2014
	297	AH 10/04		Randomisierte Phase III Studie bei Patienten mit nicht-seminomatösen Hodentumoren Stadium I high-risk	3	DKG	01.03.2007
	407	AIO-LQ-0211 Qolitime		Nicht interventionelle Studie zur Erfassung der Lebensqualität bei Patienten mit metast. hormonrefraktärem Prostatakarzinom unter Cabazitaxel, die zuvor eine docetaxel-haltige Chemotherapie erhalten haben		Sanofi-Aventis	01.01.2012	30.09.2013
	300	ALSYMPCA-Studie (BC1-06)	2007-006195-11	A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.	3	Algeta ASA	01.07.2008	01.10.2013
	816	ANPro-Studie		Athermaler Nervenerhalt im Rahmen der roboter-assistierten radikalen Prostatektomie mit applizierbarer Gelatine-Thrombin Matrix - Eine Pilot - Studie zur klinischen Evaluation (ANPro-Studie)		Prof. Haferkamp	06.10.2011	31.03.2016
	299	Antisense LY2181308 beim HRPCA (H8Z-MC-JACR)	2007-004907-37	Vergleich von LY2181308 in Kombination mit Docetaxel vs. Docetaxel hormonrefraktären Prostatakarzinom	2	Lilly	08.02.2008	29.03.2012
	798	ARAMIS	2013-003820-36	multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Wirksamkeit und Sicherheit von ODM-201 bei männlichen Hochrisikopatienten mit nicht metast., kastrationresitentem Prostatakrebs	3	Bayer Pharma	20.11.2014
	661	ARN-509-003	2012-004322-24	multicenter, randomized, double blind, placebo-controlled, Phase III study of ARN-509-003 Study in men with non-metastatic ( M0) castration resistant prostate cancer	3	Jansen	29.10.2013	09.05.2019
	1229	B8011006		A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF‑06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer	3	Pfizer
	604	BAY 88-8223	2012-000075-16	Radium-223 Dichloride ( Alpharadin) in Castration-Resistant ( Hormnon-Refractory) Prostate Cancer Patients with Bone Metastasis	3	Bayer Healthcare AG	21.01.2013
	622	BNIT-PRV-301	2010-021196-85	randomizierte, doppelblind, Phase 3 Wirksamkeitsstudie von PROSTVAC-V/F+GM-CSF bei Männern mit asymtomatisch oder minimal symptomatischen , metastasierten, kastrationsresistenten Prostatakarzinom	3	Bavarian Nordic	24.07.2013	25.09.2017
	964	C21005	2010-018662-23	A Phase 3,Randomized,Double-Blind, Multicenter Trial Comparing Orteronel(TAK-700) PLus Prednisolon With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy	3	Millennium Pharmaceuticals	30.03.2012	02.08.2012
	1230	CA209-7DX	2019-002030-36	Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX:CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)	3	Bristol Myers Squibb
	885	CABAZL07266		SCOPE-nicht interventionelle Studie zur Untersuchung des Einflusses der Vorbehandlung vor der Verabreichung von Cabazitaxel auf das Behandlungsergebnis bei Patienten mit metastasiertem kastrationsresisiten Prostatakarzinom		Sanofi-Aventis
	965	Cassiope		Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy		Ipsen Group	20.11.2018
	829	CESAR C-II-010	2013-005504-34	randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)	2		11.07.2014
	612	COMET-1 (S528)	2012-001834-33	A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100	3	Exelixis	22.10.2012	01.01.2014
	1231	Contact-03	2020-000502-29	A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment	3	Hoffmann-La Roche
	1322	CovidSurg Week		GlobalSurg Week - Determining the optimal timing for surgery following SARS-CoV-2 infection
	880	CPZP034ADE15 (PAZOREAL)		Nicht-interventionelle Studie zur Untersuchung der Effizienz und Sicherheit von Pazopanib und Everolimus im Real-Life Setting bei fortgeschrittenem Nierenzellkarzinom in einer wachsenden Therapieumgebung	4	Novartis
	301	CV-9103-001 (CureVac-Studie)	2008-003967-37	Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease	2	CureVac	08.12.2008	10.12.2012
	298	HAROW-Studie		Beobachtungsstudie zur Versorgungssituation bei Prostatakarzinom		Stiftung Männergesundheit	01.10.2008	30.06.2013
	1349	HoLEP vs SoLEP		Vergleich der Holmium Laser Enukleation der Prostata (HoLEP) versus Thulium Faser Laser (TFL) Enukleation der Prostata (SoLEP) bei dem benignen Prostatasyndrom (BPS) – eine prospektiv randomisierte NichtUnterlegenheitsstudie		Goethe-Universität Frankfurt
	778	HYPOSTAT2		Hypofraktionierte Strahlenchirurgie bei lokal begrenztem Prostatakarzinom	2	Universitätsklinikum Kiel	19.01.2016
	429	IMCL CP15-0805 (Parexel)	2009-018015-11	A Randomized , open label Study of Human Monoclonal Antibody with or without Mitoxantrone and Prednisone or Mitoxantrone and Prednisone alone in Metastatic Castration-Refractory Prostate Cancer (MCRPC) following Disease Progression on Docetaxel-based Chemotherapy	2	Imclone	20.10.2010	01.10.2013
	1235	iTind		One-arm, multi-center, international prospective study to assess the efficacy, safety and durability of Medi-Tate Temporary Implantable Nitinol Device (iTind) in subjects with Symptomatic Benign Prostatic Hyperplasia (BPH)		MEDI-TATE LTD.
	815	KoReP		Kontinenz nach Rekonstruktion des vesiko-urethralen Übergangs im Rahmen der roboter-assistierten Prostatektomie		Dekan der Universität Frankfurt	02.03.2012	31.03.2016
	303	M2-PK		M2-Pk im Urin als Biomarker zur Detektion von Urotheltumoren				31.12.2010
	1218	MicroRNA 371		MicroRNA-371a-3p als Serum-Biomarker für die Früherkennung von Rezidiven in der Nachsorge von Patienten mit testikulären Keimzelltumoren		Hodentumorzentrum Hamburg
	966	MK-3475-564	2016-004351-75	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)	3	Merck Sharp & Dohme GmbH	20.11.2018
	1359	MK-6482-011	2020-002075-35	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	3	Merck Serono
	1232	MK3475-EP05026.48		CLINICAL OUTCOMES IN NON-MUSCLE INVASIVE BLADDER CANCER: A GLOBAL MULTI-SITE CHART REVIEW STUDY		Merck Sharp & Dohme Corp	19.05.2020	16.02.2021
	1236	MK3475-EP05026.48		CLINICAL OUTCOMES IN NON-MUSCLE INVASIVE BLADDER CANCER: A GLOBAL MULTI-SITE CHART REVIEW STUDY		Merck Sharp & Dohme Corp
	448	MRS-Prostata-2011	N/A	Evaluierung der Wertigkeit der Diffusionsbildgebung, der Magnetresonanz-Spektroskopie und der dynamischen Bildgebung mit Tissue 4D der Prostata		Institut für Diagnostische und Interventionel	01.01.2011	16.02.2017
	1378	MS100070-0114		Avelumab in real-world treatment of urothelial cancer - The AVENUE NIS		Merck Serono
	302	NSR-Studie		Nationale Seminom-Registerstudie		AUO
	580	OGX-427-02	2011-002424-41	Phase 2 randomzierde, doppelblind,vergleichend, zur Anwendung von Gemcitabin plus Cisplatin in Kombination mit entweder OGX_427 oder Placebo bei Patienten mit fortgeschrittenem Urothelcarcinom	2	OnoGenex	22.11.2011	31.10.2013
	1233	Prepare	2016-000399-28	A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib	3	AIO-Studien-gGmbH
	567	ProFu		Zielgerichtete Prostatabiobsie mit transrektaler Bildfusion von MRT und Sonographie im Vergleich zur systematischen Prostatabioosie		Klinik für Urologie und Kinderurologie	18.02.2014	30.04.2016
	1062	Proteus (56021927PCR3011)	2018-001746-34	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy	3
	967	Radium-223 alpha Sicherheitsstudie		Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation (REASSURE)		Bayer	01.08.2016
	977	Reassure/Radium-223 alpha Sicherheitsstudie		Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation (REASSURE)		Bayer	19.05.2014
	1284	Retox		Prospektive Evaluation der Retinalen Toxizität platin-haltiger Chemotherapie mit Hodenkarzinom		Goethe-Universität Frankfurt	01.05.2020
	754	RoZyst		Studie zur Untersuchung der roboter-assistierten Zystektomie im Vergleich zum offen-chirurgischen Verfahren		Dekan der Universität Frankfurt	01.01.2012	31.03.2016
	1219	SAG TCCS		Kohortenstudie bei Patienten mit Hodenkrebs		Asklepios Klinik Hamburg Altona
	1388	Talapro-3	2021-000248-23	Talapro-3: A phase 3, randomized, double-blind, study of talazoparib with enzalutamide versus placebo with enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer	3	Pfizer	05.01.2022
	1061	Thor (42756493BLC3001)	2017-002932-18	A phase 3 study of Erdafitinib compared with Vinflunine or Docetaxel or Pembrolizumab in subjects with advanced Urothelial Cancer and selected FGFR Gene Aberrations	3
	827	Tumorprofiling		Tumorprofiling des kastrationsresistenten Prostata Ca		Klinik für Urologie und Kinderurologie	01.09.2015	31.03.2016
	520	UGO 01/10		Untersuchung zu Expressionsprofilen von Chemokinen bei Patienten mit Nierenzellkarzinom			01.05.2012	31.03.2016
	968	UGO 04/10		Expression des L1 Adhäsionsmoleküls (L1-CAM) bei Patienten mit Nierentumoren		Goethe-Universität Frankfurt	01.05.2010	31.01.2012
	760	Viable	2012-002814-38	A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel-Group Phase III study to evaluate efficacy and safety of DCVA/PCa plus Standard of Care Chemotherapy in Men with metastatic Castration Resistant Prostate Cancer	3	Sotio	12.07.2013
	559	X-TREME	N/A	Anwendungsbeobachtung zur Therapie-Persistenz von Denosumab(XGEVA) im toutinemäßigem Einsatz bei Erwachsenen mit Knochenmetatastasen aufgrund solider Tumore		Amgen	01.02.2014
	1063	XL184-313	2018-004567-31	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	3
Zahnmedizin
	1083	GAZAI	2016-002059-89	Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro	2	UFK Heidelberg	03.12.2019	28.12.2022